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Abstract 
Worldwide, tuberculosis (TB) is the leading cause of death due to a single infectious agent, 
claiming 1.6 million human lives and causing >10 million new cases in 2017 alone, mostly in low-
income regions. The intracellular pathogen Mycobacterium tuberculosis is the etiological agent and 
generally infects the lungs. Although treatments exist, curing TB requires long and often expensive 
chemotherapy, frequently accompanied by undesirable side-effects. In the absence of an effective 
vaccine and with the increasing emergence of multidrug resistance, new and more powerful 
antibiotics are urgently needed to control the global TB crisis. 
In this respect, benzothiazinones (BTZs), a class of new anti-TB compounds, have recently been 
discovered. Macozinone (PBTZ169), that has reached phase I and II clinical trials in Switzerland 
and Russia, respectively, is undoubtedly the most promising drug of this category. We derivatized 
PBTZ169 into a fluorescent chemical probe that efficiently, covalently and selectively labels the 
enzyme DprE1, thereby localizing the target of BTZs to the periplasm at the poles of 
actinobacteria. We further discuss the potential applications of such probes for in vivo imaging, 
mycobacterial detection and designing new diagnostic tools. 
In general, the search for novel anti-mycobacterial drugs is an extremely long process, delaying the 
progression of new compounds down the pipeline and to the clinic. Assessing drug efficacy in vivo 
typically requires extensive resources and is time-consuming. This process can be shortened by 
applying alternative and innovative methods devised in this thesis, namely the implementation of in 
vivo imaging procedures and use of the zebrafish embryo model of mycobacterial infection for drug 
discovery and development. 
In vivo imaging enables bacterial loads in animal models to be assessed in real time, by means of 
fluorescence or bioluminescence imaging. We constructed, optimized and characterized genetically 
engineered near-infrared fluorescent reporters of the pathogens Mycobacterium marinum and 
M. tuberculosis that allow direct visualization of bacteria in infected zebrafish and mice, 
respectively. Furthermore, we show that the fluorescence level accurately reflects the bacterial 
load, as determined by colony forming unit enumeration, thus enabling the efficacy of antibiotic 
treatment to be assessed in live animals. Alternatively, we applied autobioluminescent 
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M. tuberculosis to evaluate drug efficacy in mice and demonstrated that our system enables the 
therapeutic response to be followed in real time. Longitudinal imaging also reduces the number 
animals required thus providing a substantial gain of time and resources. Finally, the zebrafish 
embryo is an inexpensive and faster alternative model that has been applied to investigate 
mycobacterial pathogenesis. We implemented this model of M. marinum infection and successfully 
applied it to assess the activity of several drugs in vivo.  
Altogether, the innovative methods described in this work are advantageous for TB drug discovery 
and development, especially for the in vivo evaluation of new anti-mycobacterial candidates, and 
provide more ethically acceptable approaches and biomedical applications. 
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Résumé 
La tuberculose est la majeure cause de décès due à un agent infectieux unique, dans le monde 
entier. Plus de 10 millions de personnes ont été atteintes par cette maladie et 1.6 millions en sont 
mortes en 2017 uniquement, principalement dans des régions à bas revenu. Le pathogène 
intracellulaire Mycobacterium tuberculosis est l’agent étiologique responsable de cette maladie et 
infecte généralement les poumons. Bien que des remèdes existent, soigner la tuberculose requiert 
un long traitement chimio-thérapeutique, souvent cher et fréquemment accompagné d’effets 
secondaires indésirables. En l’absence d’un vaccin efficace et avec l’émergence de multiples 
résistances aux traitements, de nouveaux antibiotiques plus puissants sont rapidement requis dans 
le but de contrôler l’épidémie de tuberculose. 
Dans cette optique, les benzothiazinones (BTZs), une classe de nouveaux composés 
antituberculeux, ont récemment été découverts. La macozinone (PBTZ169), qui est récemment 
entrée en phase clinique I en Suisse et en phase clinique II en Russie, représente sans doutes la 
molécule la plus prometteuse de cette catégorie. Nous avons transformé le PBTZ169 en sonde 
chimique fluorescente permettant de marquer efficacement, sélectivement et de manière covalente 
l’enzyme DprE1, indiquant la localisation de la cible des BTZs dans le périplasme de certaines 
actinobactéries, au niveau de leurs pôles. Nous discutions plus en détail les applications potentielles 
de telles marqueurs pour l’imagerie in vivo, pour la détection de mycobactéries et pour le design 
d’outils de diagnostic novateurs. 
En général, la recherche de nouvelles molécules antimicrobiennes représente un processus 
extrêmement long, retardant la progression des composés candidats vers leurs applications 
cliniques. L’évaluation de ces molécules in vivo requiert typiquement un temps considérable et 
d’importantes ressources. Ce processus peut cependant être accéléré en appliquant certaines 
méthodes alternatives et innovantes, telles que l’implémentations de procédures d’imagerie in vivo 
et l’utilisation d’embryons de poissons-zèbres comme modèles d’infection mycobactérienne. Leur 
application à la découverte et au développement des composés antituberculeux est amplement 
discutée dans cette thèse. 
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L’imagerie in vivo permet d’évaluer la charge bactérienne dans des modèles animaux en temps 
réel, grâce à des techniques basées sur les phénomènes de fluorescence et de bioluminescence. 
Dans cet ouvrage, nous décrivons la construction, l’optimisation et la caractérisation de pathogènes 
(Mycobacterium marinum et M. tuberculosis) génétiquement modifiés afin de créer des souches 
fluorescentes dans le proche infrarouge. Ces souches permettent de visualiser directement les 
bactéries dans des poissons-zèbres des souris infectés, respectivement. De plus, nous démontrons 
que le niveau de fluorescence reflète précisément la charge bactérienne déterminée par énumération 
de colonies, ce qui permet d’évaluer l’efficacité d’un traitement antibiotique dans des animaux 
vivants. Comme méthode alternative, nous avons utilisé une souche de M. tuberculosis 
autobioluminescente pour tester l’efficacité d’un médicament dans des souris et démontrons que 
notre system permet de suivre la réponse thérapeutique en temps réel. L’imagerie en série permet 
également de réduire le nombre d’animaux requis, apportant ainsi une considérable économie de 
temps et de ressources en général. Finalement, l’embryon de poisson-zèbre est un modèle animal 
alternatif, rapide et peu cher, qui peut être utilisé pour étudier la pathogénèse mycobactérienne. 
Nous avons implémenté ce modèle d’infection avec M. marinum et l’avons appliqué avec succès à 
l’évaluation in vivo de plusieurs antibiotiques en cours de développement. 
Globalement, les méthodes innovantes décrites dans cet ouvrage sont avantageuses pour la 
recherche et le développement de nouvelles molécules antituberculeuses, notamment pour leur 
évaluation in vivo, et fournissent des approches et des applications biomédicales éthiquement plus 
acceptables. 
 
Mots-clés 
Tuberculose, mycobactéries, benzothiazinones, découverte et développement de nouveaux 
médicaments, sondes fluorescentes, imagerie in vivo, imagerie par fluorescence proche infrarouge, 
imagerie par bioluminescence, modèle murin, modèle de poisson-zèbre. 
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Zusammenfassung 
Tuberkulose (TB) ist die weltweit führende Todesursache durch Infektionen, die durch einen 
einzelnen Krankheitserreger bedingt sind; allein im Jahre 2017 hat sie über 10 Millionen 
Erkrankungen verursacht und 1.6 Millionen Menschenleben gefordert, wobei vornehmlich 
Gegenden tiefer Einkommensschichten betroffen sind. Das intrazelluläre Pathogen Mycobacterium 
tuberculosis ist der Krankheitsverursacher und infiziert primär die Lungen. Obwohl Behandlungen 
existieren, ist für eine vollständige Genesung eine lange und zum Teil teure Chemotherapie 
vonnöten, die häufig von Nebenwirkungen begleitet wird. Da kein effizienter Impfstoff zur 
Verfügung steht und zudem vermehrt Multiresistenzen auftreten, besteht ein dringender Bedarf für 
neue, wirksamere Antibiotika, damit die globale TB-Krise unter Kontrolle gebracht werden kann. 
Benzothiazinone (BTZs) stellen eine Gruppe neuer, kürzlich entdeckter anti-TB Wirkstoffe dar. 
Macozinon (PBTZ169) befindet sich bereits in klinischen Studien (Phase I in der Schweiz, Phase II 
in Russland) und ist das vielversprechendste Mitglied seiner Kategorie. Hier wird ein 
fluoreszierendes Derivat des PBTZ169 beschrieben, das als Sonde selektiv und kovalent an das 
Enzym DprE1 bindet, wodurch das Zielenzym der BTZs als sich an den Polen im Periplasmum 
befindend lokalisiert werden konnte. Wir diskutieren das Potenzial solcher Sonden für die In-vivo-
Bildgebung, Mykobakteriendetektion und für die Entwicklung neuer diagnostischer Werkzeuge. 
Die Suche nach neuen antimykobakteriellen Medikamenten ist in der Regel ein sehr langwieriger 
Prozess, wodurch neue Verbindungen erst nach längerer Zeit weiteren Studien und letzten Endes 
klinischen Versuchen unterzogen werden können. Die In-vivo-Beurteilung von 
Medikamentenwirksamkeit benötigt viel Zeit und verlangt nach substantiellen Ressourcen. Dieser 
Prozess kann durch geeignete, alternative und innovative Methoden, die in dieser Dissertation 
beschrieben sind, verkürzt werden: Durch die Implementierung von In-vivo-Bildgebungsverfahren 
einerseits, und durch die Verwendung eines Zebrafischembryomodells für Mykobakterieninfektion 
und -medikamentenentwicklung andererseits. 
 
 
Zusammenfassung 
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Fluoreszenz- oder Biolumineszenzbildgebung erlaubt die In-vivo-Beurteilung der bakteriellen 
Belastung in tierischen Modellorganismen in Echtzeit. In dieser Arbeit werden gentechnisch 
Nahinfrarot-Stämme für die Krankheitserreger Mycobacterium marinum und M. tuberculosis 
entwickelt, optimiert und charakterisiert, welche eine unmittelbare Sichtbarkeitsmachung der 
Bakterien in infizierten Mäusen und Zebrafischen ermöglichen. Zudem wird gezeigt, dass die 
Stärke der Fluoreszenz mit der bakteriellen Belastung korreliert, was durch Zählen der 
kolonienformierenden Einheiten (CFUs) bestätigt wurde; damit kann nunmehr die Wirksamkeit 
einer antibiotischen Behandlung in lebenden Tieren beurteilt werden. Autobioluminiszente M. 
tuberculosis werden zur Beurteilung der Medikamentenwirksamkeit in Mäusen hinzugezogen und 
es wird gezeigt, dass sich der therapeutische Effekt damit in Echtzeit verfolgen und bewerten lässt. 
Überdies werden durch longitudinale Bildgebung weniger Versuchstiere benötigt, womit Zeit und 
Ressourcen eingespart werden können. Zebrafischembryos stellen ein kostengünstiges, schnelles 
Alternativmodell zur Untersuchung der mykobakteriellen Pathogenese dar. Anhand der Infektion 
mit M. marinum wird die Aktivität verschiedener Medikamente in vivo beurteilt. 
Die hier beschriebenen, innovativen Methoden sind der Entwicklung und Entdeckung neuer TB-
Medikamente dienlich; sie ermöglichen im Speziellen die In-vivo-Beurteilung neuer potenziell 
antimykobakterieller Verbindungen und die Verwendung ethisch besser akzeptabler 
Versuchsprotokolle. 
 
Schlagwörter 
Tuberkulose (TB), Mycobakterien, Benzothiazinone, Fluoreszenzmarkierte Sonde, 
Medikamentenentdeckung und -entwicklung, , In-vivo-Bildgebung, Nahinfrarotbildgebung, 
Biolumineszenzbildgebung, Mausmodell, Zebrafischmodell. 
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EN MILLION. This corresponds to the estimated number of people who fell ill with 
tuberculosis (TB) in 2017 alone, according to the World Health Organization (WHO).1 
Among them, the disease claimed 1.6 million deaths, including 300’000 among HIV-
positive people. Worldwide, TB is the leading cause of death due to infection with a single 
pathogenic agent, Mycobacterium tuberculosis. The increasing emergence of drug-resistant strains 
of M. tuberculosis and the absence of an effective vaccine are major drivers of this long-lasting TB 
epidemic, highlighting the urgent need for new and more efficient antibiotics. In order to 
understand the global challenges related to TB and the strategies ongoing to tackle the disease, let 
us start with a general introduction in which I would like to present some approaches that I 
investigated during my doctoral studies, in order to refine and accelerate the TB drug discovery 
process. 
TUBERCULOSIS – ENDING THE EPIDEMIC BY 2035? 
Tuberculosis in the 20th century 
In March 1882, Robert Koch, a German doctor, announced his discovery of the bacillus 
M. tuberculosis, that he described as the etiological agent responsible for the TB disease,2 although 
there is now evidence that humans were already affected by TB more than 8’000 years ago.3 His 
discovery earned him the Nobel Prize in 1905. Since the end of the 19th century, fresh air, sunlight, 
outdoor exercise and good diet were associated with a better control of TB and were the only 
medical prescriptions for patients. This led to the apparition of sanatoria, which are medical 
institutions commonly installed in the mountains and dedicated to hosting and treating TB patients. 
In Switzerland, signs of such facilities still exist in Davos and Leysin for instance but they have 
been repurposed. Of note, the isolation of TB patients in sanatoria was also likely a collateral 
benefit for society. 
Between 1906 and 1919, Calmette and Guérin obtained an attenuated strain of Mycobacterium 
bovis, the mycobacterial agent of bovine TB, following multiple passages in vitro.4 This strain had 
indeed lost its capability to cause disease in animals and is today known as Bacille Calmette-
Guerin (BCG). Attenuation of BCG has been attributed to the loss of RD1, a genetic region 
encoding virulence factors in pathogenic mycobacteria. BCG was used for the first time in 1921 as 
a vaccine in an attempt to prevent TB in humans. Vaccination with BCG proved to be protective 
against miliary and meningeal TB in children. However, it does not prevent primary infection nor 
the progression of latent pulmonary infection to active TB in adults.1 The impact of BCG 
vaccination on transmission of the disease is therefore limited and this explains partly why the 
T 
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epidemic has not been eradicated. Almost 100 years after its discovery, BCG also remains the only 
vaccine available as preventive treatment for human TB, although with considerably limited 
efficacy.1 
In 1940, the discovery of streptomycin5, the first effective antibiotic against TB, constituted a 
major breakthrough and paved the way for anti-TB chemotherapy and further drug discovery. For 
20 years, fruitful research and development led to the marketing of many anti-TB drugs. With the 
extensive utilization of these drugs in regimens, along with the social and economic development, a 
substantial decline in TB cases and deaths has been experienced worldwide. In the late 1980s, 
however, a resurgence of TB was seen mainly due to the HIV/AIDS pandemic and the emergence 
of drug-resistant strains of M. tuberculosis. This situation led the WHO to declare TB a global 
health emergency in 1993. 
Tuberculosis today and modern challenges 
Worldwide, TB is the major cause of death due to a single infectious agent and ranks above 
HIV/AIDS and malaria. In Western Europe and North America, high-income regions, the disease 
burden is extremely low with <10 cases and even <1 death per 100’000 inhabitants. In contrast, 
two thirds of TB cases are distributed among eight countries: India, China, Indonesia, The 
Philippines, Pakistan, Nigeria, Bangladesh and South Africa (Figure 1). In 2017, among the 1.3 
million new TB cases in HIV-negative people and the 300’000 new cases among HIV-positive 
people, the WHO estimated that 580’000 patients were not responding to rifampicin, a frontline 
anti-TB drug. Among rifampicin-resistant (RR) TB patients, 82% had multidrug-resistant (MDR) 
TB, meaning resistance to at least rifampicin and isoniazid (a second frontline drug). Drug 
resistance is certainly today one of the greatest threats and challenges related to the TB epidemic. It 
is thought that one quarter of the world's population is infected with M. tuberculosis, 90% of them 
carrying latent TB, which is an inactive and non-contagious form of the disease. These people, who 
often remain undiagnosed, represent therefore a major reservoir. Aging and weakening of the 
immune system (sometimes associated with HIV co-infection for instance) are, however, major 
drivers of TB reactivation in latently infected patients. Hence, the end of TB as an epidemic is still 
for many countries, an aspiration rather than a reality.1 
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Figure 1. Estimated TB incidence rates, 2017. Adapted from the WHO’s Global 
Tuberculosis Report 2018.1 
 
 
Figure 2. Desired decline in the global TB incidence rates to reach the 2035 targets. 
Adapted from the WHO’s End TB Strategy brochure.6  
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The End TB Strategy 
The overall goal of the WHO’s End TB Strategy is to end the global TB epidemic by achieving 
substantial reduction of TB deaths and incidence rate1. The major target fixed by the strategy is in 
2035 and sets the following indicators: reduction of TB deaths by 95%, reduction of TB incidence 
rate by 90% and zero TB-affected households experiencing disastrous costs due to the disease. The 
actual global trend concerning the TB incidence rate is a decline of 1.5% per year (Figure 2) and in 
order to meet the fixed milestones and targets, the strategy relies on three pillars: 1) integrated, 
patient-centred care and prevention, 2) bold policies and supportive systems and 3) intensified 
research and innovation.6 Notably, the third pillar promotes the discovery and development of new 
tools and strategies, and this has been a major source of inspiration for the different approaches that 
will be presented in this thesis, including the amelioration of the drug discovery process by 
implementing real-time evaluation of antibiotic efficacy in vivo and the exploitation of the 
zebrafish embryo as a faster and cheaper surrogate to the mouse model of disease. 
MICROBIOLOGY AND PATHOGENESIS 
M. tuberculosis and mycobacteria 
The TB disease is caused by a range of mycobacteria closely genetically related and part of the 
M. tuberculosis complex (MTBC)7, including, M. tuberculosis and Mycobacterium africanum, 
causing TB in humans. Several animal-adapted strains from the MTBC cause TB in non-human 
species, exemplified by M. bovis, primarily causing TB in cattle.8 Not included in the MTBC are 
Mycobacterium ulcerans, causing Buruli ulcer in humans, and Mycobacterium leprae, the agent 
responsible for leprosy. Nontuberculous mycobacteria (NTM) are opportunistic pathogens that can 
cause disease in immunosuppressed humans, such as HIV-positive patients. NTM typically include 
species from the Mycobacterium avium complex, Mycobacterium kansasii, Mycobacterium 
marinum and Mycobacterium abscessus. Finally, Mycobacterium smegmatis is a rapid-growing 
bacterial species from the genus Mycobacterium commonly used in laboratories as a surrogate to 
M. tuberculosis, as it is not pathogenic and grows fast (generation time ~3 h). 
M. tuberculosis is a slow-growing (generation time ~20 h in laboratory media), obligate aerobe; 
facultative intracellular and rod-shaped bacterium.9 It is neither Gram-positive nor Gram-negative 
but acid-fast and can be identified by Ziehl–Neelsen staining. It carries a single circular 
chromosome of ~4.4 Mbp.7 Its thick cell envelope, containing complex lipids and sugars, is a 
dominant feature of M. tuberculosis.9 Unlike the uncultivable pathogen M. leprae, M. tuberculosis, 
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as well as M. marinum and M. smegmatis, are genetically accessible and multiple tools are 
available to study the essentiality of certain genetic features or to express heterologous genes, for 
example coding for fluorescent proteins, to construct mycobacterial reporters. 
Pathogenesis 
The disease is spread when people with active TB cough or sneeze, expelling bacteria into the 
environment in aerosol droplets. The common route of entry of M. tuberculosis into the body is by 
inhalation via the respiratory tract (Figure 3). The bacteria are then translocated towards the lower 
respiratory tract where they are generally engulfed by phagocytic cells.10 Alveolar macrophages are 
the dominant cell type being infected by M. tuberculosis and the bacteria can actively block the 
fusion of the phagosome with the lysosome, avoiding host cell clearance and promoting their 
intracellular survival.9,11 Migration of infected cells to the lung parenchyma generates a 
multicellular (including neutrophils, monocytes and lymphocytes) host response resulting in the 
formation of a granuloma. The granulomatous structure is constituted of several types of immune 
cells, as simplified and depicted in Figure 3. It contains the bacteria and limits the propagation of 
the infection, leading to latent TB.10 This situation applies to >90% of immunocompetent 
individuals and infected patients will remain asymptomatic and non-contagious while the 
pathogens persist in a dormant state.12 AIDS and immunosuppressive treatments may cause 
reactivation and progression to active TB disease, following failure of the immune containment.10 
In some cases, M. tuberculosis may disseminate to other sites such as the lymph nodes, pleura or 
the spinal cord (Pott’s disease).13 
 
Figure 3. Infection with M. tuberculosis. The infection begins when bacteria are inhaled and 
directed to the lower respiratory tract, where they are generally taken up by phagocytic cells. If 
this first line of defence does not eliminate the bacteria, migration of the infected cells to the 
parenchyma leads to the recruitment of more immune cells to constitute a granuloma. The 
granulomatous structure contains M. tuberculosis, preventing the progression of the infection. 
Upon failure of this containment, reactivation and dissemination of the bacteria can give rise to 
the active and contagious form of the TB disease. Figure adapted from9. 
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STRATEGIES TO ADDRESS THE GLOBAL TB SITUATION 
Antibiotics 
Antibiotics are generally small molecule drugs aimed at controlling and eliminating the bacterial 
agent responsible for an infection, while minimizing side-effects on the body and the normal flora. 
Since the discovery of streptomycin in 1943, antibiotic treatments, as well as social and economic 
development, have dramatically reduced the TB burden. Subsequently discovered drugs, with 
better safety profiles, enabled shorter and more efficient treatment to be implemented in the 
following years (Figure 4). It was soon observed that the administration of streptomycin alone 
rapidly led to the apparition of resistant strains and TB has since then mainly been managed by the 
administration of regimens containing two or more drugs (Figure 4). The regimen recommended by 
the WHO nowadays for treating active and drug-sensitive TB is composed of an intensive 2 months 
treatment phase with the frontline drugs isoniazid, rifampicin, pyrazinamide and ethambutol, 
followed by a continuation phase with isoniazid and rifampicin for four months.12 In the case of 
drug-resistant TB, however, the treatment is much longer, heavier and has more undesirable side-
effects. It consists of four second-line drugs, including a fluoroquinolone (moxifloxacin, 
levofloxacin, gatifloxacin), a parenteral agent (amikacin, capreomycin, kanamycin), a core second-
line drug (ethionamide, prothionamide, cycloserine, terizidone, para-aminosalicylic acid) and an 
add-on drug, as recommended by the WHO since 2016. 
The apparition and transmission of MDR M. tuberculosis and the onset of the HIV/AIDS pandemic 
led to a resurgence of TB and revived the search for new and more efficient antibiotics. Meanwhile, 
new patient data have arisen and the WHO has revised the guidelines for MDR/RR-TB treatment, 
leading to key changes in the recommended regimen, published in a communication in August 
2018.14 The revised recommendation, based on the latest evidence regarding the balance of 
effectiveness to safety, now includes: 1) medicines to be prioritized (levofloxacin or moxifloxacin, 
bedaquiline and linezolid), 2) medicines to be added next (clofazimine, cycloserine or terizidone) 
and 3) medicines to be added to complete the regimen, especially if some of the previous drugs 
cannot be used (ethambutol, delamanid, pyrazinamide, imipenem-cilastatin or meropenem, 
amikacin, ethionamide or prothionamide, para-aminosalicylic acid). The second-line injectable 
agents kanamycin and capreomycin are not recommended anymore. While immediate application 
of the new guidelines to every MDR-TB patient is not possible, strategic planning will be required. 
The revision of these guidelines reflects consideration of the most recent advances in terms of drug 
discovery and development, promoted by the third pillar of the End TB Strategy. However, the 
current status of the rare new or repurposed drugs remains insufficient to face the global TB 
epidemic. 
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Figure 4. History of drug discovery and development of treatment regimens for TB. 
Adapted from15. 
 
Vaccines 
Bacille Calmette-Guérin (BCG), used for the first time in 1921, remains nowadays the only 
licensed TB vaccine for human beings. It has proven to be effective against severe childhood TB 
(meningeal and miliary) while the protective effect of BCG vaccination is variably lost in adults.16 
Although BCG vaccination has been widely used and has protected many infants, the need for 
protection against TB infection and reactivation in adults remains unmet. Much effort is currently 
needed for TB vaccine development and different novel strategies are being investigated. These 
new vaccine candidates are for instance based on protein/adjuvant mixtures containing 
M. tuberculosis antigens (e.g. Ag85B, ESAT-6), viral vectors to deliver M. tuberculosis antigens 
into host cells, mycobacterial whole cell or extracts and live attenuated mycobacterial strains.17 
Notably, MTBVAC is the first live attenuated M. tuberculosis based vaccine reaching clinical 
trials18 and new recombinant strains of BCG are being investigated, BCG ?ureC::hly (VPM1002) 
being the most advanced one (in clinical phase III).19 
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Diagnostic tools 
A limited number of tools are available for the diagnosis of TB and the choice of the available 
methods depends on whether the patient is suspected to have latent TB or active disease.10 In the 
first case, two tests are available: the tuberculin skin test (TST) and the interferon-gamma (IFN-?) 
release assay (IGRA). Tuberculin, a sterilized M. tuberculosis extract initially developed by Robert 
Koch as a potential, albeit unsuccessful cure for TB, induces a skin reaction in people who have 
cell-mediated immunity to antigens contained in the preparation, when injected intradermally.10,20 
The size of the resulting induration is the major readout of this diagnostic test but it fails to 
discriminate between patients truly infected with M. tuberculosis and those who had been 
previously vaccinated with BCG (likely due to an overlap of the antigens from both species, 
contained in the tuberculin preparation). IGRA was introduced in the 2000s and is an in vitro blood 
test quantifying T-cell release of IFN-? following stimulation with ESAT-6 and CFP-10, two RD1-
encoded proteins.21 More specific for M. tuberculosis than TST, IGRA remains less accessible in 
low-resource settings as it requires specific reagents, and advanced equipment and laboratory skills. 
The diagnosis of active TB relies mainly on the isolation and identification of M. tuberculosis in 
samples from infected patients. The most accessible and widely used technique is smear 
microscopy, where bacilli are visually identified from sputum samples.22 However, this method 
generates a high percentage of error and is poorly sensitive. Culture-based methods are applied but 
necessitate laboratory settings and require more time before a precise diagnosis can be made. 
Molecular assays have become a an attractive option since 2010, exemplified by the Xpert 
MTB/RIF technology (Cepheid Inc.), a nucleic acid amplification test that can additionally detect 
rifampicin resistance from sputum samples.23 Thanks to its sensitivity and specificity, this system is 
now recommended by the WHO as first-line diagnostic test for people suspected to have active TB. 
In clinical settings, microscopy, culture- and molecular-based assays are complemented by imaging 
techniques, such as chest X-ray radiography or positron emission tomography coupled to computed 
tomography (PET/CT), to detect and analyse TB-induced lesions in the lungs.24,25 
Each of the proposed diagnostic solutions has diverse advantages and limitations in terms of 
sensitivity, specificity or cost, and the need for a rapid, precise and cost-effective point-of-care 
diagnostic tool providing prognosis value, remains unmet. 
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DISCOVERING AND DEVELOPING NEW ANTI-TB DRUGS 
The urgent need for new anti-TB drugs 
“In the absence of an effective vaccine and with the increasing emergence of drug-resistant 
M. tuberculosis, there is an urgent need for new, more efficient, faster-acting and better tolerated 
treatments for TB”. This type of statement is recurrent in many recent publications related to TB 
and drug discovery, and describes well the importance and the need for new antibiotics and 
strategies to confront TB. Ideally, new drugs should permit shorter treatments (especially for 
MDR-TB), have limited side-effects, be easy to administer, affordable and compatible with other 
TB drugs, and with antiretroviral therapies. 
The drug discovery and development process 
The leads in the TB drug development pipeline (Figure 5) commonly arose from phenotypic 
screening of a large library of compounds, assessed for their efficacy in cell-based assays. The 
subsequent target identification, validation and mechanism of action is typically investigated with 
whole-genome sequencing of resistant mutants.26 More rarely, rational drug design and a target-to-
drug approach has been applied.27 The following hit-to-lead stage typically involves structure-
activity relationship (SAR) studies, determination of the physicochemical properties, cytotoxicity 
and in vitro stability studies.28 The subsequent lead optimization process involves further medicinal 
chemistry, combination and in vivo efficacy investigations. If successful, the optimized lead further 
continues to preclinical and clinical studies, in which the safety, tolerability, 
pharmacokinetics/pharmacodynamics and efficacy are investigated. The in vivo efficacy is 
commonly assessed in mouse models of TB infection, although such assays are time-consuming 
and require substantial resources. Strategies to boost the evolution of a lead compound at this stage 
will be investigated and discussed later. 
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Figure 5. 2018 Global new TB drug pipeline. This figure describes new molecular entities or 
repurposed drugs not yet approved (or only conditionally approved), being developed for TB 
treatment, as proposed by the Working Group on New TB Drugs. Adapted from 
https://www.newtbdrugs.org/pipeline/clinical, the WHO’s Global TB Report 20181 and28. 
Compounds are listed under their current stage. Note the drugs macozinone and bedaquiline, 
currently in clinical phases I/II and III, respectively, which will be applied to in vivo imaging 
experiments further in the present work. Beside new or repurposed drugs, new regimen (not 
shown) are currently in clinical trials, aiming to shorten treatment duration for MDR-TB. 
 
 
Figure 6. Molecular structure of macozinone, bedaquiline and clofazimine. 
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Focus on some promising TB drugs 
The drugs presented in the current pipeline in Figure 5 are either new chemical entities or 
repurposed drugs. I would like to discuss three famous examples (Figure 6), relevant for the 
coming chapters of this thesis. 
(i) Macozinone, previously known as PBTZ169, is a preclinical candidate optimized from the 
lead compound BTZ043. It is a piperazine-containing benzothiazinone (BTZ), a new class of 
highly specific anti-mycobacterial compounds, targeting the essential enzyme DprE1, that is 
necessary for the synthesis of key cell wall components.29–31 Notably, macozinone covalently 
inhibits DprE1 by forming a semimercaptal adduct with Cys378 in the active site of this 
enzyme, in M. tuberculosis.32 It shows synergistic effects with bedaquiline33 and 
clofazimine34 in preclinical models. Macozinone has completed phase I clinical trials in 
Switzerland and has started a phase II in Russia. Beside its potential as anti-TB drug, 
macozinone has been derived into a fluorescent chemical probe for specific labelling of 
DprE1 in several BTZ-sensitive actinobacteria.35 Fluorescent BTZ derivatives are the subject 
of the second chapter of this work and potential applications of mycobacterial labelling in 
vivo with fluorescent BTZ analogues are discussed in chapter 3. 
(ii) Bedaquiline (TMC-207), a diarylquinoline drug discovered in 2005, is an inhibitor of the 
proton pump of the adenosine triphosphate (ATP) synthase in M. tuberculosis. Point 
mutations in atpE, encoding a part of the F0 subunit of the ATP synthase, conferred 
bedaquiline resistance.36 The Food and Drugs Administration (FDA) granted accelerated 
approval for bedaquiline (commercial name SIRTURO™) – the first approved new TB drug 
in 40 years – as part of combination therapy for adults with MDR-TB.37 Interestingly, 
bedaquiline is also active against the NTM M. abscessus38 and is probably one of the most 
advanced, promising and entirely new anti-mycobacterial drugs discovered to date, along 
with the BTZs. The comparative efficacy of bedaquiline and other drugs in mice, assessed 
with in vivo imaging, will be discussed in chapters 4 and 5. 
(iii) Clofazimine is a drug used to treat leprosy, a disease caused by long-term infection with 
M. leprae. In combination with rifampicin and dapsone, it is recommended by the WHO for 
the treatment of leprosy39 and was recently repurposed for the treatment of MDR-TB.40 The 
precise mode of action of clofazimine is poorly understood and cannot be assessed in 
M. leprae as this organism cannot be cultured in vitro. An investigation of a potential 
mechanism of resistance to clofazimine is described in the zebrafish model of M. marinum 
infection in chapter 6. 
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ANIMAL MODELS OF TB  
In the context of infectious diseases and more precisely TB, different animal models have been 
exploited to gain more insights into the pathogenesis, the pathophysiology and the response of the 
host to a microbial infection. Animal models are also necessary to test new vaccine candidates in 
terms of safety and protective efficacy, to help with assessing new antimicrobials and designing 
new therapies. Even if a given species used as a model is closely genetically related to Homo 
sapiens, it is important to remember that animals are not humans and observations made in animal 
models do not guarantee that identical events will happen in humans.41 I will present below some 
animal models with particular relevance to the subject of this thesis, that have proven to be useful 
for the understanding of TB pathogenesis and then focus on their application to drug development. 
The mouse model 
Mice are one of the most accessible mammalian species to study TB and provide a living, 
breathing, vertebrate lung with the capacity to perform a large variety of experiments. Major 
knowledge regarding the immune response to M. tuberculosis infection has been obtained with this 
model.42 Several routes of infection with the pathogen have been explored, including 
intraperitoneal or intravenous injection, intranasal or intratracheal instillation and aerosol exposure, 
the latter mimicking more realistically the natural route of infection by reproducibly delivering a 
suspension of bacteria into the lungs of the animals following inhalation.43 The susceptibility to TB 
varies among inbred mouse strains. For instance, C57BL/6J and BALB/c mice are more resistant to 
M. tuberculosis infection and will survive much longer than their CBA, C3HeB/FeJ, DBA/2 or 
129SvJ counterparts.44 The development of gene knockout mice allowed the importance and 
necessity of immune cell types or signaling molecules to be recognized. For example, mice with 
the gene for interferon-gamma (IFN-?) knocked out, mice lacking tumor necrosis factor alpha 
(TNF-?) receptor or granulocyte-macrophage colony-stimulating factor (GM-CSF) are much more 
susceptible to infection, demonstrating the important role of these cytokines in TB immunity.45–47 
Immunodeficient mice are obviously much more susceptible to TB than wild type BALB/c or 
C57BL/6J. For instance, infection of athymic BALB/c (nude) mice with M. tuberculosis underlined 
the importance of T-cells in host immune response.48 Severe combined immunodeficiency (SCID) 
mice carry the loss-of-function prkdcscid mutation, resulting in incomplete V(D)G recombination 
and inability for T- and B-cells to fully mature. SCID mice have therefore both impaired cellular 
and humoral immunity and are highly permissive to M. tuberculosis expansion. Indeed, while the 
bacterial burden in BALB/c plateaus around 106 – 107 colony forming units (CFUs)49, a higher 
bacterial load can be achieved in SCID animals. CB-17 SCID mice have been used for in vivo 
optical imaging of M. tuberculosis.50,51 Based on previous observations and in an effort to increase 
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the sensitivity of in vivo imaging, we introduce in this work SCID Hairless Outbred (SHO) mice 
for real-time monitoring of TB infection and drug assessment, by means of whole body imaging. 
The application of the mouse model of chronic TB infection to evaluate drug efficacy in vivo 
generally involves the resistant mouse strains BALB/c or C57BL/6J and the following scheme. 
Groups of mice are initially exposed to aerosolized M. tuberculosis and kept without treatment for 
one month, until the bacterial load reaches ~106 CFUs per lung. Treatment is then administered by 
oral gavage for different periods of time but typically for at least one month. Relapse experiments, 
to evaluate the efficacy and durability of drug treatments, last much longer and the treatment is in 
this case administered for up to six months and the animals are then held for several months to 
assess the frequency and extent of relapse. To assess the efficacy of a given treatment, mice are 
sacrificed at different time points, lungs are excised, homogenized and serial dilutions are plated on 
agar media for CFU enumeration. Note that it takes 4 weeks or so for M. tuberculosis colonies to 
form on agar plates. Overall, drug testing in mice requires extensive resources, large numbers of 
animals, is time-consuming, and the measurements are in general endpoints requiring the 
euthanasia of the animals. The implementation of in vivo optical imaging for rapid, real-time and 
longitudinal assessment of antibiotic efficacy with luminescent and fluorescent reporters is a major 
subject of this thesis, described and discussed in chapters 4 and 5. 
The zebrafish model 
As discussed above, human TB typically affects the lungs and upper respiratory tract. It seems 
therefore contradictory to use fish as a model for TB, as they do not have lungs and are furthermore 
cold-blooded, which may be a major disadvantage for M. tuberculosis infection (optimal growth at 
37°C).52 Despite these considerations, zebrafish (Danio rerio) prove to be excellent subjects to 
investigate the pathogenesis of several pathogens, as they possess both innate and adaptive 
immunity, and extensive homology with the human immune system.53 The zebrafish model of TB 
involves the opportunistic human pathogen Mycobacterium marinum, a close genetic relative to 
M. tuberculosis and a natural pathogen for fish with an optimal growth temperature around 30°C. 
Interestingly, systemic infection of zebrafish with M. marinum results in bacterial phagocytosis by 
macrophages and formation of granulomatous structures histologically similar to human 
granulomas caused by M. tuberculosis infection.54,55 Notably, zebrafish embryos solely rely on the 
innate immune system and larvae are optically clear, permitting real-time monitoring with 
microscopy.52,54 Both the bacteria and the host are genetically tractable, enabling the roles of 
different immune cells, macrophages and neutrophils for instance, to be readily observed.56–58 On 
the bacterial side, the role of several mycobacterial virulence factors have been understood by 
tracking mutant M. marinum upon zebrafish embryo infection.59–62 
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Beside the investigation of mycobacterial pathogenesis and virulence factors, M. marinum-infected 
zebrafish embryos have been used to assess the efficacy of new anti-mycobacterial 
compounds.33,63–65 The application of the M. marinum-zebrafish embryo infection model to the 
search for new anti-TB drugs can dramatically accelerate the drug development process. Indeed, 
drug testing in this model can be performed in vivo, over a short period (5 days) and with a 
medium/high throughput. This topic is discussed in chapter 6. 
Alternative animal models 
Non-human primates (NHP) are perhaps the most clinically relevant experimental animal model of 
tuberculosis. Cynomolgus and rhesus macaques share many anatomical and physiological features 
with humans, are highly susceptible to M. tuberculosis infection and recapitulate the full spectrum 
of pathological and clinical manifestation as seen in humans with TB.66 NHP models of TB have 
been reported for pathophysiological investigations, as well as for preclinical evaluation of 
vaccines and drugs.66 More recently, the use of the common marmoset for TB modeling has been 
reported, with the advantage of their smaller size compared to macaques,67 while experiments 
involving NHP remain extremely more expensive than experimentations involving rodents. 
Notably, PET/CT imaging has been successfully applied to NHP to assess bacterial loads, virulence 
and response to chemotherapy in the context of M. tuberculosis infection.68–70 PET/CT imaging 
typically utilizes 2-deoxy-2-[18F]fluoro-D-glucose (FDG) as contrast agent to map tuberculous 
lesions and this imaging technique, unlike optical imaging, is translatable to humans.25 
Guinea pigs are highly susceptible to M. tuberculosis infection and display some pathological 
features similar to humans, such as necrotic lesions in the lungs and disease dissemination, and 
have been used as experimental models of TB,71 while rabbits and rats have been much less 
reported.41 Finally, cattle are natural hosts of M. bovis and a general target and reservoir of bovine 
TB. Experimental infections and natural transmission studies (in the field) can be applied in this 
context to evaluate the efficacy of vaccines aimed at preventing TB propagation in cattle and such 
investigations may benefit for humans as well, thanks to the close genetic proximity of M. bovis 
and M. tuberculosis in the MTBC.41 
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IN VIVO IMAGING OF MYCOBACTERIAL INFECTIONS 
Various imaging modalities have been applied to visualize bacteria and monitor microbiological 
events, ranging from time-lapse microscopy to follow the growth of bacteria in microfluidic 
devices72 to PET/CT imaging of tuberculous lesions and response to anti-TB treatment in living 
humans.25 Obviously, the choice of the imaging technique depends on the subject being imaged. 
For instance, imaging of fluorescent mycobacteria in transparent zebrafish embryos can be 
performed with standard fluorescence microscopy (wide-field, confocal, light sheet, etc.) while 
monitoring bacterial infection in mice requires a larger setup enabling whole body imaging with 
high spatial and temporal precision. The depth of imaging is the major limitation for signal 
measurement, and detecting M. tuberculosis reporters deep in the lungs of an infected rodent 
appears more challenging than detecting a labeled subcutaneous tumor, for example. For small 
rodents such as mice, fluorescent and bioluminescent sources can generally be measured with 
optical imaging and a depth of penetration of 1-2 cm is achievable.73 Importantly, quantification of 
a photonic signal is highly desirable to precisely correlate with the number of bacteria in the lungs 
of an infected mouse. For bigger animals and humans, radiolabeled probes are necessary for deep 
tissue imaging (PET, single photon emission CT (SPECT)) and non-optical methods are generally 
applied (radiography, CT, magnetic resonance imaging (MRI)). The latter have virtually no depth 
of penetration limit but contrast has to be optimized to distinguish different structures of interest. 
Biophotonic imaging 
Biophotonic imaging is a technique enabling the detection of light emanating from an organism.74 
Light is defined here as an electromagnetic radiation, situated amongst a certain portion of the 
electromagnetic spectrum. The wavelength of visible light roughly ranges from 400 to 700 nm. 
Below 400 nm, the radiation is called ultraviolet and above 700 nm infrared. Light exists as 
photons, which are a type of elementary particles, carrying a defined amount of energy associated 
with the electromagnetic radiation. In vivo imaging systems permit to detect and collect light 
arising from a source within an animal, with highly sensitive detectors such as charge-coupled 
device (CCD) cameras. The procedure is noninvasive and the source of the signal can be spatially 
located and quantified, providing real-time and quantitative information. Notably, red-shifted 
wavelengths are best suited for in vivo biophotonic imaging, as red-shifted light is less subject to 
scattering and absorption by mammalian tissues. The possible sources of radiation for in vivo 
optical imaging are of two types, bioluminescence or fluorescence, and are discussed further below. 
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Bioluminescence imaging 
Bioluminescence is the emission of photons upon an enzymatic reaction catalyzed by a luciferase, 
involving the oxidation of a substrate (a luciferin) and generally requiring reduced flavin 
mononucleotide (FMNH2) or ATP as sources of energy, and Mg2+ and/or O2 as cofactors. This 
phenomenon is widespread in nature and genetic engineering enabled the generation of luciferase-
based reporter systems in eukaryotic cells and bacteria, for in vitro and in vivo applications. The 
luciferases from the firefly Photinus pyralis, the sea pansy Renilla reniformis, the copepod Gaussia 
princeps and various bacteria (Photorhabdus luminescens, Vibrio and Photobacterium sp.) 
represent the common luciferases used as reporter systems.74 More recently, the luciferase from the 
shrimp Oplophorus gracilirostris has been engineered (NanoLuc, commercialized by Promega) 
and highly efficient and ATP-independent bioluminescence has been reported.75 Further 
improvements have been initiated with the development of different synthetic imidazo[1,2?
?]pyrazines substrates, optimal for in vivo imaging.76 The firefly luciferase (FFluc) is known to 
produce one of the most efficient reactions77 and requires the exogenous addition of its substrate, 
D-luciferin, generally injected intraperitoneally in mice immediately before performing in vivo 
bioluminescence imaging. Notably, D-luciferin is not toxic for cells and mice.74 In contrast, the 
luxCDABE operon from P. luminescens, encoding a luciferase heterodimer (LuxAB) and the 
enzymes necessary for the biosynthesis of its substrate, has been successfully cloned in 
heterologous bacteria, thereby generating autobioluminescent systems.78 An optimized, red-shifted 
and thermostable firefly luciferase gene (fflucRT) has been cloned in M. tuberculosis and enabled 
in vivo quantification of the bacterial load in immunodeficient CB-17 SCID mice.51,79 The 
luxCDABE operon has been cloned in M. tuberculosis and applied as a marker of bacterial viability 
in vitro80 and for quantification of the bacterial burden in mice, although not by means of whole 
body imaging.81 Quantitative bioluminescence imaging of M. tuberculosis infection in vivo as a 
method to accelerate and refine anti-mycobacterial drug assessment will be discussed in chapter 5 
of this thesis. 
Fluorescence imaging 
Fluorescence takes place when a fluorescent compound is irradiated with light at a suitable 
wavelength. This triggers an electronic transition to the excited state and upon relaxation, a photon 
is emitted, giving rise to fluorescence.74 As vibrational energy is lost in the process, the emitted 
photon is of lower energy than the exciting light and its wavelength is therefore shifted to the red 
(Stokes shift). Fluorescence labelling, of mycobacteria for instance, can be performed with 
chemical probes attached to a fluorochrome moiety or via genetic engineering and expression of 
genes encoding fluorescent proteins. 
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Chemical dyes can be used to label a specific target such as a protein or tagged protein, or nucleic 
acids, acidic cellular compartments and lipophilic structures such as membranes. The advantage of 
this approach is that many fluorochromes are commercially available and can be easily chemically 
coupled to other molecules to generate specific probes. As an example, we designed several 
fluorophore-coupled benzothiazinones to visualize their covalent target, the essential enzyme 
DprE1.35 This enabled the polar and periplasmic localization of DprE1 to be highlighted on living, 
intact bacteria with fluorescence microscopy, as described in chapter 2. The further application of 
such probes to detect mycobacteria in vivo upon infection is discussed in chapter 3. 
Alternatively, fluorescent proteins can be used to generate bacterial reporters. In this case, the gene 
encoding a fluorescent protein is cloned and transformed in bacteria. As discussed above, red-
shifted light is more appropriate for in vivo imaging in rodents thanks to lower light scattering and 
absorption. Autofluorescence originating from animal tissues is also attenuated and the penetration 
of incident light is enhanced for red-shifted wavelengths. The wavelengths for fluorescence in vivo 
imaging are theoretically optimal in the near-infrared (NIR) range of the electromagnetic spectrum, 
i.e. above 700 nm. However, fluorescent protein variants derived from the well-known green 
fluorescent protein (GFP) from the jelly fish Aequorea victoria or the red fluorescent protein 
DsRed from the coral Discosoma sp. hardly reach such far-red-shifted spectral properties. 
Recently, a NIR fluorescent protein derived from a bacterial phytochrome and specifically 
engineered for in vivo imaging, was reported with a maximal emission at 713 nm.82 However, use 
of this protein, named iRFP, has never been reported for mycobacteria. We exploited iRFP for 
fluorescence in vivo imaging of TB infection in mice and zebrafish embryos, as described in 
chapter 4. 
Performing in vivo optical imaging in mouse models of TB infection 
To generate the data presented in this thesis, imaging of M. tuberculosis-infected mice was 
performed with a Photon Imager Optima (Biospace Lab, France) in vivo imaging platform, 
enabling both epi-fluorescence and luminescence imaging on the same system. This device consists 
of a light-tight chamber in which up to 10 mice are aligned on a heated (37°C) plate and 
maintained immobile through delivery of anesthetic gas (1-2% isoflurane). The detection system is 
composed of lenses to vary the field of view, optical cut-off filters to select the appropriate 
wavelength upon fluorescence imaging, and a cooled intensifier tube (photocathode) coupled to a 
charge-coupled device (iCCD) for signal collection. When the fluorescence modality is used, 
optical fibers guide the excitation light from a halogen lamp through optical filters to the sample 
being irradiated and “background” fluorescence, acquired with a lower excitation wavelength, is 
subsequently subtracted with spectral deconvolution algorithms. Image analysis with the M3 
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Vision software enabled the production of pictures superimposing black and white photographic 
images of the animals with the bioluminescent or fluorescent signal (overlaid in false colors to ease 
visualization) and the regional quantification of the biophotonic signal. The full system was 
operated in a biosafety level III (BSL3) animal facility. 
RATIONALE AND THESIS OUTLINE 
Since 1980, the HIV/AIDS epidemic and the emergence of MDR M. tuberculosis strains gave rise 
to a resurgence of TB incidence, mainly in low-income countries. In the absence of an effective 
vaccine, new and more powerful anti-tubercular agents are necessary to combat the global TB 
epidemic. Here, macozinone (PBTZ169) has proven to be a highly potent new antibiotic and has 
progressed through clinical trials since its discovery a few years ago.29,33 A particularity of the 
PBTZ169 molecule is the flexibility of the 2-substituent of the BTZ ring, enabling the linkage of 
different chemical groups without losing its specificity and bactericidal activity. We took 
advantage of this fact to attach different fluorochromes to a PBTZ moiety, thereby generating 
highly specific fluorescent probes that selectively target DprE1 and label BTZ-sensitive bacteria, as 
discussed in chapter 2. We subsequently assessed the capability of fluorescent BTZ probes to 
detect mycobacteria in vivo, for instance M. tuberculosis in mice and M. marinum in zebrafish 
embryos. This approach for imaging purposes is outlined in chapter 3. 
In vivo imaging of M. tuberculosis infection permits the bacterial load to be assessed in real time 
and measurements can be repeated on a single group of animals, typically mice, thus reducing the 
number required per experiment. This is strongly encouraged by the 3R policy (refine, reduce, 
replace) and favors the ethical suitability regarding the utilization of laboratory animals in this 
context. Besides reducing the absolute number of animals required, in vivo imaging enables the 
efficacy of new anti-TB candidate compounds to be assessed much faster, which is especially 
important given the slow growth rate of M. tuberculosis. This furthermore permits a substantial 
gain of time and resource saving, and favors the progression of new antibiotics down the pipeline 
and towards the clinic. We explored these possibilities by implementing in vivo optical imaging for 
assessment of drug activity in a mouse model of TB infection. The development of NIR fluorescent 
mycobacterial reporters and their application for in vivo imaging of TB in mice is explained in 
chapter 4. Alternatively, although following the very same motivation, the application of 
bioluminescent M. tuberculosis strains for longitudinal treatment follow up is described in 
chapter 5. 
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The mouse model of TB infection is an unavoidable stage to test the efficacy of antibiotics in vivo. 
Since 1990, zebrafish have however become attractive animal models for biomedical research, 
including TB pathogenesis and drug discovery. Following the general trend of this thesis aiming at 
improving the anti-TB drug discovery process, we implemented the zebrafish embryo model of 
mycobacterial infection and optimized drug efficacy assays with this organism for several classes 
of novel anti-mycobacterial compounds, as discussed in chapter 6. The implementation of the 
zebrafish embryo model in this context follows the 3R policy by replacing the standard mouse 
model by a substitute. 
In a nutshell, this thesis investigates alternatives to the standard techniques for in vivo assessment 
of anti-TB compounds, by implementing quantitative, longitudinal in vivo imaging with fluorescent 
BTZ-derived probes, NIR fluorescent and bioluminescent M. tuberculosis reporters, as well as the 
application of zebrafish embryos in order to accelerate and refine the anti-TB drug discovery and 
development process. 
  
General Introduction 
35 
REFERENCES 
1. WHO. Global tuberculosis report 2018 (World Health Organisation, Geneva, 2018). 
2. Koch, R. Die Ätiologie der Tuberkulose (1882) in Robert Koch. Klassische Texte der 
Wissenschaft (ed. Gradmann, C.) 113–131 (Springer Spektrum, Berlin, 2018).  
3. Hershkovitz, I. et al. Tuberculosis origin: the Neolithic scenario. Tuberculosis 95 Suppl 1, 
S122-126 (2015). 
4. Brosch, R. & Behr, M. Comparative genomics and evolution of Mycobacterium bovis BCG in 
Tuberculosis and the Tubercle Bacillus (eds. Cole, S. T., Eisenach Davis, K., McMurray, D. 
N. & Jacobs, Jr., W. R.) 155–164 (ASM Press, Washington, DC, 2005). 
5. Schatz, A., Bugle, E. & Waksman, S. A. Streptomycin, a substance exhibiting antibiotic 
activity against Gram-positive and Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 55, 66–
69 (1944). 
6. WHO. The End TB Strategy (World Health Organisation, Geneva, 2015). 
7. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete 
genome sequence. Nature 393, 537–544 (1998). 
8. Gagneux, S. Host–pathogen coevolution in human tuberculosis. Philos. Trans. R. Soc. B Biol. 
Sci. 367, 850–859 (2012). 
9. Koch, A. & Mizrahi, V. Mycobacterium tuberculosis. Trends Microbiol. 26, 555–556 (2018). 
10. Pai, M. et al. Tuberculosis. Nat. Rev. Dis. Primer 2, 16076 (2016). 
11. Russell, D. G. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. 
Immunol. Rev. 240, 252–268 (2011). 
12. Zumla, A., Raviglione, M., Hafner, R. & Fordham von Reyn, C. Tuberculosis. N. Engl. J. 
Med. 368, 745–755 (2013). 
13. Rivas-Garcia, A., Sarria-Estrada, S., Torrents-Odin, C., Casas-Gomila, L. & Franquet, E. 
Imaging findings of Pott’s disease. Eur. Spine J. 22, 567–578 (2013). 
General Introduction 
36 
14. WHO. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant 
tuberculosis (MDR/RR-TB) (World Health Organisation, Geneva, 2018). 
15. Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J. & Wang, X. Global tuberculosis drug 
development pipeline: the need and the reality. The Lancet 375, 2100–2109 (2010). 
16. Trunz, B. B., Fine, P. & Dye, C. Effect of BCG vaccination on childhood tuberculous 
meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-
effectiveness. The Lancet 367, 1173–1180 (2006). 
17. Zhu, B., Dockrell, H. M., Ottenhoff, T. H. M., Evans, T. G. & Zhang, Y. Tuberculosis 
vaccines: Opportunities and challenges. Respirology 23, 359–368 (2018). 
18. Spertini, F. et al. Safety of human immunisation with a live-attenuated Mycobacterium 
tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir. Med. 
3, 953–962 (2015). 
19. Gengenbacher, M., Nieuwenhuizen, N. & Kaufmann, S. BCG — old workhorse, new skills. 
Curr. Opin. Immunol. 47, 8–16 (2017). 
20. Daniel, T. M. The history of tuberculosis. Respir. Med. 100, 1862–1870 (2006). 
21. Pai, M. et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis 
infection. Clin. Microbiol. Rev. 27, 3–20 (2014). 
22. Kik, S. V., Denkinger, C. M., Chedore, P. & Pai, M. Replacing smear microscopy for the 
diagnosis of tuberculosis: what is the market potential? Eur. Respir. J. 43, 1793–1796 (2014). 
23. Steingart, K. R. et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin 
resistance in adults. Cochrane Database Syst. Rev. 1, CD009593 (2014). 
doi:10.1002/14651858.CD009593.pub3 
24. Pande, T., Pai, M., Khan, F. A. & Denkinger, C. M. Use of chest radiography in the 22 highest 
tuberculosis burden countries. Eur. Respir. J. 46, 1816–1819 (2015). 
25. Chen, R. Y. et al. PET/CT imaging correlates with treatment outcome in patients with 
multidrug-resistant tuberculosis. Sci. Transl. Med. 6, 265ra166 (2014). 
26. Lechartier, B., Rybniker, J., Zumla, A. & Cole, S. T. Tuberculosis drug discovery in the post-
post-genomic era. EMBO Mol. Med. 6, 158–168 (2014). 
General Introduction 
37 
27. Sala, C. & Hartkoorn, R. C. Tuberculosis drugs: new candidates and how to find more. Future 
Microbiol. 6, 617–633 (2011). 
28. Manjunatha, U. H. & Smith, P. W. Perspective: Challenges and opportunities in TB drug 
discovery from phenotypic screening. Bioorg. Med. Chem. 23, 5087–5097 (2015). 
29. Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan 
synthesis. Science 324, 801–804 (2009). 
30. Trefzer, C. et al. Benzothiazinones: prodrugs that covalently modify the 
decaprenylphosphoryl-?-D-ribose 2’-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. 
Chem. Soc. 132, 13663–13665 (2010). 
31. Trefzer, C. et al. Benzothiazinones are suicide inhibitors of mycobacterial 
decaprenylphosphoryl-?-D-ribofuranose 2’-oxidase DprE1. J. Am. Chem. Soc. 134, 912–915 
(2012). 
32. Foo, C. S.-Y. et al. Characterization of DprE1-mediated benzothiazinone resistance in 
Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 60, 6451–6459 (2016). 
33. Makarov, V. et al. Towards a new combination therapy for tuberculosis with next generation 
benzothiazinones. EMBO Mol. Med. 6, 372–383 (2014). 
34. Lechartier, B. & Cole, S. T. Mode of action of clofazimine and combination therapy with 
benzothiazinones against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59, 
4457–4463 (2015). 
35. Sommer, R. et al. Fluorescent benzothiazinone analogues efficiently and selectively label 
DprE1 in mycobacteria and actinobacteria. ACS Chem. Biol. 13, 3184–3192 (2018). 
36. Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium 
tuberculosis. Science 307, 223–227 (2005). 
37. Mahajan, R. Bedaquiline: First FDA-approved tuberculosis drug in 40 years. Int. J. Appl. 
Basic Med. Res. 3, 1–2 (2013). 
38. Dupont, C. et al. Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus and is 
effective in infected zebrafish. Antimicrob. Agents Chemother. 61, e01225-17 (2017). 
General Introduction 
38 
39. WHO Regional Office for South-East Asia. Guidelines for the diagnosis, treatment and 
prevention of leprosy. (World Health Organization, Regional Office for South-East Asia, 
2018). 
40. Van Deun, A. et al. Short, highly effective, and inexpensive standardized treatment of 
multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182, 684–692 (2010). 
41. Williams, A. & Orme, I. M. Animal models of tuberculosis: an overview in Tuberculosis and 
the Tubercle Bacillus, Second Edition (eds. Jacobs, Jr., William R., McShane, Helen, Mizrahi, 
Valerie and Orme, Ian M.) 131–142 (ASM Press, Washington, DC, 2017).  
42. Orme, I. M. & Ordway, D. J. Mouse and guinea pig models of tuberculosis in Tuberculosis 
and the Tubercle Bacillus, Second Edition (eds. Jacobs, Jr., William R., McShane, Helen, 
Mizrahi, Valerie and Orme, Ian M.) 143–162 (ASM Press, Washington, DC, 2017). 
43. Ordway, D. J. & Orme, I. M. Animal models of mycobacteria infection. Curr. Protoc. 
Immunol. 94, 19.5.1-19.5.50 (2011). 
44. Medina, E. & North, R. J. Resistance ranking of some common inbred mouse strains to 
Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype 
and Nramp1 genotype. Immunology 93, 270–274 (1998). 
45. Cooper, A. M. et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. 
Exp. Med. 178, 2243–2247 (1993). 
46. Flynn, J. L. et al. Tumor necrosis factor-alpha is required in the protective immune response 
against Mycobacterium tuberculosis in mice. Immunity 2, 561–572 (1995). 
47. Gonzalez-Juarrero, M. et al. Disruption of granulocyte macrophage-colony stimulating factor 
production in the lungs severely affects the ability of mice to control Mycobacterium 
tuberculosis infection. J. Leukoc. Biol. 77, 914–922 (2005). 
48. North, R. J. Importance of thymus-derived lymphocytes in cell-mediated immunity to 
infection. Cell. Immunol. 7, 166–176 (1973). 
49. Dharmadhikari, A. S. & Nardell, E. A. What animal models teach humans about tuberculosis. 
Am. J. Respir. Cell Mol. Biol. 39, 503–508 (2008). 
General Introduction 
39 
50. Zelmer, A. et al. A new in vivo model to test anti-tuberculosis drugs using fluorescence 
imaging. J. Antimicrob. Chemother. 67, 1948–1960 (2012). 
51. Andreu, N. et al. Rapid in vivo assessment of drug efficacy against Mycobacterium 
tuberculosis using an improved firefly luciferase. J. Antimicrob. Chemother. 68, 2118-2127 
(2013). 
52. van Leeuwen, L. M., van der Sar, A. M. & Bitter, W. Animal models of tuberculosis: 
zebrafish. Cold Spring Harb. Perspect. Med. 5, a018580 (2014). 
53. Renshaw, S. A. & Trede, N. S. A model 450 million years in the making: zebrafish and 
vertebrate immunity. Dis. Model. Mech. 5, 38–47 (2012). 
54. Davis, J. M. et al. Real-time visualization of mycobacterium-macrophage interactions leading 
to initiation of granuloma formation in zebrafish embryos. Immunity 17, 693–702 (2002). 
55. Ramakrishnan, L. Looking within the zebrafish to understand the tuberculous granuloma. Adv. 
Exp. Med. Biol. 783, 251–266 (2013). 
56. Clay, H. et al. Dichotomous role of the macrophage in early Mycobacterium marinum 
infection of the zebrafish. Cell Host Microbe 2, 29–39 (2007). 
57. Meijer, A. H. et al. Identification and real-time imaging of a myc-expressing neutrophil 
population involved in inflammation and mycobacterial granuloma formation in zebrafish. 
Dev. Comp. Immunol. 32, 36–49 (2008). 
58. Yang, C.-T. et al. Neutrophils exert protection in the early tuberculous granuloma by oxidative 
killing of mycobacteria phagocytosed from infected macrophages. Cell Host Microbe 12, 301–
312 (2012). 
59. Stoop, E. J. M. et al. Zebrafish embryo screen for mycobacterial genes involved in the 
initiation of granuloma formation reveals a newly identified ESX-1 component. Dis. Model. 
Mech. 4, 526–536 (2011). 
60. Phan, T. H. et al. EspH is a hypervirulence factor for Mycobacterium marinum and essential 
for the secretion of the ESX-1 substrates EspE and EspF. PLoS Pathog. 14, e1007247 (2018). 
General Introduction 
40 
61. Stoop, E. J. M. et al. Mannan core branching of lipo(arabino)mannan is required for 
mycobacterial virulence in the context of innate immunity. Cell. Microbiol. 15, 2093–2108 
(2013). 
62. van der Woude, A. D. et al. Analysis of SecA2-dependent substrates in Mycobacterium 
marinum identifies protein kinase G (PknG) as a virulence effector. Cell. Microbiol. 16, 280–
295 (2014). 
63. Takaki, K., Davis, J. M., Winglee, K. & Ramakrishnan, L. Evaluation of the pathogenesis and 
treatment of Mycobacterium marinum infection in zebrafish. Nat. Protoc. 8, 1114–1124 
(2013). 
64. Takaki, K., Cosma, C. L., Troll, M. A. & Ramakrishnan, L. An in vivo platform for rapid 
high-throughput antitubercular drug discovery. Cell Rep. 2, 175–184 (2012). 
65. Adams, K. N. et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-
induced efflux mechanism. Cell 145, 39–53 (2011). 
66. Peña, J. C. & Ho, W.-Z. Non-human primate models of tuberculosis in Tuberculosis and the 
Tubercle Bacillus, Second Edition (eds. Jacobs, Jr., William R., McShane, Helen, Mizrahi, 
Valerie and Orme, Ian M.) 163–176 (ASM Press, Washington, DC, 2017). 
67. Scanga, C. A. & Flynn, J. L. Modeling tuberculosis in nonhuman primates. Cold Spring Harb. 
Perspect. Med. 4, a018564 (2014). 
68. Via, L. E. et al. Differential virulence and disease progression following Mycobacterium 
tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect. Immun. 
81, 2909–2919 (2013). 
69. Lin, P. L. et al. Radiologic responses in cynomolgus macaques for assessing tuberculosis 
chemotherapy regimens. Antimicrob. Agents Chemother. 57, 4237–4244 (2013). 
70. Coleman, M. T. et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in 
macaques and humans with tuberculosis. Sci. Transl. Med. 6, 265ra167 (2014). 
71. McMurray, D. N., Collins, F. M., Dannenberg, A. M. & Smith, D. W. Pathogenesis of 
experimental tuberculosis in animal models in Tuberculosis (ed. Shinnick, T. M.) 157–179 
(Springer Spektrum, Berlin, 1996). 
General Introduction 
41 
72. Wakamoto, Y. et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science 339, 
91–95 (2013). 
73. Andreu, N., Elkington, P. T. & Wiles, S. Molecular imaging in TB: from the bench to the 
clinic in Understanding Tuberculosis - Global Experiences and Innovative Approaches to the 
Diagnosis (ed. Cardona, Pere-Joan). 307–332 (INTECH, 2012). doi:10.5772/30595 
74. Andreu, N., Zelmer, A. & Wiles, S. Noninvasive biophotonic imaging for studies of infectious 
disease. FEMS Microbiol. Rev. 35, 360–394 (2011). 
75. Hall, M. P. et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel 
imidazopyrazinone substrate. ACS Chem. Biol. 7, 1848–1857 (2012). 
76. Coutant, E. P. & Janin, Y. L. Synthetic routes to coelenterazine and other imidazo[1,2-
?]pyrazin-3-one luciferins: essential tools for bioluminescence-based investigations. Chem. 
Eur. J. 21, 17158–17171 (2015). 
77. Ando, Y. et al. Firefly bioluminescence quantum yield and colour change by pH-sensitive 
green emission. Nat. Photonics 2, 44–47 (2008). 
78. Craney, A. et al. A synthetic luxCDABE gene cluster optimized for expression in high-GC 
bacteria. Nucleic Acids Res. 35, e46 (2007). 
79. Andreu, N. et al. Optimisation of bioluminescent reporters for use with mycobacteria. Plos 
One 5, e10777 (2010). 
80. Sharma, S. et al. Simple and rapid method to determine antimycobacterial potency of 
compounds by using autoluminescent Mycobacterium tuberculosis. Antimicrob. Agents 
Chemother. 58, 5801–5808 (2014). 
81. Zhang, T., Li, S.-Y. & Nuermberger, E. L. Autoluminescent Mycobacterium tuberculosis for 
rapid, real-time, non-invasive assessment of drug and vaccine efficacy. Plos One 7, e29774 
(2012). 
82. Filonov, G. S. et al. Bright and stable near-infrared fluorescent protein for in vivo imaging. 
Nat. Biotechnol. 29, 757–761 (2011). 
 

 43 
PART I FLUORESCENT BENZOTHIAZINONES 
FLUORESCENT 
BENZOTHIAZINONES 
 

 45 
Chapter 2. Fluorescent Benzothiazinones to Label DprE1  
Fluorescent Benzothiazinone Analogues 
Efficiently and Selectively Label DprE1 
in Mycobacteria and Actinobacteria 
 
 
 
This chapter is a post-print version of an article published in ACS Chemical Biology as: 
Sommer, R., Neres, J., Piton, J., Dhar, N., van der Sar, A., Mukherjee, R., Laroche, T., Dyson, P. 
J., McKinney, J. D., Bitter, W., Makarov, V., and Cole, S. T. Fluorescent Benzothiazinone 
Analogues Efficiently and Selectively Label DprE1 in Mycobacteria and Actinobacteria. 
ACS Chem. Biol. 13, 3184–92 (2018). DOI: 10.1021/acschembio.8b00790 
Contributions: optimization of staining procedures on live bacteria, microscopy (wide field, high 
resolution, super-resolution), image analysis and figure construction, MICs, generation of BTZ-
resistant mutants, in vivo staining on infected zebrafish embryos and mice (unpublished data).
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ABSTRACT 
Benzothiazinones (BTZ) are highly potent bactericidal inhibitors of mycobacteria and the lead 
compound, BTZ043, and the optimized drug candidate, PBTZ169, have potential for the treatment 
of tuberculosis. Here, we exploited the tractability of the BTZ scaffold by attaching a range of 
fluorophores to the 2-substituent of the BTZ ring via short linkers. We show by means of 
fluorescence imaging that the most advanced derivative, JN108, is capable of efficiently labeling 
its target, the essential flavoenzyme DprE1, both in cell-free extracts and after purification as well 
as in growing cells of different actinobacterial species. DprE1 displays a polar localization in 
Mycobacterium tuberculosis, M. marinum, M. smegmatis, and Nocardia farcinica but not in 
Corynebacterium glutamicum. Finally, mutation of the cysteine residue in DprE1 in these species, 
to which BTZ covalently binds, abolishes completely the interaction with JN108, thereby 
highlighting the specificity of this fluorescent probe. 
INTRODUCTION 
Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis, has reemerged in 
recent decades as an important global health problem and was responsible for 1.8 million deaths in 
2015.1,2 The main reasons for this alarming situation are the appearance of multidrug-resistant 
(MDR-TB) and extensively drug-resistant (XDR-TB) strains with high mortality rates, the synergy 
with the HIV/AIDS pandemic, and increased poverty.2?4 The fruits of substantially increased 
investment in the research on novel anti-TB drugs in the past decade led to replenishment of the 
drug discovery pipeline with drug candidates in different stages of development.5,6 Among these 
novel, promising anti-TB drugs are the 8-nitro-benzothiazinones (BTZs) BTZ043 with an MIC99 of 
1 ng/mL (Figure 1) and PBTZ169, an improved BTZ analogue with an even lower MIC99 against 
M. tuberculosis (0.3 ng/mL) and improved solubility, which is currently in clinical trials.7,8 The 
BTZs are among the most potent antitubercular agents known to date and act by inhibiting the 
enzyme decaprenyl-phospho-?-D-ribose oxidase (DprE1), which is one of the most attractive 
targets for anti-TB drug discovery.8,9 DprE1 and DprE2 (decaprenylphosphoryl-D-2-keto erythro 
pentose reductase) catalyze the epimerization of decaprenylphosphoryl-?-D-ribose (DPR) to its 
arabinose isomer DPA. DPA is the sole donor of arabinose sugars that are essential for cell wall 
biosynthesis in M. tuberculosis.10 
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Figure 1. Structures of BTZ043, PBTZ169 and BTZ-TAMRA. 
 
BTZs are suicide inhibitors of DprE1, selectively forming irreversible covalent adducts with 
Cys387 in the active site of this enzyme, as previously demonstrated by biochemical and structural 
methods.11,12 A nitroso species is produced by nitroreduction, and this reacts with the thiol side 
chain of Cys387 to form a semimercaptal covalent adduct with DprE1. The nitro group of the BTZs 
is crucial for their mechanism of inhibition, as its replacement by amine, hydroxylamine, pyrrole, 
or many other functional groups invariably led to near complete loss of antimycobacterial 
activity.8,12,13 
We recently showed that a fluorescently labeled BTZ analogue (BTZ-TAMRA, Figure 1) retained 
modest antimycobacterial activity (MIC99 = 6 ?g/mL) and selectively labeled the poles of 
M. tuberculosis in vitro as observed by fluorescence microscopy, pointing to a polar localization of 
DprE1 in mycobacteria.11 Given these results, we investigated the SAR of the fluorescently labeled 
BTZs further to improve their antimycobacterial activity and explore their potential as imaging 
agents for in vitro and in vivo studies with actinobacteria. Here, we report the development of a 
highly active and selective fluorescent BTZ analogue that covalently labels DprE1 and its 
application for imaging purposes. We exploited its properties to visualize the subcellular 
localization of DprE1 in several BTZ-sensitive actinobacteria and track the behavior of 
mycobacteria in time-lapse fluorescence microscopy. 
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RESULTS AND DISCUSSION 
Design and Synthesis of Fluorescent BTZ Analogues 
The first fluorescent BTZ synthesized, BTZ-TAMRA, showed a promising MIC99 of 6 ?g/mL 
against M. tuberculosis11 and was used as a starting point for further optimization. Previously 
reported SAR studies on the BTZ and PBTZ series of DprE1 inhibitors showed that when the 8-
nitro-6-trifluoromethylbenzothiazinone core was conserved, the moiety on position 2 could 
accommodate a range of substituents retaining or even improving the MIC99 against 
M. tuberculosis.7,8,14,15 The crystal structures of DprE1 in complex with BTZ043 and PBTZ169 
provided further insight into the SAR results, as the BTZ core is located inside the active site 
forming a covalent bond with Cys387, but the 2-substituent of the BTZ ring is on the protein 
surface and makes few interactions with DprE1 residues.7,11 This explains how the presence of a tri-
PEG linker between the BTZ core and the bulky fluorophore in BTZ-TAMRA provided enough 
space to allow correct binding. 
We designed six new fluorescent BTZ and PBTZ analogues testing different fluorophores and 
spacers. The synthesis of the required tri-PEG and octyl linkers was performed through the 
synthetic route shown in Scheme 1, following published procedures. 2-(2-(2-
Chloroethoxy)ethoxy)ethanol or 8-chlorooctan-1-ol (3) were converted to the respective azides, 
which were reduced with triphenylphosphine to the respective amines. The amines were Boc-
protected and the respective alcohol groups converted to the bromides 1 and 6. The Boc-protected 
linkers were then reacted with piperazine forming the required Boc-protected piperazine-linkers 2 
and 8 for subsequent coupling to form the PBTZ-linker molecules. In addition, the Boc-protected 
8-bromo-octylamine 6 was converted to Boc-protected 8-amino-octylamine 7 to synthesize the 
alkyl linker version of BTZ-TAMRA. 
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Scheme 1. Synthesis of linkers. (a) Piperazine, EtOH, 60 °C, NaN3; (b) DMF, 100 °C; (c) (1) 
PPh3, H2O, THF, rt, (2) Boc2O, NaOH, ACN, H2O; (d) CBr4, K2CO3, PPh3, DCM, rt; (e) NH3, 
H2O, DME, 75 °C. 
 
 
Scheme 2. Synthesis of fluorescent BTZ analogues. (a) 5-Carboxyfluorescein NHS ester, 
DIPEA, DMF, rt; (b) compound 7, EtOH, 50 °C; (c) TFA, DCF, rt; (d) 5-carboxy-TAMRA 
NHS ester, DIPEA, DMF, rt; (e) compound 5, EtOH, 50 °C; (f) BODIPY-FL NHS ester, 
DIPEA, DMF, rt; (g) compound 8, EtOH, 50 °C; (h) NH4Cl, NaHS, EtOH, H2O, rt. 
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The fluorescein analogue of BTZ-TAMRA was synthesized from intermediate 9 (previously 
described11) by coupling with the NHS ester of 5-carboxyfluorescein, affording JN23 (Scheme 2). 
The synthesis of the remaining analogues was started by coupling the key 3-methylthio-
benzothiazinone intermediate 1016 with each of the linkers described above, providing the Boc-
protected intermediates 11, 12 and 13. Boc hydrolysis, followed by coupling with the desired 
fluorophore NHS esters in the presence of diisopropylethylamine, afforded the final compounds 
JN96, JN62, JN94, and JN108. To obtain the 8-amine version of JN108, the 8-nitro group of 
intermediate 13 was reduced using sodium hydrosulfite to give compound 14, which was then 
subjected to Boc hydrolysis and coupling with the NHS ester of 5-carboxy-TAMRA, to afford 
JN105. The propyl-TAMRA control compound JN111 was prepared by coupling n-propylamine 
with the NHS ester of 5-carboxy-TAMRA. 
Antimycobacterial Activity of Novel Fluorescent BTZs 
The antimycobacterial potency of the various fluorescent BTZ analogues synthesized was 
evaluated using the standard REMA assay (Table 1). The data show that fluorescein-labeled JN23 
was inactive against both M. tuberculosis and M. smegmatis, in contrast to its TAMRA-labeled 
BTZ-TAMRA analogue. Therefore, further SAR was mostly focused on TAMRA-labeled 
analogues. A BTZ-TAMRA analogue with a hydrophobic octyl linker (JN96), prepared to assess 
the influence of the spacer hydrophobicity on the antimycobacterial activity, presented a 
M. tuberculosis MIC99 25-fold lower than that of BTZ-TAMRA. Similarly, the compound JN108 
with an octyl linker between a PBTZ core and TAMRA had an MIC99 against M. tuberculosis 400-
fold lower than JN62, the PBTZ analogue with a tri-PEG linker. JN108 also presented an MIC99 
fourfold lower than its simpler BTZ analogue JN96. The smaller BODIPY-FL fluorophore was 
also evaluated in compound JN94 and led to a fourfold improvement in potency when compared to 
its TAMRA analogue JN62. Compound JN105, an 8-amino version of the PBTZ-TAMRA 
compound JN108, was 100-fold less potent (MIC99 6.2 ?g/mL) than the latter, as expected (Table 
1). Compounds JN105, the inactive NH2-derivative of JN108, and JN111, a propyl-TAMRA 
analogue inactive against mycobacteria, were synthesized for use as negative controls to assess the 
possible effect of nonspecific binding. From the SAR studies, JN108 was the best fluorescently 
labeled BTZ analogue, and this was confirmed in further work, described below. 
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MIC99 (?g/mL) 
M. tuberculosis 
H37Rv 
M. smegmatis 
mc2155 
M. marinum 
E11 
BTZ-TAMRA 6.2 50 ND 
JN23 >50 >50 40 
JN62 25 >50 >50 
JN94 6.2 6.2 ND 
JN96 0.25 0.75 3.5 
JN108 0.06 0.08 0.1 
JN105 6.2 12.5 >25 
JN111 >50 >50 ND 
 
Table 1. Minimum inhibitory concentrations of fluorescent BTZs against mycobacteria. 
ND: not determined. 
 
In vitro Labeling of Recombinant DprE1 
Our previous study reported successful covalent labeling of recombinant M. smegmatis DprE1 by a 
BODIPY-X labeled BTZ.12 Using a similar strategy, we tested the new fluorescent BTZs 
synthesized here for their ability to label recombinant M. tuberculosis DprE1, produced as 
described elsewhere,17 and analyzed the reaction products by SDS-PAGE and fluorescence 
scanning. Both the fluorescein- and TAMRA-labeled BTZ analogues bound to DprE1 irrespective 
of the linker used in their construction. All the nitro-BTZ fluorescent derivatives (JN23, JN94, 
JN29, JN62, JN96, and JN108) bound strongly to purified DprE1 (Figure 2). JN29, JN62, JN96, 
and JN108 were detected in the TAMRA channel, whereas JN23 and JN94 were detected in the 
fluorescein channel. The noncovalent fluorescent BTZ derivative, JN105, with an amino instead of 
the nitro group, bound much less strongly, as did JN111, a propyl-TAMRA derivative lacking the 
BTZ pharmacophore. Similarly, very weak labeling was seen when DprE1 was inactivated by 
heating for 10 min at 95 °C before adding JN108 to the reaction, most likely due to nonspecific 
binding. Likewise, labeling was abolished when the reducing agent DTT was included. These 
findings are consistent with the known mechanism of action of the BTZ12,18 and suggest that the 
lack of antimycobacterial activity of several derivatives, such as JN62, may be due to its inability 
to reach DprE1 in the periplasm.19 
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Figure 2. Labeling purified DprE1 with different fluorescent BTZ derivatives. The reactions 
were performed as outlined in the Methods section and contained recombinant wild-type (WT) 
DprE1, boiled DprE1, DTT, and the fluorescent BTZ derivatives indicated at top. After SDS-
PAGE electrophoresis, the gels were Coomassie blue stained (top panel), scanned using the 
TAMRA channel (excitation 523 nm/emission 580 nm, middle panel) of the Typhoon scanner, 
or scanned in the fluorescein channel (excitation 488 nm/emission 520 nm, lower panel). The 
size of the bands is about 50 kDa. 
 
Labeling of DprE1 in M. tuberculosis Cell-Free Extracts 
To further investigate the interaction of JN108 with its target DprE1 and to assess the extent of 
binding to other proteins in M. tuberculosis, JN108 was incubated with cell-free extracts and then 
analyzed by SDS-PAGE and fluorescence scanning. Because DprE1 is not an abundant protein, in 
most but not all cases the extracts were supplemented with purified DprE1 or with its variants, in 
which Cys387 had been replaced by Ser or Gly.20 As can be seen from Figure 3, in addition to 
DprE1, JN108 only labeled two highly M. tuberculosis abundant proteins with apparent molecular 
weights of 60 and 15 kDa. The 15 kDa band was identified by mass spectrometry as GroES. The 
signal strength of the target-specific labeling was proportional to the amount of DprE1 present, and 
the enzyme could be detected at 0.5 ?M but not at 0.1 ?M. No labeling occurred when BTZ-
resistant DprE1 variants were used bearing C387S or C387G substitutions and, again, this is 
consistent with the mechanism of action of BTZ and with prior findings.7,8,11,20 
Exploring Human Hepatocyte Extracts 
To establish whether JN108 could label any human proteins the compound was incubated with an 
extract of the human hepatocyte cell line HepG2 supplemented with or without DprE1. From 
Figure 3 it is apparent that no labeling of human proteins was observed whereas DprE1 was once 
again detectable at the 0.5 ?M level. The combined results indicate that if off-target covalent 
labeling of human proteins occurs it must be below the limit of detection of this assay. 
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Figure 3. Labeling cell-free extracts of M. tuberculosis (a, b) or HepG2 (c, d) cells with 
JN108. The reactions were performed as outlined in the Methods section and contained JN108, 
JN111, or the DprE1 enzymes, as indicated at top. After SDS-PAGE electrophoresis the gels 
were (a, c) Coomassie blue stained and (b, d) scanned using the TAMRA channel. 
 
Single Cell Analysis and Labeling of Living Mycobacteria 
To visualize the effect and specificity of fluorescently labeled BTZ-derivatives on mycobacteria in 
real time, M. smegmatis cells constitutively expressing GFP were grown in a microfluidic device 
and monitored using time-lapse microscopy.21 The culture medium was supplemented with either 
700 ng/mL JN108 or its inactive NH2-derivative (JN105, 700 ng/mL), and the results were 
compared. When JN105 was used, no growth inhibition was observed, and all bacterial cells were 
weakly stained on the surface although the stain could be removed by flowing JN105-free 7H9 
medium through the device (Supplementary Figure 1a and Supplementary Movie 2). By contrast, 
when JN108 was employed growth ceased within a few hours of exposure, and polar localization 
of the fluorophore was clearly visible in most of the cells (Supplementary Figure 1a and 
Supplementary Movie 1). On continuing exposure to JN108, some cells started to lyse (indicated 
by loss of GFP signal), and some cells started leaking cellular material, which was also stained with 
the fluorophore. 
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Similar staining was also performed using M. tuberculosis cells constitutively expressing GFP 
protein. Bacteria that were grown in a microfluidic device were exposed to either JN105 or JN108 
(400 ng/mL), and staining was monitored by time-lapse microscopy. As was seen in the case of 
M. smegmatis, the active derivative, JN108, exhibited clear polar localization with a large fraction 
of the cells subsequently lysing (Supplementary Figure 1b and Supplementary Movie 3). In 
contrast, when exposed to JN105, most of the cells exhibited faint staining of the whole cell 
surface, which was probably indicative of nonspecific binding (Supplementary Figure 1b). 
Subcellular Localization of DprE1 
The Wag31-GFP fusion protein is an additional independent marker for the poles of 
M. smegmatis.22 When JN108 was used to stain DprE1 in this bacterium, strong colocalization of 
the GFP and TAMRA signals could be observed at the poles using high-resolution microscopy 
(Supplementary Figure 2). When the Rv3789-GFP fusion protein23 was used to label the plasma 
membrane of M. smegmatis or M. marinum, JN108 also displayed bright foci at the poles of the 
bacilli and beyond the GFP-labeled membrane, indicating that the localization of DprE1 is similar 
in M. smegmatis and M. marinum (Figures 4a and b, Supplementary Figure 3a). Structured 
illumination microscopy (SIM) with JN108-stained M. smegmatis confirmed these previous 
observations at the super-resolution level (Figures 4a and b). 
 
Figure 4. SIM imaging of M. smegmatis producing Rv3789-GFP (membrane, green channel) 
stained with JN108 (red channel). (a) BTZ-sensitive bacteria stained with JN108 show bright 
spots at their tips in the red channel. (b) Magnification of the tip on a single cell from panel a 
showing JN108-stained DprE1 beyond the membrane. (c) BTZ-resistant bacteria bearing a 
C394S mutation in DprE1 display only background staining when exposed to JN108, but no 
polar foci are observed. Scale bars: 5 ?m in panels a and c, 500 nm in panel b. 
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Labeling Other Actinobacteria 
Many actinobacteria are susceptible to BTZ, including certain species of the genera 
Corynebacterium and Nocardia.8,24 This prompted us to investigate whether DprE1 could also be 
localized with JN108 at the poles of species from these genera. The MIC99 of N. farcinica for 
JN108 was evaluated at 0.01 ?g/mL by standard REMA techniques, confirming its general 
susceptibility to benzothiazinones. On staining N. farcinica with JN108 bright foci were visible at 
the poles of the cells and at the branching points, which are characteristic of Nocardia spp., thereby 
suggesting that DprE1 plays a role during tip extension not only at the poles of bacilli but also at 
budding locations in branching bacteria (Figure 5a). 
The MIC99 of C. glutamicum for JN108 was found to be 1.1 ?g/mL. A mixture of M. smegmatis 
expressing a GFP-labeled membrane protein23 and C. glutamicum was incubated with JN108 and 
examined by wide field fluorescence microscopy. In this experiment, polar labeling of 
M. smegmatis was seen, as expected, but C. glutamicum cells appeared to be uniformly labeled 
suggesting that, unlike mycobacteria, DprE1 is not located at the poles (Figure 5b). To determine 
whether this result was a general property of Corynebacteria spp., we repeated the experiment 
using Corynebacterium diphtheriae and again observed that JN108 stained cells uniformly (data 
not shown). Thus, for Mycobacterium and Nocardia spp. but not for Corynebacterium spp., the 
localization of DprE1 indicated by JN108 staining coincides with the sites of cell wall synthesis, as 
can be observed by nascent peptidoglycan staining (Supplementary Figure 4). Interestingly, when 
JN108 staining was performed on nonreplicating, streptomycin-starved M. tuberculosis 18b 
(SS18b), a model system for latent TB,25,26 polar labeling could still be observed (Supplementary 
Figure 5). Since SS18b is not susceptible to BTZ, nor to other mycobacterial cell wall inhibitors, 
this suggests that JN108 can still interact with its target, DprE1, in nonreplicating cells and that in 
growing mycobacteria the bactericidal effect follows this interaction. 
Figure 5. Labeling whole cells of N. farcinica, 
M. smegmatis, and C. glutamicum with JN108. (a) 
Staining of N. farcinica with JN108 localizes 
DprE1 at the poles of the cells and at nascent 
branching points. Top panel, TAMRA channel 
fluorescence image of JN108-labeled N. farcinica. 
Middle panel, corresponding phase contrast image. 
Lower panel, merged channels. Arrows indicate 
the polar localization of the TAMRA signal, and 
the arrowheads show foci at nascent branching 
points. (b) Staining of a mixture of M. smegmatis 
and C. glutamicum with JN108. The top panel 
shows the fluorescence image, and the lower panel 
is the corresponding phase contrast micrograph. Arrows indicate polar localization of DprE1 
in M. smegmatis expressing GFP-labeled membrane protein Rv3789, whereas no such polar 
labeling was seen with C. glutamicum. Scale bars: 5 ?m. 
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BTZ-Resistant Bacteria Do Not Display Polar Labeling 
The mechanism of action of BTZ and PBTZ involves the covalent binding of the drug to a 
conserved cysteine in the substrate-binding site of DprE1.11,12 In vitro, mutated versions of the 
enzyme were not labeled by JN108 (Figure 3), and we sought to validate that the same happens 
when staining living bacteria. BTZ-resistant mutants of M. tuberculosis and M. smegmatis were 
previously described.8 Spontaneous BTZ-resistant mutants of M. marinum and N. farcinica were 
selected on 7H10 medium containing 300 ng/mL or 1 ?g/mL PBTZ169, respectively. The presence 
of the mutations C389S and C419S in DprE1 were confirmed by PCR sequencing of mmar5352 
and nfa1970, the dprE1 orthologues in M. marinum and N. farcinica, respectively. MICs for 
PBTZ169 were >1000 and >10?000 ng/mL for resistant M. marinum and N. farcinica, respectively, 
while the BTZ-sensitive parent strains had MICs of 0.3 and 0.6 ng/mL. As expected, JN108 
staining of the BTZ-resistant N. farcinica did not display polar localization but only a faint 
background (Figure 6). Similarly, BTZ-resistant M. smegmatis (Figure 4c), M. marinum 
(Supplementary Figure 3b), and M. tuberculosis (Supplementary Figure 6) do not display polar 
foci, unlike their wild-type counterparts. This confirms that labeling by JN108 in all the tested 
actinobacterial species is highly specific for DprE1 and follows the same mode of action as 
benzothiazinone-based antimycobacterials. 
 
 
Figure 6. Labeling N. farcinica carrying Rv3789-mNeonGreen as a membrane marker. (a) 
BTZ-sensitive bacteria show polar DprE1 labeling (arrows). (b) BTZ-resistant bacteria do not 
display polar labeling but only faint background staining. The left panel shows fluorescence in 
the green channel (membrane); the middle panel shows red fluorescence (JN108), and the right 
panel is a merge of the green and red channels. Scale bars: 5 ?m. 
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CONCLUDING REMARKS 
Here, we exploited the tractability of the 2-substituent of the BTZ and PBTZ scaffolds to attach a 
range of fluorophores via an alkyl linker, thereby creating tool compounds for detecting 
mycobacteria in different settings. We demonstrate that the most advanced derivative, JN108, 
which is TAMRA-labeled, retains significant antimycobacterial activity and can efficiently label its 
target DprE1 in vitro and at the poles of live mycobacteria in culture. The high specificity of JN108 
is confirmed by the absence of labeling on BTZ-resistant mutant bacteria carrying Cys ? Ser 
mutation in DprE1. This exciting result shows the potential of fluorescent PBTZ analogues to 
detect mycobacteria in more complex settings, such as for in vivo imaging. We are currently 
exploring these avenues with JN108 in the zebrafish model of mycobacterial infection and plan to 
evaluate additional JN108 analogues with near-infrared range (NIR) fluorophores for their ability 
to detect M. tuberculosis in infected mice by in vivo imaging techniques. Although BTZ-derived 
probes display weak bactericidal activity on BTZ-sensitive bacteria that might limit precise 
quantitative applications, they nonetheless have the potential to detect M. tuberculosis in infected 
tissues or in sputum samples. 
METHODS 
Chemistry: General Methods and Materials 
All commercial reagents (Sigma-Aldrich, Acros, Alfa-Aesar) were used as provided. All reactions 
were performed under an inert atmosphere of dry N2 in oven-dried (150 °C) glassware. Column 
chromatography was performed with a Varian 971-FP Flash purification system with prepacked 
silica gel cartridges supplied by Luknova, with the indicated solvent system. 1H and 13C NMR 
spectra were recorded on Bruker Avance 400 MHz spectrometer. 1H chemical shifts are reported in 
ppm from an internal standard of residual chloroform (7.26 ppm) or methanol (3.31 ppm), and 13C 
chemical shifts are reported using an internal standard of residual chloroform (77.1 ppm), or 
methanol (49.0 ppm). Proton chemical data are reported as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, m = multiplet, br = broad), coupling constant, and integration. High-
resolution mass spectra were obtained on a Waters Q-TOF Ultima instrument equipped with an ESI 
interface. Details of the synthetic routes used to produce the compounds outlined in Schemes 1 and 
2 are given in the Supporting Information. 
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Bacterial Strains, Cell Lines, Cell Extracts, and Culture Conditions 
All mycobacterial strains, BTZ-resistant mycobacterial mutants, and M. tuberculosis strain H37Rv 
were grown at 37 °C with shaking in Middlebrook 7H9 (Difco) broth supplemented with 10% 
albumin–dextrose–catalase (ADC) enrichment, 0.2% glycerol, and 0.05% Tween 80. M. marinum 
strains E11 and M were grown in the same medium at 30 °C. C. glutamicum (ATCC13032) and 
N. farcinica (ATCC3318) were grown in brain–heart infusion medium (Difco) at 30 °C. Plasmids 
based on mNeonGreen27,28 were constructed by PCR amplification and subcloning in appropriate 
vectors. DNA was transformed in competent bacteria by electroporation. To prepare proteins, 
H37Rv was grown and processed as described previously.29 Briefly, cell lysates were prepared by 
resuspending cell pellets in lysis buffer (PBS containing Roche protease inhibitor cocktail tablets), 
bead-beating with 100 ?m glass beads, and were then clarified by centrifugation. The human 
hepatocyte cell line HepG2 was grown in DMEM medium supplemented with fetal bovine serum 
(heat inactivated). After trypsin–EDTA treatment, ?108 cells were lysed by bead-beating, and the 
extract was clarified by centrifugation. Protein concentrations were determined using the 
bicinchoninic acid (BCA) assay (Pierce BCA protein assay kit; Thermo Scientific). 
Drug Susceptibility Testing 
The in vitro activities against bacterial strains were measured by the resazurin reduction microplate 
assay (REMA) by performing 2× serial dilutions of compounds in the working bacterial culture in 
96-well plates (100 ?L final volume). Bacterial viability was determined by adding sterile resazurin 
(10 ?L, 0.025% w/v), incubating, and measuring resazurin turnover by fluorescence (excitation 
560 nm/emission 590 nm) using a TECAN Infinite M200 microplate reader. For M. marinum, the 
strains carried an integrative plasmid containing the Lux operon encoding luciferase,30 and cell 
viability was evaluated by measuring luminescence after 3 days of exposure to the drug. 
Fluorescent Labeling of Purified DprE1 
Purified M. tuberculosis DprE1 (5 ?M) was incubated at 30 °C for 2 h with different fluorescent 
compounds (10 ?M), farnesyl-phosphoryl-?-D-ribofuranose (FPR; 200 ?M), and FAD (5 ?M) in 
enzyme assay buffer (50 mM glycylglycine pH 8.0, 200 mM potassium glutamate, 0.002% Brij-35) 
in a final volume of 20 ?L. Reactions were stopped by addition of SDS-PAGE buffer without 
reducing agent and heating 5 min at 95 °C before loading on an SDS-PAGE gel. After 
electrophoresis, gels were scanned using a GE Typhoon Trio scanner, and fluorescence was 
measured in the fluorescein channel for JN23 and JN94 (excitation 488 nm/emission 520 nm) or 
TAMRA channel for JN29, JN62, JN96, JN108, JN105, and JN111 (excitation 523 nm/emission 
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580 nm). Finally, gels were stained with Coomassie blue. To denature DprE1, the purified enzyme 
was heated at 95 °C for 10 min before adding JN108 to the reaction. 
Labeling of Cell-Free Extracts of M. tuberculosis or Hepatocytes 
Cell-free extracts of M. tuberculosis and HepG2 cells were prepared by bead-beating as described 
above. Proteins (68 ?g) from cell-free extracts were added to the reaction mixture containing FPR 
(200 ?M), FAD (5 ?M), glycylglycine (50 mM pH 8.0), potassium glutamate (200 mM), and Brij-
35 (0.002%) in a final volume of 20 ?L. Reactions were stopped, and proteins were processed for 
fluorescence scanning as outlined above. In some cases, purified recombinant M. tuberculosis 
DprE1 was added to the protein extracts as a positive control for labeling. 
Time-Lapse Imaging 
Time-lapse microscopy of bacteria was carried out as described before.21,31 Briefly, bacteria from 
exponentially growing cultures of M. smegmatis or M. tuberculosis were implanted in a custom-
fabricated microfluidic device,31 and imaging was carried out using a 100× objective (Olympus 
UPLFL 100× PH, 1.3 NA) on a personal DV microscope system (GE Healthcare Life Sciences). 
Images were acquired every 15 min (M. smegmatis) or every 60 min (M. tuberculosis) on the FITC 
(excitation 490/20, emission 528/38), RD-TR-PE (excitation 542/27, emission 585/29), and phase 
channels. Complete 7H9 medium with or without the fluorophores (JN108 or JN105, 400 ng/mL 
for M. tuberculosis, 700 ng/mL for M. smegmatis) was pumped through the device at a flow rate of 
15–20 ?L/min. The images were subsequently processed and analyzed using Deltavision SoftWorx 
4.1 (GE Healthcare Life Sciences) and ImageJ v 1.47a (http://rsb.info.nih.gov/ij/). 
Subcellular Localization of DprE1 
To visualize JN108 labeling at the subcellular level, the bacteria were incubated with 8 ?M JN108 
in complete 7H9 medium, washed twice with PBS containing 0.05% Tween-80, resuspended, 
adsorbed on an agarose pad, and covered by a glass coverslip. The specimen was then observed 
with an Olympus IX81 inverted microscope or an LSM 700 inverted confocal microscope (Zeiss). 
For super-resolution imaging (structured illumination microscopy), 1 ?L of bacterial suspension 
was spotted between two coverslips and imaged with a Nikon Eclipse Ti inverted setup, and images 
were reconstructed with NIS-Elements software. 
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SUPPORTING INFORMATION 
Synthesis of compounds from Scheme 1: 
tert-Butyl (2-(2-(2-(piperazin-1-yl)ethoxy)ethoxy)ethyl)carbamate (2). To a solution of 
piperazine (0.41 g, 4.80 mmol) in DMF (20 mL) was added tert-butyl (2-(2-(2-
bromoethoxy)ethoxy)ethyl)carbamate 1 (0.5 g, 1.60 mmol, synthesized according to a literature 
procedure1), and the reaction mixture was stirred at 60 °C for 4 h. The solvent was removed under 
vacuum, the residue resuspended in EtOAc (30 mL) and extracted with 1 N NaOH (20 mL). The 
aqueous layer was back-extracted with 2 x 20 mL EtOAc. The combined organic layers were 
washed with brine, dried with anhydrous MgSO4 and the solvent removed under vacuum. The 
residue was purified by column chromatography with a DCM/[MeOH/Ammonia 9:1] gradient, 
affording the title product (0.50 g, 99%) as a pale yellow oil: Rf  0.73 (EtOAc); 1H NMR (400 MHz, 
CDCl3) ? 1.43 (s, 9H), 1.83 (br s, 1H), 2.46 (br s, 4H), 2.58 (t, J=6.0 Hz, 2H), 2.88 (t, J=4.9 Hz, 
4H), 3.28-3.31 (m, 2H), 3.52(t, J=5.0 Hz, 2H), 3.58-3.62 (m, 6H). 13C NMR (100 MHz, CDCl3) ? 
28.5, 40.5, 55.1, 58.5, 68.9, 70.35 (2C), 7.40, 79.2, 156.1. MS (ESI+) calcd for C11H22BrNO4 [M + 
H]+, 318.2; found 318.3. 
8-Azidooctan-1-ol (4). 8-Chlorooctan-1-ol 3 (2 g, 12.1 mmol) and sodium azide (1.18 g, 18.2 
mmol) were suspended in DMF (40 mL) and stirred at 100 °C for 4h. The reaction mixture was 
cooled to room temperature and the solid in suspension removed by filtration. The solvent was 
removed under vacuum. The residue was resuspended in dichloromethane, filtered through celite 
and the solvent removed under vacuum, affording the title compound (2.1 g, 100%) as a clear oil: 
Rf  0.26 (EtOAc); 1H NMR (400 MHz, CDCl3) ? 1.27-1.40 (m, 8H), 1.50-1.61 (m, 4H), 1.79 (s, 
1H), 3.23 (t, J=7.0 Hz, 2 H), 3.60 (t, J=6.6 Hz, 2 H). 13C NMR (100 MHz, CDCl3) ? 25.7, 26.7, 
28.9, 29.2, 29.3, 32.7, 51.5, 62.9. 
tert-Butyl (8-hydroxyoctyl)carbamate (5). To a solution of 8-azidooctan-1-ol 4 (2.1 g, 12.1 
mmol) in THF (40 mL) was added triphenylphosphine (3.49 g, 13.3 mmol) followed by stirring for 
3 h at room temperature. Water (40 mL) was added to the reaction mixture and stirring continued 
for 20 h. The resulting solution was concentrated under vacuum to remove most of the THF, 
affording a suspension of 2-(2-(2-aminoethoxy)ethoxy)ethanol in water, which was diluted with 
acetonitrile (40 mL). To the resulting solution was added Boc2O (2.63 g, 12.1 mmol) and NaOH 
(10 mL 1 N solution). The reaction mixture was stirred for 3 h at room temperature and the solvent 
was removed under vacuum. Purification by column chromatography with an n-hexane/EtOAc 
gradient afforded the title product (2.64 g, 89%) as a white solid: Rf  0.48 (n-hexane/EtOAc 7:1); 1H 
NMR (400 MHz, CDCl3) ? 1.27-1.36 (m, 8H), 1.43 (s, 9H), 1.42-1.48 (m, 2H), 1.50-1.58 (m, 2H), 
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3.09 (t, J=7.1 Hz, 2 H), 3.62 (t, J=6.6 Hz, 2 H). 13C NMR (100 MHz, CDCl3) ? 25.8, 26.8, 28.6, 
29.3, 29.4, 30.1, 32.8, 40.9, 63.1, 79.3, 156.2. 
tert-Butyl (8-bromooctyl)carbamate (6). To a solution of tert-butyl (8-hydroxyoctyl)carbamate 5 
(2.59 g, 10.6 mmol) and carbon tetrabromide (4.39 g, 13.2 mmol) in dichloromethane (30 mL) was 
added potassium carbonate (2.2 g, 15.9 mmol). A solution of triphenylphosphine (4.2 g, 16.0 
mmol) in dichloromethane (25 mL) was then slowly added over 15 min. with stirring at room 
temperature. Stirring continued for 4 h. The white solid in suspension was removed by filtration, 
the filtrate concentrated under vacuum and the residue purified by column chromatography (n-
hexane/EtOAc gradient), affording the title compound (1.98 g, 61%) as a clear oil: Rf  0.76 (n-
hex/EtOAc 7:3); 1H NMR (400 MHz, CDCl3) ? 1.25-1.35 (m, 6H), 1.35-1.49 (m, 13H), 1.78-1.85 
(m, 2H), 3.07 (t, J=7.1 Hz, 2 H), 3.37 (t, J=6.8 Hz, 2 H). 13C NMR (100 MHz, CDCl3) ? 26.7, 28.1, 
28.5, 28.7, 29.1, 30.1, 32.8, 34.0, 40.8, 79.1, 156.1.  
tert-Butyl (8-aminooctyl)carbamate (7). To a solution of tert-butyl (8-bromooctyl)carbamate 6 
(90 mg, 0.29 mmol) in dimethoxyethane (10 mL) was added ammonia (1 mL, 35% solution in 
water) in a sealed vessel. The reaction mixture was heated to 75 °C for 6 h. The solvent was 
evaporated and the residue was purified by column chromatography (EtOAc/MeOH gradient), 
affording the title product (68 mg, 96%) as a pale yellow oil: Rf  0.23 (DCM/MeOH/Ammonia 
9:0.9:0.1); 1H NMR (400 MHz, CD3OD) ? 1.30-1.51 (m, 19H), 1.63-1.71 (m, 2H), 2.92 (t, J=7.6 
Hz, 2H), 3.01 (t, J=7.0 Hz, 2H). 13C NMR (100 MHz, CD3OD) ? 27.3, 27.7, 28.5, 28.8, 30.1 (2 
carbons), 30.9, 40.8, 41.3, 79.8, 158.5. MS (ESI+) calcd for C13H29N2O2 [M + H]+, 245.2; found 
245.1. 
tert-Butyl (8-(piperazin-1-yl)octyl)carbamate (8). To a solution of piperazine (1.95 g, 22.7 
mmol) in DMF (20 mL) was added tert-butyl (8-bromooctyl)carbamate 6, and the reaction mixture 
was stirred at 60 °C for 4 h. The solvent was removed under vacuum, the residue re-suspended in 
EtOAc (30 mL) and extracted with 1 N NaOH (20 mL). The aqueous layer was back-extracted with 
2 x 20 mL EtOAc. The combined organic layers were washed with brine, dried with anhydrous 
MgSO4 and the solvent removed under vacuum. The residue was purified by column 
chromatography with a DCM/[MeOH/Ammonia 9:1] gradient, affording the title product (1.28 g, 
90%) as a pale yellow oil: Rf  0.27 (DCM/MeOH/Ammonia 9:0.9:0.1); 1H NMR (400 MHz, 
CD3OD) ? 1.27-1.38 (m, 8H), 1.38-1.56 (m, 13H), 2.33-2.37 (m, 2H), 2.48 (br s, 4H), 2.88 (t, J=4.8 
Hz, 4H), 3.01 (t, J=6.9 Hz, 2H), 4.92 (s, 1H). 13C NMR (100 MHz, CDCl3) ? 26.6, 26.8, 27.5, 28.5, 
29.3, 29.5, 30.1, 40.6, 45.8, 54.2, 59.4, 79.0, 156.0. MS (ESI+) calcd for C17H36N3O2 [M + H]+, 
314.3; found 314.4. 
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Synthesis of compounds from Scheme 2: 
General procedure 1: linker coupling with 2-(methylthio)-8-nitro-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-4-one (10). 
To a solution of 2-(methylthio)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3] thiazin-4-one 102 (1.0 
equiv.) in 5 mL EtOH was added the appropriate linker prepared above (1.03 equiv.). The reaction 
mixture was heated to 50°C with stirring and under N2 for 18 h. The solvent was removed under 
vacuum and the residue purified by flash chromatography, to afford the desired product. 
General procedure 2: Boc hydrolysis from coupled benzothiazinone-linker compounds, and amine 
coupling with fluorophores. 
The benzothiazinone derivative obtained from coupling of 10 with the appropriate Boc-protected 
linker (1.2 equiv.) was dissolved in DCM/TFA (1:1, 2 mL) and the resulting solution was stirred at 
room temperature for 2 h. The reaction mixture was concentrated under vacuum and the residue 
dried under high-vacuum, affording the free amine product as a thick oil, which was used without 
further purification for the next step.  
To a solution of the product obtained above in 2 mL anhydrous DMF was added 
diisopropylethylamine (6 equiv.) and the solution was stirred under N2 for 15 min. The NHS ester 
of the desired fluorophore (1.0 equiv.) was added to the solution and stirring continued under N2 at 
room temperature for 7 h. The solvent was removed under vacuum and the residue dried overnight 
under high-vacuum. Purification by column chromatography (DCM/[MeOH/Ammonia 9:1] 
gradient) afforded the title product as a solid. 
3',6'-dihydroxy-N-(2-(2-(2-((8-nitro-4-oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-
yl)amino)ethoxy)ethoxy)ethyl)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxamide 
(JN23). Prepared using general procedure 2, with compound 9 (22.5 mg, 0.042 mmol, previously 
described3) and the NHS ester of 5-carboxyfluorescein (16.6 mg, 0.035 mmol). The residue 
obtained after evaporation of the solvent from the reaction mixture was purified by preparative 
HPLC, affording the title product (4 mg, 15%) as an orange solid: Rf  0.25 (EtOAc/MeOH 9:1); 1H 
NMR (400 MHz, CD3OD) ? 3.62 (t, J=5.4 Hz, 2H), 3.69-3.77 (m, 10H), 6.55 (dd, J=2.1, 8.7 Hz, 
2H), 6.61 (d, J=8.7 Hz, 2H), 6.68 (d, J=2.1 Hz, 2H), 7.33 (d, J=8.0 Hz, 1H), 8.19 (dd, J=1.6, 8.0 
Hz, 1H), 8.42 (s, 1H), 8.82 (d, J=1.6 Hz, 1H), 8.88 (d, J=1.6 Hz, 1H). HRMS (ESI+) calcd for 
C36H28F3N4O11S [M + H]+, 781.1422; found 781.1428 (error: 0.8 ppm). 
tert-butyl (8-((8-nitro-4-oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-
yl)amino)octyl)carbamate (11). Prepared using general procedure 1, with tert-butyl (8-
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aminooctyl)carbamate 7 (90 mg, 0.28 mmol). Purification by flash chromatography (n-
hexane/EtOAc gradient), afforded the title compound (77 mg, 53%) as a solid: Rf  0.5 (n-
hexane/EtOAc, 1:1); 1H NMR (400 MHz, CDCl3) ? 1.23-1.50 (m, 19H), 1.64-1.70 (m, 2 H), 3.04-
3.10 (m, 2H), 3.61-3.71 (m, 2H), 4.65 (br s, 1H), 7.70 (br s, 1H), 8.73 (s, 1H), 9.07 (s, 1H). 13C 
NMR (100 MHz, CDCl3) ? 26.6, 26.8 (2C), 28.5, 28.8, 29.1, 30.0, 40.7, 43.4, 79.4, 122.6, 126.1, 
127.2, 129.3, 133.6, 135.7, 143.4, 156.3, 163.3, 167.3. 
3',6'-bis(dimethylamino)-N-(8-((8-nitro-4-oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-
yl)amino)octyl)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxamide (JN96). 
Prepared using general procedure 2, from compound 11 (5.7 mg, 0.011 mmol) and the NHS ester 
of 5-carboxytetramethylrhodamine (5 mg, 0.0095 mmol), affording the title product (4.1 mg, 52%) 
as dark purple solid: Rf  0.61 (DCM/[MeOH/Ammonia 9:1] 9:1); 1H NMR (400 MHz, CD3OD) ? 
1.30-1.50 (m, 8H), 1.60-1.72 (m, 2H), 3.27 (s, 12H), 3.45 (t, J=6.5 Hz, 2H), 3.57 (t, J=6.8 Hz, 2H), 
6.87 (d, J=2.5 Hz, 2H), 7.01 (dd, J=2.5, 9.5 Hz, 2H), 7.25 (d, J=9.5 Hz, 2H), 7.37 (d, J=7.9 Hz, 
1H), 8.04 (dd, J=1.8, 7.9 Hz, 1H), 8.49 (d, J=1.8 Hz, 1H), 8.84 (s, 1H), 8.91 (s, 1H). HRMS (ESI+) 
calcd for C42H42F3N6O7S [M + H]+, 831.2782; found 831.2787 (error: 0.6 ppm). 
tert-butyl (2-(2-(2-(4-(8-nitro-4-oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-
yl)piperazin-1-yl)ethoxy)ethoxy)ethyl)carbamate (12). Prepared using general procedure 1, with 
tert-butyl (8-aminooctyl)carbamate 2 (82 mg, 0.26 mmol). Purification by flash chromatography 
(EtOAc/MeOH gradient), afforded the title compound (136 mg, 92%) as a solid: Rf  0.25 
(EtOAc/MeOH, 9:1); 1H NMR (400 MHz, CDCl3) ? 1.37 (s, 9H), 2.60-2.65 (m, 6 H), 3.23-3.26 
(m, 2H), 3.48 (t, J=5.1 Hz, 2H), 3.56 (s, 4H), 3.59 (t, J=5.5 Hz, 2H), 4.00 (br s, 4H), 8.68 (d, J=2.0 
Hz, 1H), 9.00 (d, J=2.0 Hz, 1H). 13C NMR (100 MHz, CDCl3) ? 28.4, 40.3, 46.4, 52.9, 57.3, 68.7, 
70.18, 70.22, 70.3, 79.2, 122.4, 126.0, 126.7, 129.5, 133.3, 134.1, 143.9, 155.9, 162.0, 166.4.  MS 
(ESI+) calcd for C24H33F3N5O7S [M + H]+, 592.2; found 592.0. 
3',6'-bis(dimethylamino)-N-(2-(2-(2-(4-(8-nitro-4-oxo-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-2-yl)piperazin-1-yl)ethoxy)ethoxy)ethyl)-3-oxo-3H-spiro[isobenzofuran-
1,9'-xanthene]-5-carboxamide (JN62). Prepared using general procedure 2, with compound 12 
(12.4 mg, 0.021 mmol) and the NHS ester of 5-carboxytetramethylrhodamine (9 mg, 0.017 mmol), 
affording the title product (9 mg, 58%) as a dark purple solid: Rf  0.35 (DCM/[MeOH/Ammonia 
9:1] 9:1); 1H NMR (400 MHz, CD3OD) ? 2.55-2.67 (m, 6H), 3,27 (s, 12H), 3.65-3.77 (m, 10H), 
4.00 (br s, 4H), 6.67 (d, J=2.4 Hz, 2H),  6.99 (dd, J=2.5, 9.4 Hz, 2H), 7.23 (d, J=9.4 Hz, 2H), 7.56 
(d, J=7.9 Hz, 1H), 8.15 (dd, J=1.8, 7.9 Hz, 1H), 8.57 (d, J= 1.8 Hz, 1H), 8.84 (d, J=2.0 Hz, 1H), 
8.90 (d, J=2.0 Hz, 1H). HRMS (ESI+) calcd for C44H45F3N7O9S [M + H]+, 904.2941; found 
904.2952 (error: 1.2 ppm). 
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5,5-difluoro-7,9-dimethyl-3-(3-((2-(2-(2-(4-(8-nitro-4-oxo-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-2-yl)piperazin-1-yl)ethoxy)ethoxy)ethyl)amino)-3-oxopropyl)-5H-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide (JN94). Prepared using general 
procedure 2, from compound 12 (5.6 mg, 0.0094 mmol) and the NHS ester of BODIPY-FL (3 mg, 
0.0078 mmol), affording the title product (2.2 mg, 37%) as a light orange solid: Rf  0.48 (EtOAc); 
1H NMR (400 MHz, CD3OD) ? 2.17 (s, 3H), 2.41 (s, 3H), 2.60-2.73 (m, 8H), 3.19 (t, J=7.9 Hz, 
2H), 3.40 (t, J=5.4 Hz, 2H), 3.57 (t, J=5.4 Hz, 2H), 3.63 (s, 4H), 3.66 (t, J=5.2 Hz, 2H), 4.00 (br s, 
4H), 6.06 (s, 1H), 6.31 (d, J=4.0 Hz, 1H), 6.93 (d, J=4.0 Hz, 1H), 7.24 (s, 1H), 8.82 (d, J=1.9 Hz, 
1H), 8.88 (d, J=1.9 Hz, 1H). HRMS (ESI+) calcd for C33H38BF5N7O6S [M + H]+, 766.2607; found 
766.2623 (error: 2.0 ppm). 
tert-butyl (8-(4-(8-nitro-4-oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-yl)piperazin-1-
yl)octyl)carbamate (13). Prepared using general procedure 1, with tert-Butyl (8-(piperazin-1-
yl)octyl)carbamate 8 (0.4 g, 1.28 mmol). Purification by flash chromatography (n-hexane/EtOAc 
gradient), afforded the title compound (0.52 g, 89%) as a solid: Rf  0.77 (EtOAc/MeOH, 9:1); 1H 
NMR (400 MHz, CDCl3) ? 1.28-1.32 (m, 8H), 1.41-1.51 (m, 13 H), 2.36-2.40 (m, 2H), 2.57 (br s, 
4H), 3.07-3.12 (m, 2H), 3.88 (br s, 2H), 4.15 (br s, 2H), 4.50 (s, 1H), 8.75 (d, J=2.0 Hz, 1H), 9.09 
(d, J=2.0 Hz, 1H). 13C NMR (100 MHz, CDCl3) ? 26.6, 26.7, 27.3, 28.4, 29.2, 29.4, 30.0, 40.6, 
46.3, 52.6, 58.2, 79.0, 122.4, 126.0, 126.7, 129.7, 133.4, 134.1, 143.9, 156.0, 166.4.  
3',6'-bis(dimethylamino)-N-(8-(4-(8-nitro-4-oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-
2-yl)piperazin-1-yl)octyl)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxamide 
(JN108). Prepared using general procedure 2, from compound 13 (28 mg, 0.047 mmol) and the 
NHS ester of 5-carboxytetramethylrhodamine (20 mg, 0.038 mmol), affording the title product (11 
mg, 32%) as dark purple solid: Rf  0.24 (DCM/[MeOH/Ammonia 9:1] 9:1); 1H NMR (400 MHz, 
CD3OD) ? 1.25-1.49 (m, 8H), 1.50-1.61 (m, 2H), 1.65-1.74 (m, 2H), 2.48 (t, J=7.4 Hz, 2H), 2.60 
(br s, 4H), 3.26 (s, 12H), 3.48 (t, J=6.5 Hz, 2H), 4.00 (br s, 4H), 6.79 (d, J=2.2 Hz, 2H), 6.99 (dd, 
J=2.2, 9.4 Hz, 2H), 7.23 (d, J=9.4 Hz, 2H), 7.45 (d, J=7.9 Hz, 1H), 8.08 (d, J=7.9 Hz, 1H), 8.51 (s, 
1H), 8.88 (s, 1H), 8.89 (s, 1H). HRMS (ESI+) calcd for C46H49F3N7O7S [M + H]+, 900.3355; found 
900.3366 (error: 1.2 ppm). 
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tert-Butyl (8-(4-(8-amino-4-oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-yl)piperazin-1-
yl)octyl)carbamate (14). To a suspension of compound 13 (60 mg, 0.102 mmol) and ammonium 
chloride (1 mg, 0.019 mmol) in 8 mL EtOH was slowly added a solution of sodium hydrosulfide 
(0.114 mg, 2.04 mmol) in water (4 mL), with stirring at room temperature. Stirring continued for 
18 h. The solvent was removed under vacuum and the residue purified by flash chromatography 
(EtOAc/MeOH gradient), affording the title compound (21 mg, 37%) as a sticky solid: Rf  0.29 
(EtOAc/MeOH, 8:1); 1H NMR (400 MHz, CDCl3) ? 1.24-1.37 (m, 8H), 1.37-1.55 (m, 13 H), 2.35-
2.39 (m, 2H), 2.54 (br s, 4H), 3.06-3.13 (m, 2H), 3.85 (br s, 4H), 4.08 (br s, 2H), 4.51 (s, 1H), 7.11 
(s, 1H), 8.19 (s, 1H). 
N-(8-(4-(8-amino-4-oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-yl)piperazin-1-
yl)octyl)-3',6'-bis(dimethylamino)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-
carboxamide (JN105). Prepared using general procedure 2 from compound 14 (11 mg, 0.020 
mmol) and the NHS ester of 5-carboxytetramethylrhodamine (9 mg, 0.017 mmol), affording the 
title product (7.5 mg, 43%) as a dark purple solid: Rf  0.64 (DCM/[MeOH/Ammonia 9:1] 5:1); 1H 
NMR (400 MHz, CD3OD) ? 1.36-1.58 (m, 10H), 1.69-1.76 (m, 2H), 2.37-2.42 (m, 2H), 2.51 (t, 
J=4.7 Hz, 4H), 3.26 (s, 12H), 3.52 (t, J=6.5 Hz, 2H), 3.90 (br s, 4H), 6.71 (d, J=2.4 Hz, 2H), 6.96 
(dd, J=2.4, 9.5 Hz, 2H), 7.18 (d, J=1.5 Hz, 2H), 7.23 (d, J=9.5 Hz, 1H), 7.53 (d, J=7.9 Hz, 1H), 
7.80 (d, J=1.4 Hz, 1H), 8.10 (dd, J=1.8, 7.9 Hz, 2H), 8.54 (d, J=1.8 Hz, 1H). HRMS (ESI+) calcd 
for C46H51F3N7O5S [M + H]+, 870.3614; found 870.3624 (error: 1.1 ppm). 
2-(6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl)-5-(propylcarbamoyl)benzoate 
(JN111). To a solution of the NHS ester of 5-carboxytetramethylrhodamine (4 mg, 0.076 mmol) in 
0.5 mL anhydrous DMF was added propylamine (20 uL, 0.24 mmol), and the resulting solution 
was stirred for 3 h at room temperature. The solvent was evaporated and the residue purified by 
column chromatography (DCM/MeOH gradient) affording the title product (2.5 mg, 70%) as a 
dark purple solid: Rf  0.41 (DCM/MeOH 4:1); 1H NMR (400 MHz, CD3OD) ? 1.02 (t, J=1.4 Hz, 
1H), 1.65-1.72 (m, 2H), 3.14 (s, 12H), 3.49 (br s, 2H), 6.68-6.68 (m, 4H), 6.94 (d, J=7.9 Hz, 1H), 
7.23 (d, J=7.3 Hz, 1H), 8.20 (d, J=7.3 Hz, 1H), 8.53 (s, 1H). HRMS (ESI+) calcd for C28H30N3O4 
[M + H]+, 472.2231; found 472.2236 (error: 1.0 ppm). 
Staining of nascent peptidoglycan 
Labeling of the sites of incorporation of new peptidoglycan in living bacteria was adapted from 
Siegrist et al, 2013.4 Briefly, bacteria were grown in the presence of 5 mM of (R)-?-
Propargylglycine, washed with PBS containing 0.05% Tween-80 and fixed in PFA.  The click 
chemistry reaction was performed at room temperature for 1 h with 1 mM CuSO4, 1 mM Tris(3-
hydroxypropyltriazolylmethyl)amine, 20 ?M of Rhodamine 110-azide and 1.2 mM sodium 
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ascorbate in PBS. Finally, bacteria were washed, resuspended and mounted on an agarose pad. 
Micrographs were acquired with the FITC (excitation 490/20, emission 528/38) and phase or trans 
light channels and images processed with ImageJ software. 
 
 
Supplementary Figure 1. The active fluorescent benzothiazinone analog JN108 accumulates 
at mycobacterial cell poles. M. smegmatis (a) or M. tuberculosis (b) bacteria were cultured in 
microfluidic devices and were subsequently stained with JN108 or the inactive form (JN105). 
The arrows point to the polar localization seen with JN108. The arrowheads indicate regions of 
non-polar labeling where the cellular material is leaking out. The white scale bar shown at 
bottom left represents 5 ?m. Also see Movies S1-S3.  
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Supplementary Figure 2. Labeling M. smegmatis cells expressing Wag31-GFP with JN108. 
Arrows highlight cell poles where Wag31-GFP colocalizes with JN108. Scale bar 5 ?m. 
 
 
 
Supplementary Figure 3.  Labeling M. marinum in vitro with JN108. BTZ-sensitive M. 
marinum carrying Rv3789-GFP (a) displays polar JN108 labeling (arrows) while BTZ-
resistant M.marinum carrying Rv3789-mNeonGreen (b) displays only a faint uniform JN108 
labeling. The green channel shows the plasma membrane and red channel shows JN108 
fluorescence. Scale bar 5 ?m.  
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Supplementary Figure 4. Staining of nascent peptidoglycan indicating growth by tip 
extension in (a) C. glutamicum, (b) M. smegmatis and (c) N. farcinica. Merge of phase contrast 
or trans-light micrographs with green fluorescence channel (Rhodamine-110). Scale bars 5 ?m.
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Supplementary Figure 5. Labeling non-growing M. tuberculosis (streptomycin-starved 18b) 
with JN108. M. tuberculosis strain 18b was passaged three times without streptomycin until 
the culture reached a stable OD. JN108 was added and bacteria were incubated for 24h before 
preparation for microscopy. Micrographs represent a merge of the phase contrast image (grey) 
and red fluorescence channel (red). Scale bars 5 ?m. 
 
 
 
Supplementary Figure 6. Labeling M. tuberculosis with JN108. M. tuberculosis strain H37Rv 
wild-type (a, b) or BTZ-resistant (NTB1, c) were exposed overnight to JN108. (a) and (b) are 
micrographs from two independent experiments and display similar polar labeling while BTZ-
resistant bacteria display uniform background staining. JN108 fluorescence is shown in red 
and phase contrast in grey. Scale bars 5 ?m.  
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Supplementary Movie 1. Timelapse imaging of M. smegmatis exposed to JN108 
Representative timelapse microscopy movie in which M. smegmatis bacteria expressing GFP were 
grown in the microfluidic device over a period of 50 h, under a constant flow of 7H9 medium. The 
bacteria were exposed to JN108 from 10.25 h to 33 h. Images were recorded every 15 min, on the 
green (GFP) and red (TAMRA - JN108) channels. Time is indicated on the top right. Scale bar is 
shown on the bottom right. The signal on the red channel has been normalized over time to allow 
for better visualization against the background 
Supplementary Movie 2. Timelapse imaging of M. smegmatis exposed to JN105 
Representative timelapse microscopy movie in which M. smegmatis bacteria expressing GFP were 
grown in the microfluidic device over a period of 17 h, under a constant flow of 7H9 medium. The 
bacteria were exposed to JN105 from 5.75 h to 16.25 h. Images were recorded every 15 min, on the 
green (GFP) and red (TAMRA - JN105) channels. Time is indicated on the top right. Scale bar is 
shown on the bottom right. The signal on the red channel has been normalized over time to allow 
for better visualization against the background. Some out-of-focus images have been removed from 
the time-lapse series. 
Supplementary Movie 3. Timelapse imaging of M. tuberculosis exposed to JN108 
Representative timelapse microscopy movie in which M. tuberculosis bacteria expressing GFP 
were grown in the microfluidic device over a period of 232 h, under a constant flow of 7H9 
medium. The bacteria were exposed to JN108 from 1 h to 126 h. Images were recorded every 60 
min, on the green (GFP) and red (TAMRA - JN108) channels. Time is indicated on the top right. 
Scale bar is shown on the bottom right. The signal on the red channel has been normalized over 
time to allow for better visualization against the background.  Some out-of-focus images have been 
removed from the time-lapse series. The period of growth before addition of JN108 is not shown. 
 
The Supporting Information and the movies are available free of charge on the ACS Publications 
website at DOI: 10.1021/acschembio.8b00790.  
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Chapter 3. Fluorescent Benzothiazinone Analogues for Mycobacterial Detection 
Fluorescent Benzothiazinone Analogues 
to Detect Mycobacteria in vivo 
 
 
 
 
 
 
 
 
 
 
This chapter explains the application of the probes described in the previous chapter in an attempt 
to detect mycobacteria in live infected zebrafish embryos and mice. Although written in a 
manuscript format, the following are unpublished data.  
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INTRODUCTION 
The 8-nitro-benzothiazinones (BTZs) BTZ0431 and PBTZ1692 (macozinone) are promising new 
anti-tuberculosis (TB) drugs with an MIC99 of 1 and 0.3 ng/mL, respectively. BTZs are potent 
inhibitors of decaprenyl-phospho-?-D-ribose oxidase (DprE1), an essential enzyme required for the 
synthesis of the cell wall in mycobacteria. BTZs form irreversible covalent adducts with Cys387 in 
DprE13,4 and the 2-substituent of the BTZ core can be coupled with fluorophores without 
suppressing their anti-mycobacterial activity.5 JN108, a TAMRA-labelled PBTZ molecule has 
successfully been used to label DprE1 in vitro and in living BTZ-sensitive actinobacteria, 
highlighting the polar and periplasmic localization6 of DprE1. We further synthesized a PBTZ-
molecule linked to the near-infrared (NIR) fluorophore Dy-750, which has a maximal excitation 
and emission at 747 and 776 nm, respectively. This fluorescent probe, named JN139, has an MIC99 
against M. tuberculosis of 80 ng/mL suggesting that despite coupling with Dy-750, the molecule 
can still bind to DprE1 and exhibit a bactericidal effect, as observed with JN108. 
We sought to assess the feasibility of mycobacterial detection in two models of mycobacterial 
infection commonly used for in vivo studies of TB, namely, M. marinum-infected zebrafish 
embryos and M. tuberculosis in the lungs of living infected mice. For the latter, the utilization of 
JN139 is recommended as NIR fluorophores permit deeper in vivo imaging, since the scattering 
and absorption of light by mammalian tissues drops above 700 nm.7 On the other hand, the 
transparency of zebrafish embryos permits the utilisation of JN108 (TAMRA maximal emission is 
around 580 nm) and observation with confocal microscopy is sufficient to visualize the probe in 
vivo. The feasibility of these two approaches for mycobacterial detection is investigated in this 
chapter. The results obtained are presented and the limitations of the technique are discussed. 
RESULTS 
Visualization of M. marinum in zebrafish embryos with JN108 
We previously described that JN108, a TAMRA-coupled PBTZ molecule, specifically labels 
DprE1 in several actinobacteria and mycobacteria, including M. marinum.5 We therefore aimed to 
test if JN108 could detect M. marinum in infected zebrafish embryos. To do so, 24 h old zebrafish 
embryos were infected with green fluorescent M. marinum constitutively producing the 
mNeonGreen protein8,9 (M. marinum mNeon), via caudal vein microinjection. The bacteria were 
visible in the embryos by examination under a confocal microscope, as early as 24 h post infection 
(Figure 1). At this point, a solution of JN108 was microinjected in the common cardinal vein 
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(CCV) of the embryos. Note that injection in the CCV is easier than injection in the caudal vein for 
embryos older than 30 h post fertilization. The fluorescent probe was uniformly distributed in the 
tissues of the fish 2 h after the injection of JN108, except in the notochord, as can be seen in the 
red channel in Figure 1a. This indicates that injection in the CCV permits a global distribution of 
the dye in the embryo via the circulatory system. No fluorescence was visible in the red and green 
channels for uninfected embryos that did not receive JN108, showing that red and green 
fluorescence is specific for JN108 and M. marinum mNeon, respectively. Two hours after 
administration of JN108, red and green fluorescence did not co-localize, suggesting that the probe 
had not labelled the bacteria at this time point. Similar observations were performed 24 h post 
injection of JN108, where the red fluorescence intensity in muscular tissue had slightly decreased. 
Despite adjustment of contrast, JN108 appeared to have remained uniformly distributed, whereas 
M. marinum mNeon formed clusters, visible in green fluorescence (Figure 1c). A view with a lower 
magnification 48 h post administration of JN108 showed that the fluorescent probe had mainly 
accumulated in the yolk of the 4 d old embryos but still did not precisely co-localize with the 
mycobacteria. These observations suggest that despite an appropriate distribution of JN108 
following microinjection in M. marinum-infected zebrafish embryos, the probe cannot specifically 
detect M. marinum in this context. 
 
 
Figure 1. Visualization of M. marinum in infected zebrafish embryos. (a) Zebrafish embryo 
infected with M. marinum mNeon and receiving JN108, imaged 2 h after injection of the 
probe. (b) Non-infected embryos imaged without administration of JN108, validating specific 
fluorescent signals seen in panel a. (c, d) Infected embryos imaged 24 h (panel c) and 48 h 
(panel d) after injection of JN108. The contrast was adjusted for the red fluorescence channel 
to highlight the localization of JN108. Indications at left specify the time at which images were 
acquired, with respect to initial JN108 injection. TL = trans-illumination. Scale bars: 100 ?m. 
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Visualization of M. tuberculosis in infected mice with JN139, a near-infrared PBTZ 
derivative 
The Photon Imager platform allows for multiplexing of fluorescence and bioluminescence imaging 
modalities for in vivo imaging in small animals. The aim of this study was to test whether the NIR 
fluorescent PBTZ analogue JN139 could detect M. tuberculosis in the lungs of infected mice. If 
this were the case, NIR fluorescent (JN139) and bioluminescent (M. tuberculosis Lux, described in 
detain in chapter 5) signals should co-localize in the thoracic area of the infected animals. 
Thirty five days after low dose aerosol infection of SCID Hairless Outbred (SHO) mice with 
M. tuberculosis Lux, an autobioluminescent reporter (see Chapter 5 of this thesis), the animals 
received several doses of JN139 (one dose = 2 ?g) via the intraperitoneal route. A group of non-
infected mice was treated similarly to serve as comparison. Previous trials with intravenous (tail 
vein) injections resulted in a weak distribution of JN139 in the body and a rapid accumulation of 
the probe in the liver, as measured by whole body fluorescence imaging (data not shown). Mice 
were imaged immediately after JN139 injection and a bright fluorescent signal was observable on 
the entire abdominal area, confirming successful intraperitoneal injection. 16 h later, the mice were 
imaged again and the fluorescence had slightly decreased in the abdomen (Figure 2d) but no signal 
was visible in the thoracic area. A second dose of JN139 was administered and subsequent imaging 
17 h later led to similar observations. Finally, a double dose of JN139 was injected. To allow 
additional time for the distribution of the probe and to eliminate the excess of JN139, mice were 
imaged 30 h after the last injection. As can be seen in Figure 1b and c, the fluorescence mainly 
focalized in the abdomen. However, luminescence measurements indicated a precise and clear 
signal in the thorax of infected mice (Figure 2c), absent in uninfected mice. The fluorescent and 
luminescent signals did not co-localize, suggesting that JN139 had not labelled M. tuberculosis in 
vivo. 
Quantitative ex vivo fluorescence and luminescence measurements were performed subsequently 
on excised lungs from mice receiving JN139 (Figure 2e). An increase in luminescence intensity of 
more than two orders of magnitude was observed between lungs from uninfected and infected 
mice, suggesting that the M. tuberculosis Lux reporter permits quantitative evaluation of the 
bacterial load with luminescence measurements. An average of 1.128·108 CFU/lung was evaluated 
for these organs after plating and culture of lung homogenates. In contrast, NIR fluorescence 
intensities were similar between lungs from uninfected and infected mice. These observations 
indicate yet again that JN139 cannot quantitatively label M. tuberculosis in the murine model of 
tuberculosis infection or that labeling is below the limit of detection. 
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Figure 2. Multimodal imaging of tuberculosis infection. (a-c) The pictures were taken during the last 
imaging session (just before sacrifice) with mice receiving JN139 (panels b and c) in comparison with 
control animals (panel a). Panels on the left show fluorescence (JN139) and panels on the right display 
luminescent signals (M. tuberculosis Lux). Only mice from panel c are infected with M. tuberculosis Lux. 
Images display black and white photographs and the fluorescent, respectively luminescent signals are 
overlaid in false colour. (d) Quantification of the fluorescence in the abdomen of mice receiving JN139 via 
the intraperitoneal route at indicated time points and comparison with non-injected mice (NI). (e) Ex vivo 
luminescence and fluorescence quantification on excised lungs for mice receiving JN139. The dashed line 
represents the average fluorescence on lungs from control mice that did not receive JN139. Bars show 
averages and S.E.M. ns = non-significant, ** P > 0.001  
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DISCUSSION 
We have recently demonstrated that several fluorophore-coupled benzothiazinone core molecules 
could specifically and covalently label DprE1 in vitro in bacterial lysates.5 JN108, a probe with a 
TAMRA fluorochrome attached on a PBTZ moiety via a hydrophobic linker, could label DprE1 at 
the poles of live BTZ-sensitive bacteria, such as M. smegmatis, M. tuberculosis, M. marinum and 
N. farcininca. Besides precisely labelling DprE1, fluorescent PBTZ molecules have the potential 
for detection of BTZ-sensitive mycobacteria in more complex settings. This was investigated in the 
present study for in vivo imaging, in the zebrafish embryo model of M. marinum infection and in 
mice infected with luminescent M. tuberculosis. 
In the first case, green fluorescent M. marinum bacteria were easily visualized with confocal 
fluorescence microscopy at different time points post infection, as previously described.10–12 
Injection of JN108 24 h post infection in the CCV proved to be an optimal route of administration 
as the probe had distributed along the organism via the circulation and could be tracked with 
fluorescence microscopy. 24 and 48 h post injection, however, the fluorescent probe had mainly 
accumulated in the yolk and no clear co-localization with the bacteria was observed. This suggests 
that JN108 is not sensitive enough to detect M. marinum in infected zebrafish embryos using the 
method described here. Notably, DprE1, the target of JN108, is only present at the poles of the 
bacteria. This means that JN108 labelling is restricted to the tips of the bacilli, therefore weakening 
the limit of detection. In the zebrafish model, the limit of detection seems situated below the 
background level of fluorescence, rendering the bacteria invisible in the red fluorescence channel 
and precluding the utilization of JN108 in this context. 
For mycobacterial detection in the mouse model, a near-infrared fluorescent PBTZ derivative was 
designed and produced by coupling a Dy-750 dye to a PBTZ pharmacophore. Dy-750 has a 
maximum of emission above 750 nm, which is particularly suitable for fluorescence imaging in 
rodents, as mentioned earlier. The biodistribution of the probe, however, gave rise to considerable 
issues. Intravenous injection led to rapid accumulation in the liver and intraperitoneal 
administration created a large zone of fluorescence in the abdominal area, while no specific signal 
was visible in the thoracic area of the infected mice. In contrast, a clear luminescent signal could be 
recorded in vivo and ex vivo and this is further discussed in chapter 5 of this thesis. The 
fluorescence measured on explanted lungs did not corroborate the true bacterial load evaluated in 
parallel by luminescence and by enumeration of CFUs. Dy-750-based probes remain a suitable 
choice for in vivo imaging as no background fluorescence from the skin or the food in the 
gastrointestinal tract overlapped with the present measurements. 
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Although fluorescent PBTZ-based probes are extremely selective towards BTZ-sensitive bacteria 
such as M. tuberculosis and M. marinum, the global intensity of labelling remains weak, rendering 
mycobacterial detection difficult in vivo. The biodistribution and background fluorescence of 
unbound probe also impairs detection. Alternatively, enzymatically switchable probes might solve 
these issues, as recently suggested13–15 and as discussed in the concluding chapter of this work. 
METHODS 
Bacterial strains and culture conditions 
M. tuberculosis and M. marinum strains were grown in Middlebrook 7H9 medium (Difco) 
supplemented with 0.2% glycerol, 10% albumin-dextrose-catalase (ADC) and 0.05% Tween-80 or 
on solid 7H10 agar plates containing 0.5% glycerol and 10% oleic acid-albumin-dextrose-catalase 
(OADC). M. tuberculosis was cultured at 37°C and M. marinum at 30°C. Liquid cultures were 
incubated with orbital shaking at 100 rpm. Hygromycin (HYG, 50 μg/mL) was added to culture 
medium when appropriate. 
Construction of the mycobacterial reporter strains 
Luminescent M. tuberculosis H37Rv (M. tuberculosis Lux) was obtained by transformation of the 
integrative plasmid pEG200,16 a gift from Neeraj Dhar. The mNeonGreen gene8,9 was PCR 
amplified and cloned in a pSMT317 vector to generate a replicative plasmid constitutively (under 
the promoter Phsp60) producing the fluorescent protein. The plasmid was transformed into wild type 
M. marinum strain M and its BTZ-resistant mutant5 to generate the M. marinum mNeon reporters. 
Transformation of DNA by electroporation was performed as described elsewhere.18 
Infection of zebrafish embryos and probe injection 
Zebrafish embryos were infected as previously described.19 Briefly, 24 h old Danio rerio (AB) 
embryos were manually dechorionated and aligned on a custom-made cavity-inlaid agarose bed 
covered with E3 medium20 (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4) 
containing 0.4 mg/mL MS-222 (Sigma). 1-2 nL of an M. marinum mNeon suspension containing 
~300 bacteria was microinjected in the caudal vein of the anesthetized embryos using a heat-pulled 
glass capillary connected to a pneumatic PicoPump PV820 (World Precision Instruments). The 
embryos were allowed to recover in fresh E3 medium and were kept at 28°C. 24 h post infection, 
the embryos were anesthetized as indicated above and received 1-2 nL of JN1085 (0.05 mg/mL) by 
microinjection in the common cardinal vein (CCV) as described elsewhere.21 Zebrafish embryos 
were recovered in MS-222-free E3 medium and prepared for imaging. 
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Imaging of infected zebrafish embryos 
2, 24 or 48 h after injection of the JN108 probe, the zebrafish embryos were anesthetized with 
0.4 mg/mL MS-222 in E3 medium. Embryos were embedded in 1.2% low melting agarose in an 8-
chambered coverslip (Ibidi) and the solidified agarose was covered with a layer of E3 containing 
0.4 mg/mL MS-222. Samples were visualized with a Zeiss LSM700 inverted confocal microscope 
equipped with Plan-Apochromat objectives (20× NA 0.8 (air), 40× NA 1.3 and 63× NA 1.4 (oil)). 
Images were processed with the ImageJ software v1.52h. 
Infection of mice and probe injection 
5-6 week old female SCID Hairless Outbred (SHO) (Charles River) were infected with 
M. tuberculosis Lux by aerosol exposure in a Madison chamber. 35 d post infection JN139 (2 ?g in 
100 ?L PBS containing 0.05% Tween-80) was administered by intraperitoneal injection. Mice 
were imaged as described below, immediately after injection of JN139. 36 d post infection, the 
same mice were imaged again and received another dose of JN139. The following day, mice were 
imaged and received a final double dose of JN139. Animals were imaged 1 and 2 d later without 
receiving further JN139. Experiments involving animals were performed under ABSL3 
containment and approved by the Swiss Cantonal Veterinary Authority (licence number 3082). 
Experiments involving mice were performed once, with 5 animals per group infected and treated 
identically. 
Enumeration of bacteria in the lungs 
After the final session of in vivo imaging, animals were euthanized by cervical dislocation while 
still under anaesthesia. Lungs were aseptically excised, imaged in a sealed Petri dish and 
homogenized in 2 mL of PBS containing 0.05% Tween 80. Serial 10-fold dilutions of lung 
homogenates were plated on 7H10 agar containing 16 ?g/mL nalidixic acid (sodium salt), 4 ?g/mL 
azlocillin (sodium salt) and 10 ?g/mL cycloheximide (all from Sigma). Plates were cultured at 
37°C for 4-5 weeks before CFU enumeration. 
In vivo and ex vivo imaging of mice 
In vivo imaging of live animals and ex vivo imaging of lungs was performed with a Photon Imager 
Optima (Biospace Labs, France). Acquisitions were performed with Photo Acquisition (version 
3.4.5.1169) software. Luminescence was recorded without filters for 5 min. Fluorescence (10 s of 
acquisition) was measured with excitation and emission band-pass filters of 725-750 nm and 780-
815 nm cut-off, respectively. Background fluorescence was quantified with a filter of 675-700 nm 
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cut-off. Luminescent or fluorescent signals were superimposed with black and white photographs 
of the specimen using M3 Vision (version 1.1.2.30843). 
For imaging live animals, mice were anaesthetized with 5% isoflurane in an induction chamber and 
transferred on the heated stage (37°C) of the Photon Imager Optima. Mice were placed on their 
back or slightly tilted towards their left side in front of a gas manifold to maintain them under 
isoflurane (reduced to 2%) anaesthesia during image acquisition. 
For quantification of the photonic signal, a region-of-interest (ROI) tool was used. Extracted lungs 
were imaged in a sealed plastic Petri dish and an ROI was drawn with the spline tool around the 
border of each organ. Radiance is expressed as photons per second per square centimetre per 
steradian (ph·s-1·cm-2·sr-1).  
Statistics 
Statistical analysis was carried out with GraphPad Prism version 7.02. For in vivo experiments, 
every group of mice contained n = 5 animals and all of them were included in statistical analyses. 
When two groups were compared, a Mann Whitney test was used. When more than two groups 
were compared, an ordinary one-way ANOVA followed by a Tukey’s multiple comparisons test 
were performed.  
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ABSTRACT 
Worldwide, tuberculosis (TB) is the leading cause of death due to infection with a single 
pathogenic agent, Mycobacterium tuberculosis. In the absence of an effective vaccine, new, more 
powerful antibiotics are required to halt the growing spread of multidrug-resistant strains and to 
shorten the duration of TB treatment. However, assessing drug efficacy at the preclinical stage 
remains a long and fastidious procedure that delays progression of drugs down the pipeline and 
towards the clinic. In this investigation, we report the construction, optimization and 
characterisation of genetically engineered near-infrared fluorescent reporter strains of the 
pathogens Mycobacterium marinum and Mycobacterium tuberculosis that enable direct 
visualization of bacteria in infected zebrafish and mice, respectively. Furthermore, we show that 
the fluorescence level accurately reflects the bacterial load, as determined by colony forming unit 
enumeration, thus enabling the efficacy of antibiotic treatment to be assessed in live animals in real 
time. 
INTRODUCTION 
Worldwide, tuberculosis (TB) remains one of the top 10 causes of death and the leading cause due 
to a single infectious agent, namely the bacillus Mycobacterium tuberculosis.1 Despite major 
progress since 1993 when the World Health Organisation (WHO) declared TB a global health 
emergency, 10 million new cases and 1.6 million deaths were estimated in 2017 alone. The absence 
of an effective vaccine preventing TB in adults and the increasing number of multidrug-resistant 
(MDR) TB cases make this disease a serious global health threat. Short course chemotherapy is 
available for drug-sensitive TB but this requires the administration of four first-line drugs 
(rifampicin, isoniazid, ethambutol and pyrazinamide) over 6 months while the treatment of drug-
resistant TB is considerably longer, more expensive and has more side effects. “Intensi?ed research 
and innovation” is one of three pillars of the WHO’s End TB Strategy, and covers the discovery 
and the development of new antibiotics to tackle drug-resistant bacteria, to cut the risk of 
developing active and contagious TB among the 1.7 billion people already latently infected, and to 
develop simpler and shorter regimens for treating the disease.1 
During drug development and translation to clinical trials, preclinical animal models are required to 
evaluate the efficacy of candidate compounds. Mice have been a model of choice for the 
elucidation of immunological and pathological pathways and can also serve to study the activity of 
drugs and vaccines.2 Aerosol exposure of mice with a suspension of bacteria enables a homogenous 
infection of several groups of animals with a route mimicking natural infection.2,3 It is particularly 
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important to minimize interindividual variation to allow appropriate comparison of different 
treatments or regimens among a cohort. This model, although it can demonstrate an efficient 
reduction of the bacterial burden following the treatment, is long, labour intensive and provides 
only retrospective information on the bacterial loads in the mice. The mouse model of chronic TB 
typically involves Balb/c or C57Bl/6 mice aerogenically infected with an M. tuberculosis 
suspension. 4-5 weeks post infection, the bacterial burden in the lungs of these strains stabilizes 
and treatment is usually administered orally for at least 4 weeks, followed by plating lung 
homogenates for colony forming unit (CFU) enumeration. Importantly, as CFU assays are endpoint 
measurements requiring the euthanasia of the animals, it is not possible to perform real time 
evaluation of the bacterial burden, longitudinal follow up and assessment of long term effects of the 
treatment, or to evaluate the kinetics of the infection upon treatment. In addition, many animals are 
required per experiment in order to gather statistically significant data on drug efficacy, which is 
arguable from an ethical point of view. 
In contrast, in vivo optical imaging of TB infection in mice can provide this information. In vivo 
optical (or biophotonic) imaging involves the measurement of photons emitted by a particular 
source to evaluate its size and spatial location.4 The two major modalities are bioluminescence, in 
which photons are emitted during a chemical reaction catalysed by luciferase, and fluorescence. In 
the latter, fluorescent proteins (FPs) or dyes reemit photons during the relaxation from the excited 
to the ground state, following irradiation with light at an appropriate wavelength. In vivo 
fluorescence imaging methods are limited by autofluorescence, absorption and scattering of 
photons by mammalian tissues, as well as by light penetration. This is particularly important in 
deep tissue imaging, as is the case for lungs, limiting the applicability of the method to proteins or 
dyes (in fluorescence imaging) with emission shifted towards the near-infrared (NIR) range (above 
650 nm), where tissue absorption and scattering are lowest.5–7 New NIR FPs have been engineered 
from bacterial phytochromes, which are photosensory receptors that absorb light in the far-red 
section of the spectrum.8–10 These NIR FPs are especially well suited for in vivo imaging as their 
spectra reside within the NIR tissue transparency window.11 For example, the NIR FP iRFP has 
been successfully used for expression and imaging in live mice and excellent signal/background 
ratio has been achieved.9,12,13 iRFP has been used to track dissemination of bacteria in the 
gastrointestinal tract14, exemplifying its potential for imaging infectious diseases. However, this is 
the only report of in vivo imaging of an infection exploiting the protein iRFP. 
In the case of mycobacterial infections, bioluminescent M. tuberculosis expressing the firefly 
luciferase gene could be visualized in the lungs of infected CB-17 SCID mice.15,16 Similarly, 
autoluminescent M. tuberculosis carrying the luxCDABE operon from Photorhabdus luminescens 
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demonstrated the efficacy of several antibiotics in vivo in Balb/c mice, although not allowing whole 
body imaging.17 A red-shifted M. tuberculosis fluorescent reporter has been used for the 
quantification of the bacterial burden with a commercial IVIS system and for the precise 
localization of the bacteria with fluorescence molecular tomography.18 However, the study 
demonstrated the efficacy of an antibiotic only during the acute and progressive phase of 
tuberculosis infection and quantitative measurements could only be done on excised lungs. 
Reporter enzyme fluorescence using a fluorogenic ?-lactamase substrate was reported to detect as 
few as 1000 CFUs in the lungs of mice, yet such a model depends on the adequate administration 
and distribution of an exogenous probe.19 Finally, monitoring of TB lesions has been accomplished 
with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) combined with 
computed tomography (CT) imaging in mice20 and in non-human primates.21 FDG accumulates in 
metabolically active inflammatory cells and enables high resolution imaging of tuberculous lesion 
dynamics, albeit without providing direct quantitative information on the true bacterial load. 
In this study, we exploit the recently described NIR FP iRFP for construction of reporters in 
M. tuberculosis and other mycobacteria. These strains permit a clear visualization of the bacteria in 
infected mice and zebrafish embryos. We report that the bacterial burden can be evaluated with 
NIR fluorescence measurement in vivo and that fluorescence levels in vivo and ex vivo correlate 
with the actual number of CFUs in the lungs of infected mice. Finally, we demonstrate that 
treatment efficacy and the subsequent reduction of the bacterial load can be tracked with 
fluorescence imaging. Here we describe for the first time a mouse model of tuberculosis with SCID 
Hairless Outbred (SHO) mice infected with NIR fluorescent M. tuberculosis. This model is applied 
for whole body in vivo fluorescence imaging and permits to assess the effect of several antibiotics 
on chronically infected living animals, which has until now been limited to quantitative 
measurements ex vivo, during the early progression of the disease.18 Overall, these results show the 
great potential of NIR fluorescence in vivo imaging for longitudinal studies, by allowing the 
kinetics of infection to be followed upon antibiotic administration, to reduce the number of animals 
required per experiment and to gain time in the process of drug development. 
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RESULTS 
Mycobacteria carrying iRFP or mIFP emit NIR fluorescence when supplemented 
with biliverdin 
Genes coding for NIR FPs derived from bacterial phytochromes have previously been expressed in 
mammalian cells, such as HEK293A8 or HeLa,9 in different bacteria (Lactococcus lactis, 
Lactobacillus plantarum and Escherichia coli)14 and in mice,13 but there are no reports of their use 
in mycobacteria yet. To assess expression of NIR FP genes in mycobacteria, the genes iRFP9 and 
mIFP10 were optimized for M. tuberculosis codon usage and cloned in episomal vectors under three 
strong mycobacterial promoters, namely G1322, Psmyc23 and Phsp6024, to generate a collection of 
plasmids (Supplementary Table 1) and to select the brightest reporter. M. smegmatis cells 
transformed with iRFP- or mIFP-containing plasmids emitted fluorescence with a maximal 
intensity at 713 nm only when the growth medium was supplemented with biliverdin (BV), the 
obligate cofactor necessary for the protein to fluoresce (Fig. 1a and b). It is known that in 
eukaryotic cells, expression of a NIR FP gene is sufficient to generate fluorescence, as BV is 
ubiquitously present as the first product of heme degradation8. In the case of bacterial cultures 
however, no fluorescence could be measured without addition of BV exogenously. Wild-type 
bacteria grown in the presence of BV do not fluoresce confirming that the fluorescence measured 
in the reporter strains originates from successful expression of the NIR FP genes, maturation of the 
protein and incorporation of BV. As higher fluorescence intensity could be reached with iRFP than 
with mIFP, iRFP was selected for further optimization and expression in M. smegmatis, 
M. marinum and M. tuberculosis. 
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Co-expression of iRFP and ho1 renders bacteria fluorescent in the absence of 
exogenous BV  
It has been previously proposed that expressing the heme oxygenase 1 (ho1) gene could boost BV 
levels in mammalian cells expressing NIR FP genes.8 Heme oxygenase catalyses the degradation of 
heme to BV. Consequently, we sought to express ho1 in mycobacteria to bypass the need for 
exogenous BV. The gene coding for the human heme oxygenase 1 was codon-optimized for 
expression in M. tuberculosis and cloned directly downstream of iRFP in the episomal plasmids 
described above (without adding a promoter or Shine Dalgarno sequence), to generate the 
NIR_G13, NIR_smyc and NIR_hsp strains (Supplementary Table 1). The new constructs were 
transformed into M. smegmatis and the transformants found to emit fluorescence without addition 
of BV or any other source of heme to the growth medium (Fig. 1c). Interestingly, colonies grown 
on 7H10 plates were slightly green after 4 days at 37°C (Supplementary Fig. 1). This suggests that 
expression of ho1 in M. smegmatis created a bifurcation in mycobacterial heme metabolism to 
generate a pool of BV, directly available for incorporation in iRFP and thereby turn the colonies 
green. In order to qualitatively assess the fluorescence emitted by the bacteria, a culture of a 
NIR_smyc strain was subjected to fluorescence intensity scanning. The excitation and emission 
spectra agree with the data previously published for iRFP9 with measured excitation and emission 
maxima at 690 and 713 nm, respectively (Fig. 1d). 
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Fig. 1. M. smegmatis reporter strains emit NIR fluorescence. a-c, Fluorescence intensity 
measured at 713 nm for M. smegmatis expressing iRFP (a), mIFP (b), cultured overnight with 
or without BV, or NIR M. smegmatis reporters without BV supplementation (c). The 
fluorescence intensity was measured with a microplate reader and normalized according to the 
cell density for each well. The dotted line indicates the background autofluorescence recorded 
in WT bacteria in the same conditions. Data represent averages and s.e.m. for n = 4 
independent clones per group. d, Fluorescence excitation and emission spectra of 
M. smegmatis NIR_smyc reporter. 
 
  
iRF
P_
G1
3
iRF
P_
sm
yc
iR
FP
_h
sp WT
iR
FP
_G
13
iRF
P_
sm
yc
iR
FP
_h
sp WT
0
50,000
100,000
150,000
200,000
Fl
uo
re
sc
en
ce
/O
D
60
0
Without BV With BV
mI
FP
_G
13
mI
FP
_s
my
c
mI
FP
_h
sp WT
mI
FP
_G
13
mI
FP
_s
my
c
mI
FP
_h
sp WT
0
50,000
100,000
150,000
Fl
uo
re
sc
en
ce
/O
D
60
0
Without BV With BV
a b
NI
R_
G1
3
NI
R_
sm
yc
NI
R_
hs
p
WT
0
100,000
200,000
300,000
400,000
Fl
uo
re
sc
en
ce
/O
D
60
0
Without BV
600 700 800
0
100
Wavelength (nm)
N
or
m
al
iz
ed
flu
or
es
ce
nc
e
(%
)
iRFP excitation
iRFP emission
c d
Near-Infrared Fluorescence Imaging of TB Infection 
98 
A NIR M. marinum strain can be quantified in the zebrafish model of mycobacterial 
infection 
Since constructs containing iRFP and ho1 under the control of different promoters enabled us to 
measure strong NIR fluorescence in M. smegmatis we tested whether the optimized system was 
suitable for use in other mycobacteria. Plasmids pNIR_G13, pNIR_smyc and pNIR_hsp were 
electroporated into M. marinum strain M. Once again, transformants carrying the constructs 
exhibited a faint green color and this was most pronounced with pNIR_G13. Several independent 
transformants were grown in liquid culture to measure the fluorescence intensity of the different 
reporters. In M. marinum, expression under G13 control led to 3-fold higher fluorescence intensity 
than expression from Psmyc or Phsp, hence M. marinum NIR_G13 was selected for further analyses 
(Fig. 2a). To test whether NIR mycobacteria can be visualized in vivo, 24 h old zebrafish embryos 
were infected with M. marinum NIR_G13 by microinjection of ~300 bacterial cells into the caudal 
vein.25,26 Bacteria could be observed with confocal microscopy in the muscular tissues of embryos 
3 days post infection (dpi, Fig. 2b). In addition, a group of infected larvae was exposed to the 
experimental TB drug macozinone (MCZ, 25 ng/mL added in E327) starting 1 dpi and continuing to 
the end of the experiment. After 4 days of infection, single embryos were distributed into the wells 
of a 96-well plate and NIR fluorescence measured. The average NIR fluorescence intensity for 
larvae treated with MCZ for 3 days corresponded to the baseline measured in uninfected fish. For 
the untreated group, however, significantly higher fluorescence levels were recorded (Fig. 2c). The 
average number of CFUs recovered from untreated fish was 4 log-fold higher than for embryos 
exposed to MCZ (Fig. 2d), thus corroborating the fluorescence measurements. These observations 
suggest that NIR M. marinum can be used for quantitative evaluation of the bacterial burden in 
infected zebrafish embryos and highlight the potential of NIR reporters for anti-mycobacterial drug 
development. 
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Fig. 2. NIR fluorescent M. marinum can be visualized and quantified in infected zebrafish 
embryos. a, Measurement of NIR fluorescence in cultures of M. marinum transformed with 
the indicated reporter constructs; n = 3 independent transformants per measurement. Bars show 
averages and s.e.m. b, Single plane confocal micrographs showing NIR M. marinum in 
zebrafish embryos at 3 dpi. Bacteria are visualized in NIR fluorescence (left), a gray picture 
(middle) is taken with trans-illumination (TL) and merged channels are shown at right. The 
bottom panel is an uninfected larva, highlighting specific fluorescence emitted by the bacteria 
(displayed in magenta). Scale bar, 100 ?m. c, NIR fluorescence measurement of live infected 
zebrafish embryos with or without MCZ treatment. d, CFUs recovered from infected embryos 
with or without MCZ treatment. Each dot corresponds to one embryo and n = 12 (c) or n = 10 
(d) elements per group. Bars show averages and standard deviations. **** P < 0.0001, ns = not 
significant.  
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Fluorescence in M. tuberculosis NIR reporters correlates with cell density and viability 
In M. tuberculosis, expression with G13 and Psmyc led to reproducibly higher fluorescence levels 
than expression with Phsp, hence NIR_G13 and NIR_smyc were selected for further analyses (Fig. 
3a). The growth rate of M. tuberculosis NIR_G13 and NIR_smyc in vitro was not affected by the 
expression of heterologous genes and the fluorescence intensity correlated with the OD600 during 
the exponential growth phase (Pearson correlation coefficient r > 0.99, measured from day 0 to day 
7, Fig. 3b and c). Notably, the fluorescence intensity continued to rise for 3 days after the culture 
had reached stationary phase (Fig. 3e). This suggests that the maturation of the NIR FP and the 
incorporation of BV may be a slow process and indicates that such reporter systems are especially 
well suited for use with M. tuberculosis, which is a slow growing species with a generation time of 
approximately 20 h. Of note, the highest fluorescence intensity reached with NIR_G13 was about 
2-fold higher than that measured with NIR_smyc. M. tuberculosis NIR_G13 was thus selected for 
ex vivo infections and the viability of THP-1 infected cells indicated that the virulence of 
M. tuberculosis NIR_G13 was slightly attenuated compared to the WT parental strain, while still 
being >5-fold more virulent than the fully attenuated ??RD1 strain (Fig. 3d). We also tested 
whether the NIR fluorescence of the NIR_G13 strain could be used as an indication of cell viability 
in vitro in the presence of a bacteriostatic (chloramphenicol, 8 ?g/mL) or bactericidal 
(moxifloxacin, 15 ?g/mL) antibiotic.18 As expected, the optical density rapidly stabilized or started 
to decrease when chloramphenicol and moxifloxacin were added, respectively. In contrast, growth 
of untreated cultures was normal (Fig. 3f). The same trends were seen when fluorescence was 
measured at the same time points (Fig. 3g). Taken together, these results indicate that the 
fluorescence of the NIR_G13 reporter is a precise indicator of bacterial viability and can serve as a 
read-out to evaluate the cidality of antimicrobials. Encouraged by these observations we 
investigated the potential of our reporter system for in vivo imaging of tuberculosis in mouse 
models. 
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Fig. 3. Characterization of NIR fluorescent reporters in M. tuberculosis. a, Higher 
fluorescence intensities can be achieved when iRFP and ho1 are expressed from the G13 or 
Psmyc promoters. The dotted line indicates background fluorescence of WT bacteria in the same 
measurement conditions. b, c The NIR fluorescence measured over 1 week of growth in liquid 
culture correlates with the OD600 for M. tuberculosis NIR_G13 (b) and NIR_smyc (c) strains. r 
is the Pearson correlation coefficient. **** P < 0.0001. The dashed lines are linear regressions. 
d,Viability of THP-1 cells upon infection with M. tuberculosis NIR_G13, the parental (WT) 
strain and the attenuated ??RD1 strain. e, Comparison of the growth curves (broken lines) and 
evolution of the fluorescence intensity (solid lines) in liquid cultures for NIR_G13, NIR_smyc 
and the parental (WT) strain. f, Measurements of the cell density in M. tuberculosis NIR_G13 
liquid cultures exposed to chloramphenicol (CAM), moxifloxacin (MXF), or untreated (NT). g, 
Measurements of NIR fluorescence in M. tuberculosis NIR_G13 liquid cultures exposed to the 
antibiotics indicated. Addition of antibiotics is indicated by an arrow. 
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NIR M. tuberculosis can be visualized in vivo in the lungs of infected mice 
NIR FPs are appropriate for in vivo imaging in rodents since their emission wavelengths are found 
in the optical window of the highest tissue transparency.11 To test if M. tuberculosis NIR_G13 
could be visualized in vivo, SCID Hairless Outbred (SHO) mice were infected by aerosol exposure 
with the reporter strain and fluorescence was monitored by imaging anaesthetized animals with the 
Photon Imager. A specific fluorescent signal could be detected in the thoracic area 45 days after the 
infection (Fig. 4a), and its strength increased further up to 58 dpi when the animals were sacrificed. 
The fluorescence in the abdomen is a non-specific signal from the food in the digestive track, as 
this is slightly autofluorescent in the NIR wavelengths. Quantification of the fluorescence in the 
thorax revealed a significant increase in signal (Fig. 4b) that can be precisely monitored over time 
in vivo and correlates with the CFUs enumerated 4 weeks later (Fig. 4c). The pNIR_G13 construct, 
which carries a kanamycin resistance cassette, was stably maintained during infection as plating of 
lung homogenates with or without kanamycin revealed no significant difference in the number of 
CFUs (Supplementary Fig. 2). Post mortem quantification of the fluorescence on excised lungs 
confirmed the correlation between fluorescence intensity and the bacterial load (Fig. 4d). 
Measurements made 30, 45 and 58 dpi are time endpoints on independent groups of mice. 
Measurements at 51 and 58 dpi were made on the same group of animals, demonstrating the 
feasibility of longitudinal imaging. Encouraged by these findings, we decided to use this model to 
assess antimicrobial activity. 
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Fig. 4. Visualization and quantification of NIR fluorescence in living infected animals. 
a, One group of mice 45 dpi analysed with NIR fluorescence. The picture is a black and white 
photograph and the NIR fluorescent signal is overlaid in false colour. The quantified zone in 
the thorax is delimited by dashes and reported in b at 45 dpi. b, Quantification of the 
fluorescence intensity in the thorax (indicated as photons per second per steradian) of different 
groups of mice at the time points indicated. Data show averages and s.e.m. The dotted line 
indicates the average background fluorescence level measured in uninfected mice. For all time 
points, n = 5 mice per group. c, d The number of CFU recovered from the lungs of mice at 30, 
45 and 58 dpi correlates with the fluorescence measured and quantified in vivo (c) and ex vivo 
on excised lungs (d). r is the Pearson correlation coefficient. **** P < 0.0001. The dashed lines 
are linear regressions. 
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Fluorescence quantification for drug efficacy testing in vivo and ex vivo 
In order to evaluate the efficacy of treatment, serial dilutions of lung homogenates are commonly 
plated for CFU enumeration and comparison with an untreated control group. Here, we took 
advantage of our fluorescent reporter to assess treatment efficacy from fluorescence measurements 
made in vivo and on excised lungs post mortem. The animals were infected by aerosol exposure 
and treated with the following antibiotics: isoniazid (INH), MCZ, and bedaquiline (BDQ) or with a 
combination of MCZ and BDQ (M+B) for 4 weeks. A significant drop in fluorescence was 
measured in live animals receiving treatment (Fig. 5a). Excised lungs from treated mice displayed 
considerably lower fluorescence than the untreated control animals. Lower fluorescence intensity 
was measured with the group receiving BDQ and M+B as compared to the groups of mice 
receiving INH or MCZ alone (Fig. 5b). This observation was confirmed by enumerating the CFUs 
in all cases (Fig. 5c) thus indicating that post mortem fluorescence imaging can serve as an 
indicator of the level of efficacy of a given treatment. Overall, these results suggest that with our 
NIR M. tuberculosis reporter, it is possible to predict in vivo, i.e. before sacrificing the animal, if an 
antibiotic is effectively reducing the bacterial burden in a mouse model of chronic TB infection. 
Post mortem fluorescence data on excised lungs permits to differentially assess the efficacy of the 
treatments and the CFU numbers enumerated 4-5 weeks later corroborate these measurements (Fig. 
5). 
 
Fig. 5. Fluorescence measurements and CFU enumeration to assess antibiotic efficacy. a, 
b Fluorescence was measured in vivo and quantified in the thorax of mice (a) or post mortem 
on excised lungs (b). For the latter, the fluorescence intensity measurement is adjusted for the 
area of the lung on which the quantification was done and expressed as photons per second per 
square centimeter per steradian. c, Serial 10-fold dilutions of lung homogenates were plated 
and CFUs were enumerated after 4-5 weeks of growth at 37°C. The dotted line indicates the 
average background fluorescence measured in uninfected mice (a) and lungs (b). Bars indicate 
the average and s.e.m. For each group n = 5 mice. NT – non-treated, INH – isoniazid, MCZ – 
macozinone, BDQ – bedaquilline, M+B – combination of macozinone and bedaquiline. 
** P < 0.01, *** P < 0.001, **** P < 0.0001.  
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DISCUSSION 
Here we report for the first time the cloning and expression in mycobacteria of genes encoding NIR 
FPs derived from bacterial phytochromes. Both iRFP and mIFP, codon-optimized for usage in 
M. tuberculosis, can be expressed in M. smegmatis, M. marinum and M. tuberculosis and the 
reporter strains emit NIR fluorescence when BV, the cofactor required for iRFP to fluoresce, is 
added to the growth medium. The BV requirement can be bypassed by co-expression of iRFP with 
the gene coding for the heme oxygenase 1 (ho1) that converts endogenous heme into BV, which is 
readily incorporated by iRFP. In M. tuberculosis, expression of iRFP and ho1 from the G13 
promoter leads to the highest fluorescence intensity measured in vitro. Moreover, the fluorescence 
intensity correlated with the number of bacteria in growing liquid culture and could be used to 
monitor the response to bacteriostatic or bactericidal antibiotics. 
Fluorescence imaging in vivo requires red-shifted probes, especially for deep imaging, because 
absorption, scattering and autofluorescence of the tissues is greatly reduced at wavelengths above 
650 nm. An M. tuberculosis fluorescent reporter producing the Turbo635 protein, which has a 
maximum of emission at 635 nm, has been reported18 to permit the visualization of M. tuberculosis 
in the lungs of CB-17 SCID mice and for quantification of the bacterial loads on excised lungs. 
However, the evaluation of antibiotic efficacy in that study18 was only performed with ex vivo 
fluorescence measurements and during acute progressive infection following intranasal instillation 
of bacteria. In contrast, and for the first time, our investigation allowed drug efficacy to be 
evaluated in living mice with NIR reporters. The low dose aerosol exposure also reproduces the 
natural route of infection, permitting homogenous infection of several groups of mice 
simultaneously, as well as allowing time for the infection to evolve before starting treatment. 
However, NIR M. tuberculosis could not be detected in vivo in infected immunocompetent furless 
SKH1 mice (data not shown). Fluorescence imaging of tuberculosis seems to be restricted, 
therefore, to immunodeficient animals, as suggested elsewhere, since the lower bacterial loads 
reached in immunocompetent mice can be much more difficult to detect in vivo.18 It may be 
possible to overcome this limitation using brighter lasers in fluorescence tomography, image 
enhancement technology, or utilizing mouse lines known to be more susceptible to TB infection, 
such as C3HeB/FeJ (the “Kramnik mouse model”).28 
The zebrafish infection model is finding wider application for assessing the activity of anti-
mycobacterial drugs and is an inexpensive and much more rapid alternative to the mouse. In this 
case, M. marinum, a natural pathogen for fish, is used to infect Danio rerio embryos via caudal 
vein microinjection. The transparency of the larvae facilitates visualization of fluorescent bacteria 
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after infection or upon treatment and this has been done successfully with fluorescent reporters of 
several colours.29 We show here that our NIR M. marinum strain can be visualized in zebrafish 
embryos, thus adding a new colour to the existing palette of fluorescent M. marinum reporters. 
Furthermore, quantification of NIR fluorescence in infected embryos enabled us to assess the 
efficacy of MCZ-treatment in this model, consistent with earlier CFU findings27, highlighting the 
versatility of our approach for several in vivo models of tuberculosis infection, and the ensuing 
applications in drug discovery and development. 
The development of NIR FPs has led to several new tools, applicable to small animal imaging and 
extending the range of available FPs for diverse in vitro assays.11 However, their use in deeper and 
more precise imaging still requires improvement due to their relatively weak brightness.30,31 While 
the Photon Imager Optima permits epi-fluorescence imaging over a wide range of wavelengths, the 
sensitivity of the detection of bacterial infections could be further improved with trans-illumination 
or tomographic methods, as well as with the development of more efficient charge-coupled device 
(CCD) detection systems. Alternatively, intravital fluorescence excitation could partially solve the 
problem of light absorption and scattering by tissue, by providing a source of light deep in the 
lungs with an optical fibre-containing microendoscope.32,33 Photoacoustic tomography constitutes a 
different emerging technology with improved spatial resolution in deep tissues, although this 
technique has not yet been exploited for imaging mycobacterial infections.34,35 Finally, the use of 
NIR fluorescent reporter strains raises the possibility of correlating biomarkers for the pathogen 
with those of the host, such as the signals obtained by PET/CT imaging.20,21 
Development of a mouse model of tuberculosis infection suitable for in vivo biophotonic imaging 
affords numerous advantages over the current models in terms of time, resources and the number of 
animals required. For instance, the slow growth rate of M. tuberculosis requires at least 4 weeks of 
incubation before CFUs can be counted. In addition, excision, homogenisation and plating of lung 
samples are endpoint measurements thus provide no information in real time. Our model with NIR 
fluorescent reporters of M. tuberculosis permits 1) to follow the evolution of the infection in real 
time, 2) to perform several measurements on the same group of mice, thus reducing the total 
number of animals required per experiment, 3) to quantify the bacterial burden with fluorescence 
imaging and 4) to evaluate the efficacy of an antibiotic in vivo.  
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METHODS 
Bacterial strains and culture conditions 
All mycobacterial strains used in this study were grown in Middlebrook 7H9 medium (Difco) 
supplemented with 0.2% glycerol, 0.05% Tween-80 and 10% albumin-dextrose-catalase (ADC) or 
on solid 7H10 agar plates containing 0.5% glycerol and supplemented with 10% oleic acid-
albumin-dextrose-catalase (OADC). M. smegmatis mc2155 and M. tuberculosis H37Rv were 
cultured at 37°C while M. marinum strain M36 was kept at 30°C. THP-1 monocyte cells were 
grown in RPMI supplemented with 10% fetal bovine serum and 1 mM sodium pyruvate at 37°C 
with 5% CO2. Hygromycin (HYG, 50 ?g/mL), kanamycin (KAN, 20 ?g/mL), chloramphenicol 
(CAM, 8 ?g/mL), moxifloxacin (MXF, 15 ?g/mL) and biliverdin HCl (BV, Sigma, 25 ?M) were 
added when appropriate. 
Construction of the fluorescent strains 
The plasmids used in this work were constructed by PCR amplification of iRFP, mIFP or ho1 
optimized for M. tuberculosis codon usage and synthesized by Gencript USA Inc. The M. marinum 
G13 promoter22 was amplified from the plasmid pMV306DIG13+FFlucRT15 (Addgene plasmid 
# 49998) along with the Shine Dalgarno sequence and cloned in pMV26137 in place of the hsp60 
promoter (Phsp60). The plasmid pCHARGE338 with the strong Psmyc promoter (M. smegmatis rpsA 
promoter with tetO operator) was a gift from Tanya Parish (Addgene plasmid # 24658). The codon-
optimized genes were subcloned in pCHARGE3 in place of turbo635 or in the multiple cloning site 
of the pMV261 backbone for expression under either Phsp60 or G13 control. The ho1 gene was 
cloned directly after irfp to generate autofluorescent reporters. pSMT324 was used as an alternative 
vector for expression of iRFP and ho1 under Phsp60. 200 – 500 ng of DNA were electroporated in 
freshly made competent mycobacteria as described elsewhere38 and selected on appropriate 
antibiotics. 
Fluorescence measurements 
M. smegmatis, M. marinum and M. tuberculosis WT and fluorescent strains were grown to an 
OD600 of 0.8-1. 100 ?L of culture were dispensed in black, clear bottom, polystyrene 96-well plates 
and fluorescence intensity was read in a M200 Tecan microplate reader (excitation / emission: 
679 / 713 nm) and normalized to the respective absorbance value at 600 nm, measured in parallel. 
Strains growing with BV were previously centrifuged and resuspended in PBS or 7H9 without BV. 
Fluorescence intensity scans were performed similarly with a Tecan Spark M10 multimode 
microplate reader. 
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Infection of zebrafish embryos 
Zebrafish embryos were infected as previously described.25 Briefly, 24 h old Danio rerio (AB) 
embryos were manually dechorionated and aligned on a custom-made cavity-inlaid agarose bed 
covered with E3 medium40 (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4) 
containing 0.4 mg/mL MS-222 (Sigma). An M. marinum NIR_G13 suspension (1-2 nL containing 
~300 bacteria) was microinjected in the caudal vein of the anesthetized embryos using a heat-
pulled glass capillary connected to a pneumatic PicoPump PV820 (World Precision Instruments). 
The embryos were allowed to recover in fresh E3 and maintained at 28°C. 24 h post infection, 
embryos were distributed in a 6-well plate (15 larvae per well) with 4 mL E3. Macozinone 
(25 ng/mL) was added directly in E3 when appropriate. 
Imaging of infected zebrafish embryos 
At 3 dpi, untreated zebrafish embryos were anesthetized with 0.4 mg/mL MS-222 and embedded in 
1.2% low melting agarose in an 8-chambered coverslip (Ibidi). The solidified agarose was covered 
with a layer of E3 containing 0.4 mg/mL MS-222. Samples were visualized with a Zeiss LSM700 
inverted confocal microscope equipped with a 20× Plan-Apochromat objective (NA 0.8) and laser 
excitation light at 639 nm. Images were processed with the ImageJ software v1.52h 
(https://imagej.nih.gov/ij/). For quantitative fluorescence imaging, single anesthetized zebrafish 
embryos infected with M. marinum NIR_G13 (4 dpi) were dispensed in a black clear-bottom 96-
well plate. Twelve fluorescence reads per well were measured with a Tecan M200 plate-reader (top 
reading, excitation / emission: 679 / 713 nm) and averaged for each well. For fluorescence 
measurements, n = 12 embryos per group. 
Enumeration of mycobacteria in infected zebrafish embryos 
Lysis and decontamination of embryos was performed as described elsewhere25 with some 
modifications. Embryos were euthanized with an overdose of MS-222 and single specimens were 
incubated in 25 ?L of 5% SDS in PBS for 5 min. Larvae were disrupted by pipetting and 25 ?L of 
BBL MycoPrep (BD) was added. The samples were incubated at room temperature for 10 min with 
shaking and neutralized by addition of 450 ?L of PBS. Serial 10-fold dilutions were plated on 
7H10 medium containing 10 ?g/mL cycloheximide and cultured at 30°C for 8 days before CFU 
enumeration. 
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Assessment of virulence in THP-1 cells 
The virulence of the NIR_G13 strain was evaluated as previously described41. THP-1 human 
monocytic cells (105/well) were seeded in 96-well plates and incubated with 100 nM phorbol-12-
myristate-13-acetate (PMA) overnight to stimulate macrophage differentiation. The cells were 
infected with the different M. tuberculosis strains (wild-type, NIR_G13 or ??RD1) at a 
multiplicity of infection of 5. Plates were incubated for 48 h at 37°C with 5% CO2. Macrophage 
viability was measured by adding 10 ?l of PrestoBlue® (ThermoFischer Scientific) and incubating 
for a further 30 min before the fluorescence intensity (excitation / emission: 560 / 590 nm) was 
measured using an Infinite M200 Tecan plate reader.  
Infection and treatment of animals 
All the experiments involving animals were performed under ABSL3 containment and approved by 
the Swiss Cantonal Veterinary Authority under licence number 3082. 6-7 weeks old female SCID 
Hairless Outbred (SHO) mice (Charles River) were infected with M. tuberculosis strain NIR_G13 
by aerosol exposure in a Madison chamber. Isoniazid (INH), bedaquilline (BDQ) and macozinone 
(MCZ), dissolved in water (INH) or in 20% hydroxypropyl-?-cyclodextrin (pH = 3.0, BDQ and 
MCZ), were administered at a dose of 25 mg/kg by oral gavage for 4 weeks, 5 days per week, 
starting 30 dpi. For all experiments, n = 5 animals per group. Infection followed by treatment with 
INH was perfomed twice and provided similar results in the two independent experiments (data not 
shown for the first experiment). Treatment with BDQ, MCZ and M+B were performed once. 
Enumeration of bacteria in the lungs 
At indicated time points and after whole body imaging, mice were euthanized by cervical 
dislocation while under anaesthesia. Lungs were aseptically removed, imaged and homogenized in 
2 mL of PBS containing 0.05% Tween 80. Serial 10-fold dilutions of lung homogenates were 
spread on 7H10 agar containing 16 ?g/mL nalidixic acid (sodium salt), 4 ?g/mL azlocillin (sodium 
salt) and 10 ?g/mL cycloheximide (all from Sigma). Alternatively, homogenates were 
decontaminated by mixing with BBL Mycoprep (50:50 V/V), incubating for 5 min and neutralizing 
with PBS before plating 10-fold serial dilutions on 7H10 containing 0.4% activated charcoal to 
prevent carryover effects. All plates were kept at 37°C for 4-5 weeks before CFU enumeration. 
In vivo and ex vivo imaging 
In vivo imaging of live animals and ex vivo imaging of lungs was performed with a Photon Imager 
Optima (Biospace Labs, France), equipped with an intensified CCD camera mounted on a light-
tight imaging chamber, a 150 W halogen lamp as source of excitation and various excitation and 
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emission band pass filters. Acquisitions were performed with Photo Acquisition (version 
3.4.5.1169) software and the following settings. An excitation filter (645-670 nm) and an emission 
filter (705-740 nm) were used to measure iRFP fluorescence. Autofluorescence was measured with 
a lower wavelength excitation filter (595-620 nm) and subtracted with the M3 Vision image 
analysis software (version 1.1.2.30843). All acquisitions were performed within 10 s of exposure 
with f/1.2 and illumination power at 100%. Fluorescence images, in false colour, were 
superimposed on black and white photographs of the specimen using M3 Vision. For quantification 
of the fluorescence, a region-of-interest (ROI) tool was used. For whole body images, an ROI was 
drawn on the thoracic area of the mice. This ROI was kept with the exact same shape and area for 
the analysis of all the animals and fluorescence intensity is expressed as photons per second per 
steradian (ph·s-1·sr-1). Excised lungs were imaged in a sealed plastic Petri dish and an ROI was 
drawn with the spline tool around the border of each organ. In this case, fluorescence is normalized 
according to the surface of the ROI and expressed as photons per second per square centimetre per 
steradian (ph·s-1·cm-2·sr-1). For imaging of live animals, mice were anaesthetized with 5% 
isoflurane in an induction chamber and transferred on the heated stage (37°C) of the Photon Imager 
Optima. Mice were placed on their back and slightly tilted towards their left side in front of a gas 
manifold to maintain them under isoflurane (reduced to 2%) anaesthesia during image acquisition. 
Statistics 
Statistical analysis was carried out with GraphPad Prism version 7.02. Fluorescence measurements 
in vitro were performed each time on 3 or 4 independent transformants and presented without 
statistical analysis. For in vivo experiments, each group of mice contained n = 5 animals and all of 
them were included in statistical analyses. Zebrafish experiments contained n = 12 embryos for 
fluorescence measurements and n = 10 larvae were homogenized and plated for CFU enumeration. 
When two groups were compared (CFU enumeration from zebrafish larvae), a Mann-Whitney test 
was used. When more than two groups were compared, an ordinary one-way ANOVA followed by 
a Tukey’s multiple comparisons test were performed. For all tests, alpha = 0.05 and adjusted P-
values (two-tailed) are indicated between compared pairs of means. To evaluate the correlation 
between fluorescence measurements and CFU counts, a Pearson correlation test was used and 
linear regression analysis was performed. The Pearson correlation coefficient r is presented with a 
two-tailed P-value. 
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SUPPLEMENTARY DATA 
 
 
Supplementary Fig. 1. A pale green colour is visible on NIR_smyc M. smegmatis colonies 
(left) compared to wild type bacteria (right). 
 
 
ns
 
Supplementary Fig. 2. Similar numbers of CFUs, recovered from the lungs of the group 
sacrificed at 30 dpi, were enumerated when the sample was plated with and without kanamycin 
(the selective marker of pNIR_G13). ns = non-significant  
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Strain name Plasmid name Plasmid backbone 
Gene 
expressed Promoter 
mIFP_G13 pmIFP_G13 pMV261-G13 mIFP G13 
mIFP_smyc pmIFP_smyc pCHARGE3 mIFP Psmyc 
mIFP_hsp pmIFP_hsp pMV261 mIFP Phsp60 
iRFP_G13 piRFP_G13 pMV261-G13 iRFP G13 
iRFP_smyc piRFP_smyc pCHARGE3 iRFP Psmyc 
iRFP_hsp piRFP_hsp pMV261 iRFP Phsp60 
NIR_G13 pNIR_G13 pMV261-G13 iRFP and ho1 G13 
NIR_smyc pNIR_smyc pCHARGE3 iRFP and ho1 Psmyc 
NIR_hsp pNIR_hsp pSMT3 iRFP and ho1 Phsp60 
 
Supplementary Table 1. Plasmids used in this study to construct the reporter strains in 
mycobacteria. 
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Chapter 5. Bioluminescence Imaging of TB Infection 
Comparative Analysis of Luciferase-Based Systems 
for Bioluminescence Imaging of Tuberculosis 
Infection in Mice 
 
 
 
 
 
 
 
 
 
This chapter is a manuscript in preparation (2019). 
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preparation.  
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ABSTRACT 
Tuberculosis (TB) remains an important global health threat particularly due to the emergence of 
multidrug-resistant strains of its causative agent, Mycobacterium tuberculosis. New, more potent 
antibiotics are needed to combat resistance and reduce the duration of treatment. Preclinical anti-
TB drug development generally involves the assessment of drug efficacy in mouse models but such 
procedures are long and laborious, given the slow growth rate of M. tuberculosis. Here, after 
comparing the performance of different luciferases and mouse lines, we demonstrate that an 
autobioluminescent M. tuberculosis reporter strain can considerably shorten this process by 
measuring the luminescence in excised lungs from infected immunocompetent mice, rather than by 
culturing lung homogenates for colony forming unit (CFU) enumeration. The luminescence 
intensity measured in the organs is proportional to the bacterial load and thus provides a measure of 
the relative efficacy of a given antibiotic or drug combination. Furthermore, we show that when 
this reporter is used to infect Severe Combined Immune Deficiency (SCID) Hairless Outbred 
(SHO) mice, longitudinal in vivo measurement of the bacterial load can be performed to evaluate 
disease progression and the response to isoniazid treatment in real time. 
INTRODUCTION 
Tuberculosis (TB) is an infectious disease caused by the pathogen Mycobacterium tuberculosis. 
Despite the availability of antibiotic regimens, TB is the leading cause of death worldwide due to a 
single pathogenic agent.1 An estimated 10 million people fell ill with TB and 1.6 million people 
died in 2017 alone. The reasons of this long-lasting pandemic are the absence of an effective 
vaccine and the emergence of single- and multidrug-resistant (MDR) strains that do not respond to 
first line drugs (isoniazid, rifampicin, pyrazinamide and ethambutol1), emphasising the need for 
new antibiotics to treat MDR-TB and to prevent the development of the disease in the 1.7 billion 
people latently infected with M. tuberculosis.1 
During the TB drug discovery process, the efficacy of new drug candidates is usually evaluated in 
vivo in mouse models of TB infection.2–6 Exposure of mice to aerosols containing M. tuberculosis 
mimics the natural route of infection. In a model of chronic TB, treatments are administered by oral 
gavage starting 4 weeks post infection, when the number of bacteria in the lungs of 
immunocompetent mice plateaus around 106 organisms per lung.5 The efficacy of the treatment is 
generally assessed by plating lung homogenates on solid media, counting the colony forming units 
(CFUs) recovered and comparison with an untreated group. This method is slow since at least 4 
weeks are required for M. tuberculosis to produce visible colonies on agar plates and inefficient by 
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today's standards as data for progression of the infection and treatment efficacy are only obtained 
retrospectively. 
A faster method has been proposed and this involves biophotonic, or in vivo imaging of the 
bacterial infection.7 Quantitative imaging of excised lungs infected with a fluorescent 
M. tuberculosis strain has been reported for the evaluation of antibiotic treatment in CB-17 Severe 
Combined Immune Deficiency (SCID) and SCID Hairless Outbred (SHO) mice.8 Similarly, 
reporter enzyme fluorescence has been used to detect mycobacteria in the lungs of infected 
animals.9–12 Bioluminescent reporters also provide powerful tools to visualize pathogens and 
quantify bacterial loads in vivo and this technique has been successfully applied to M. tuberculosis 
infection.13–15  
Several luciferase-based systems have been developed as reporters of gene expression or cell 
viability. Firefly luciferase has been genetically engineered to emit red-shifted light (FFlucRT, 
maximum of emission at 620 nm) in mycobacteria and proved to be valuable for quantifying the 
bacterial burden in immunodeficient mice.13,14 However, D-luciferin, the substrate for firefly 
luciferase, has to be administered exogenously, usually via intraperitoneal or intravenous injection, 
and its biodistribution might pose problems of variability and reproducibility. Alternatively, the 
luxCDABE operon from Photorhabdus luminescens encodes a luciferase heterodimer (LuxA and 
LuxB) along with the enzymes that produce its substrate (LuxC, LuxD and LuxE). Hence, cells that 
express this cluster emit light spontaneously. The utility of the LuxAB luciferase, which is less 
bright compared to FFlucRT systems, is limited by the wavelength of maximum light emission at 
around 490 nm and absorbance of this blue-shifted light by mammalian tissues16,17. These features 
render Lux-based reporters less appropriate for in vivo imaging.13 The full luxCDABE operon has 
been optimized for expression in high-GC bacteria18 and successfully used as a reporter of cell 
viability in vitro.19,20 P. luminescens luciferase-based autoluminescent systems have been used for 
monitoring M. tuberculosis in mice with a luminometer,15 however, there is no report of whole 
body imaging of mycobacterial infection to date. 
In this study, we investigate the respective advantages and limitations of FFlucRT- and Lux-based 
M. tuberculosis luminescent reporters in different immunocompetent and immunodeficient mouse 
models. Our aims were 1) to reduce the time of in vivo TB experimental infections for drug 
assessment and 2) to establish a system permitting longitudinal imaging on living animals in order 
to follow treatment response in real time via luminescence measurements. We demonstrate here 
that experimental infection of Balb/c and SHO mice with Lux-based M. tuberculosis reporters 
allows these goals to be reached. 
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RESULTS 
Characterization of bioluminescent reporters 
To compare the firefly and P. luminescens luciferase-based systems in mycobacteria, and to 
ultimately monitor TB infection in vivo, mycobacterial reporters were constructed in the parental 
strains M. tuberculosis H37Rv and M. smegmatis mc2155. The Lux reporters were created by 
transformation of the plasmid pEG200,19 which replicates in E. coli and contains the luxCDABE 
operon codon-optimized for expression in high-CG bacteria,18 together with the mycobacteriophage 
L5 attP and integrase sequences, required for integration of a single plasmid copy in the bacterial 
genome.21 The luxCDABE operon is expressed from the strong pUV15 promoter22 and plasmid 
pEG200 has been successfully used as a marker of cell viability in vitro.19,20 Alternatively, plasmid 
pRS200 contains the fflucRT13,14 gene, expressed from the strong mycobacterial promoter G13.23 
pRS200 also contains the attP site and is integrative but the integrase gene was excised from this 
plasmid. pRS200 was transformed in mycobacteria to generate the FFlucRT reporters. Neither 
pEG200 nor pRS200 hampered the growth of the M. tuberculosis reporter strains, as the growth 
curves resemble that of the parental strain (Figure 1a). The luminescence measured for both strains 
correlates with the optical density (OD600) during the exponential growth phase (Figure 1a, d and 
e). Note that the luminescence of the FFlucRT samples exceeded the detection capacity of the plate 
reader after 5 d of culture. The intensity of the luminescent signal is dependent on the final luciferin 
concentration for the FFlucRT reporter. Furthermore, luminescence values weaken over time 
because of substrate consumption (Figure 1b). The bioluminescence spectra, measured in 
luminescent M. smegmatis reporters, indicated emission maxima around 500 and 620 nm for the 
Lux and FFlucRT reporters, respectively (Figure 1c), as previously described.13,16,18  
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Figure 1. Characterization of the FFlucRT and Lux luminescent mycobacterial strains. 
(a) Growth curve of M. tuberculosis strains FFlucRT, Lux and H37Rv alone (WT) measured 
by luminescence (solid lines) and optical density at 600 nm (OD600, broken lines). (b) 
Dependence of the luminescence intensity on D-luciferin concentration and time, for the 
FFlucRT reporter (bacterial suspension adjusted to OD600 = 1). The different curves show 
luminescence measurements of the same samples immediately or 10, 30 or 55 min after 
addition of the substrate. The dashed line shows the stable luminescence level of the Lux 
reporter at the same optical density. (c) Normalized luminescence spectra for the M. smegmatis 
FFlucRT and Lux reporters. (d, e) Correlation between the OD600 and luminescence 
measurements for M. tuberculosis Lux (panel d) and FFlucRT (panel e) reporters. r is the 
Pearson correlation coefficient. *** P < 0.001.  
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The FFlucRT system is insufficiently sensitive in immunocompetent animals 
An M. tuberculosis reporter based on firefly luciferase has previously allowed precise 
quantification of the bacterial burden in vivo and ex vivo in CB-17 SCID mice with a good 
correlation with the CFU counts.13 However, these conclusions were only made on 
immunocompromised animals prompting us to evaluate the performance of our FFlucRT reporter 
in immunocompetent mice. To maximize the sensitivity of our assay, we selected SKH1 mice, 
which are non-pigmented and hairless (homozygous for Hrhr) yet euthymic and fully 
immunocompetent. These mice develop M. tuberculosis infection and bacterial loads reached 
104–105 CFU/lung 4 weeks after low-dose aerosol infection with M. tuberculosis H37Rv (data not 
shown). Mice were infected with the M. tuberculosis FFlucRT reporter and imaged at various time 
points immediately after intra-peritoneal administration of D-luciferin (1 g/kg). As can be seen in 
Figure 2a, a strong albeit variable luminescent signal was visible in the thorax of the infected mice 
4 weeks after infection and the average bacterial load was evaluated at 2.3·104 CFU/lung. Two 
groups of mice were treated with isoniazid (INH) or macozinone (MCZ), respectively, one month 
post infection, and a third group left untreated for control purposes. Each group was imaged at 
regular intervals during treatment and the bioluminescent signal in the thoracic area was quantified. 
The values displayed wide variability both within and between the different groups (Figure 2c), 
which greatly limited assessment of the effect of treatment in vivo. Luminescence measured on 
excised lungs was nonetheless significantly lower for the treated groups than for the untreated 
group (Figure 2b), highlighting improved sensitivity ex vivo compared to in vivo. These results 
suggest that FFlucRT M. tuberculosis reporters can be detected and visualized in SKH1 mice but 
do not enable quantitative evaluation of the bacterial load in vivo, thus precluding longitudinal 
imaging for the evaluation of treatment efficacy. 
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Figure 2. Visualization of FFlucRT M. tuberculosis reporters in SKH1 mice. (a) SKH1 
mice infected with M. tuberculosis FFlucRT imaged 31 d post infection after D-luciferin 
injection. (b) Quantification of the luminescence on excised lungs. INH – isoniazid, MCZ – 
macozinone, NT – not treated. Each dot corresponds to the lungs of one mouse and bars 
represent means and standard deviations. * P < 0.1, ** P < 0.01 on ordinary one-way ANOVA 
and Tukey’s multiple comparisons test (versus NT). (c) Quantification of the luminescent 
signal in the thoracic area of infected SKH1 mice imaged at the time points indicated (d = day) 
post infection or upon treatment with INH or MCZ. Treatments were administered from days 
30 to 65, when animals were euthanized for ex vivo imaging of the lungs. Each dot corresponds 
to one mouse and bars represent means and standard deviations. 
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M. tuberculosis carrying luxCDABE permits precise bacterial load quantification in 
immunocompetent mice ex vivo  
In order to circumvent the need for exogenous D-luciferin administration, the luxCDABE operon 
provides an alternative autoluminescent reporter. While the weak brightness and blue-shifted 
spectrum of luminescence obtained with bacterial luciferase potentially limit its application for in 
vivo imaging,16,17 luminescence remains a faster and time-saving alternative to CFU enumeration 
and can also be measured post mortem on excised lungs. To evaluate the feasibility of this model, 
Balb/c mice, routinely used to assess the efficacy of anti-TB drugs in vivo, were infected with the 
M. tuberculosis Lux reporter strain carrying pEG200. As expected, quantification of the 
luminescent signal upon in vivo whole body imaging did not permit the effect of antibiotic 
treatment to be measured as all the post-treatment measurements display values very close to the 
average luminescence signal obtained with uninfected mice. (Figure 3a) However, when imaging 
was performed on excised lungs, the luminescent signal was significantly lower in lungs from the 
treated groups compared to the untreated controls. Furthermore, lower luminescence was recorded 
in groups treated with bedaquiline (BDQ) or a combination of macozinone and bedaquiline (M+B) 
when compared with groups treated with INH or MCZ alone. (Figure 3b) The CFU values mirror 
and corroborate the luminescence measurements and display a high correlation with them. (Figure 
3c and d) Interestingly, during the course of the infection, the bacterial load reaches a stable plateau 
at ~106 CFU/lung after one month, while luminescence decreases after two months. This 
luminescence reduction is probably associated with a reduced metabolic activity of the bacteria 
entering a latent state. (Supplementary Figure 1) These findings indicate that post mortem 
luminescence measurements on excised lungs from immunocompetent mice infected with an 
M. tuberculosis Lux reporter not only demonstrate that a given treatment reduces the bacterial load, 
but can also rank the relative activities of single drugs or combinations thereof. 
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Figure 3. Evaluation of the bacterial load in Balb/c mice by post mortem luminescence 
measurements. (a) Quantification of the luminescence in the thoracic area of infected mice in 
vivo. The dashed line indicates the average luminescence measured in uninfected mice. (b) 
Quantification of the luminescence on excised lungs from mice receiving the indicated 
treatment for 4 weeks. (c) CFUs recovered from the same lungs as in panel b. (d) Correlation 
between luminescence values and CFUs depicted in panels b and c, respectively. Bars 
represent averages and S.E.M. r is the Pearson correlation coefficient and the dashed line in 
panel d is a linear regression. **** P < 0.0001. 
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In vivo quantitative longitudinal imaging with M. tuberculosis carrying luxCDABE 
It has been reported that an M. tuberculosis strain carrying the luxCDABE operon allows the 
efficacy of several antibiotics to be assessed in vivo.15 The treatments however, were administered 
for 3 days only, starting one day after infection by tail-vein injection of a bacterial suspension and 
the luminescence was measured with a benchtop luminometer. 
In view of the results presented in the preceding section and in order to increase the sensitivity of 
detection in vivo, we infected SCID Hairless Outbred (SHO) mice, which are homozygous for the 
Prkdcscid and the Hrhr mutations. SHO mice can be infected with fluorescent M. tuberculosis strains 
but the mycobacterial growth kinetics appear to be slower than in CB-17 SCID mice,8 allowing a 
larger temporal window for in vivo imaging. Mice were exposed to M. tuberculosis-containing 
aerosols to mimic the natural route of infection and 35 d post infection (dpi), a clear bioluminescent 
signal emanating from the thorax was visible (Figure 4a). Treatment with INH was initiated and the 
same group of mice was imaged at regular intervals. The luminescent signal was quantified in the 
thoracic area for each imaging session. As can be seen from Figure 4a and b, the luminescence 
intensity rapidly dropped after initiation of the treatment and continued to decrease until the end of 
the experiment. By comparison, a group of untreated mice was imaged successively at 36 and 40 
dpi before being sacrificed for CFU enumeration. Untreated mice showed an increase in the 
bioluminescent signal suggesting that the infection with M. tuberculosis remains progressive in 
SHO mice one month after aerosol exposure (Figure 4b), in contrast to the observations made in 
immunocompetent animals. The results of ex vivo imaging and luminescence quantification are 
mirrored by the number of CFUs recovered from the lungs (Figure 4c and d, Supplementary Figure 
2). In summary, the luxCDABE autobioluminescent reporter system allows treatment efficacy to be 
monitored in real time within a single group of mice, and, to our knowledge, this is the first report 
of serial whole body luminescence measurements of tuberculosis infection with this system in live 
animals.  
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Figure 4. Longitudinal in vivo follow up of M. tuberculosis load in SHO mice upon 
treatment with INH. (a) Black/white images of mice with luminescent signal overlaid in false 
colours. Imaging was performed over time on the exact same mice demonstrating the 
feasibility of longitudinal monitoring of treatment efficacy using this system. (b) 
Quantification of the luminescence in the thoracic area for the images depicted in panel a (solid 
line) and an untreated group sacrificed at 40 dpi (dotted line). The data show averages and 
S.E.M. and the dashed line is the average level of bioluminescence measured in 5 non-infected 
mice. (c) Quantification of the luminescence on excised lungs from untreated mice at 40 dpi 
(NT) or mice treated with INH for 4 weeks (INH). (d) CFU enumeration from the organs 
depicted in panel c.  
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DISCUSSION 
Measuring the activity of TB drugs in animal models is a slow and laborious process that has 
scarcely evolved since the 1930s. In recent years, attempts have been made to monitor biomarkers 
of the host and pathogen that could increase speed and sensitivity while reducing the number of 
animals required, ideally by following the same cohort for the duration of the experiment. PET/CT 
analysis is a good example of the former24 whereas the use of a fluorogenic ?-lactamase substrate 
has been proposed as a means of detecting M. tuberculosis in vivo12. In this investigation we 
compared the relative efficiency and sensitivity of M. tuberculosis reporter strains expressing two 
different luciferases, one from the firefly (FFlucRT), the other from the bacterium P. luminescens 
(Lux), in two different mouse lines. 
By infecting Balb/c mice with a Lux M. tuberculosis reporter, we showed that the measurement of 
the luminescent signal on excised lungs, but not live animals, provides precise evaluation of the 
bacterial burden and an immediate indication of antibiotic efficacy. Furthermore, the luminescence 
level also provides accurate information on the relative efficacy of different drugs and drug 
combinations since the luminescence signal mirrors the bacterial load as determined by CFU 
enumeration. Depending on the assay design, this approach permits conclusions to be drawn up to 
1.5 times faster than with the regular CFU assays (i.e. 2 instead of 3 months). 
Luminescence measurement on excised lungs is an endpoint assay. Further improvement lies in 
following evolution of the infection longitudinally, in the same animals in real time. In 
immunocompetent Balb/c mice infected with the Lux reporter, no luminescent signal could be 
quantified in the thorax probably due to their cell-mediated immunity containing and controlling 
the infection thereby limiting multiplication of bacteria to 106 CFU/lungs.5 Furthermore, their fur 
also attenuates light. These combined effects explain why the Balb/c model is not appropriate for in 
vivo imaging with luciferase-based M. tuberculosis reporters. 
In contrast, SCID Hairless Outbred (SHO) mice allowed more permissive progression of the 
infection and lack fur. When this mouse line was infected with the M. tuberculosis Lux reporter, 
luminescence could be detected and quantified on the thorax of living mice, as early as 35 dpi (low-
dose aerosol exposure). SHO mice appear less susceptible to M. tuberculosis infection than CD-17 
SCID mice, allowing for more flexibility in imaging and treatment follow up. We demonstrated 
that with this model it is possible to monitor INH treatment in real time on a single group of mice. 
Such an experiment easily provides information regarding the rate of the therapeutic effect and also 
permits the effect of different doses to be evaluated. The two drawbacks with this model are 1) the 
SCID phenotype and the lack of the adaptive immune response; and 2) outbreeding of the animals, 
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which might lead to more variability of the results. A congenic variant exists (SCID Hairless 
Congenic or SHC mice) carrying Prkdcscid and the Hrhr mutations and was obtained by 
backcrossing SKH1 onto a CB-17 SCID background. However, the utilization of SHC mice for 
TB-studies has never been reported. 
M. tuberculosis FFlucRT strains have been used for in vivo imaging in CB-17 SCID mice.13 Our 
attempts to perform similar measurements in immunocompetent (SKH1) mice were, alas, 
unfruitful. Although luminescence in the lungs of infected mice could be detected, the high 
variability among and within the different groups prevented quantitative measurement of the 
bacterial loads during antibiotic treatment. Exogenous administration of the substrate D-luciferin by 
injection and differences in its biodistribution might lead to variability and its metabolism by liver 
enzymes can also be a source of background luminescence. In contrast, when SHO mice were 
infected with the M. tuberculosis Lux reporter strain, the luminescent signal was precisely localized 
to the thorax.  
Our results indicate that infection of mice with an autoluminescent M. tuberculosis reporter 
carrying the luxCDABE operon can 1) bypass the need for exogenous substrate injection required 
for FFlucRT reporters, 2) allow assessment of bacterial loads on excised lungs from Balb/c mice 
and more rapidly indicate the relative efficacy of different antibiotic treatments than the CFU 
enumeration method and 3) enable longitudinal whole body imaging of tuberculosis infection and 
response to antibiotic treatments in real time in SHO mice. These significant improvements to the 
TB drug development process could help reduce the time to reach clinical trials. 
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METHODS 
Bacterial strains and culture conditions 
Mycobacteria were grown in Middlebrook 7H9 medium (Difco) containing 0.2% glycerol, 0.05% 
Tween-80 and 10% albumin-dextrose-catalase (ADC) or on solid 7H10 agar plates supplemented 
with 0.5% glycerol and 10% oleic acid-albumin-dextrose-catalase (OADC). Strains M. smegmatis 
mc2155 and M. tuberculosis H37Rv were cultured at 37°C. Hygromycin (HYG, 50 ?g/mL) was 
added when appropriate. 
Construction of reporter strains 
The integrative plasmid pEG200 containing the luxCDABE gene cluster optimized for expression 
in high-GC bacteria organisms was a kind gift from Neeraj Dhar.19 The plasmid pRS200 was 
constructed by PCR amplification of the region containing the G13 promoter, Shine Dalgarno and 
fflucRT gene from the plasmid pMV306DIG13+FFlucRT,13 kindly provided by Brian Robertson 
(Addgene plasmid # 49998). The amplicon was then subcloned in a vector variant of pGA4425 
(pGA118) containing a hygromycin resistance cassette and a mycobacteriophage L5 attP 
integration site. M. tuberculosis reporter strains were obtained after electroporation of 200 – 500 ng 
of DNA, as described elsewhere,26 and plating on 7H10 containing hygromycin. When needed, 
pGA8025 was co-transformed to provide the integrase in trans.  
Luminescence measurements in vitro 
100 ?L of bacterial culture were dispensed in white opaque 96-well plates. In the case of FFlucRT 
reporters, D-luciferin was added at a final concentration of 150 ?g/mL (from a stock solution 
prepared at 15 mg/mL in PBS and diluted 1:100 V/V), unless otherwise indicated, and 
luminescence was measured immediately after with a Tecan Infinite M200 (integration time 1 s). 
Luminescence spectra were acquired with M. smegmatis luminescent strains with a Tecan Spark 
10M multimode microplate reader. Scans were performed from 398 nm to 653 nm with a step size 
of 15 nm, a bandwidth of 25 nm and an integration time of 1 s. Graphs were plotted with GraphPad 
Prism version 7.02. 
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Infection and treatment of animals 
5-6 week old female Balb/c, SKH1 or SCID Hairless Outbred (SHO) mice (Charles River) were 
infected with M. tuberculosis luminescent reporter strains by aerosol exposure in a Madison 
chamber. The antibiotics isoniazid (INH), dissolved in water, bedaquiline (BDQ) and macozinone 
(MCZ), dissolved in 20% hydroxypropyl-?-cyclodextrin (pH = 3.0), were administered at 25 mg/kg 
by oral gavage for 4 weeks, 5 d per week, starting 30 d after the infection. Experiments involving 
mice were performed under ABSL3 containment and approved by the Swiss Cantonal Veterinary 
Authority (license number 3082). Experiments involving mice were performed once, with 5 
animals per group infected and treated identically. 
Enumeration of bacteria in the lungs 
At the time points indicated and after in vivo imaging, animals were sacrificed by cervical 
dislocation while anaesthetized. Lungs were aseptically excised, imaged in a black 24-well plate 
and homogenized in 2 mL of PBS containing 0.05% Tween 80. Serial 10-fold dilutions of the lung 
homogenates were plated on 7H10 agar containing 16 ?g/mL nalidixic acid (sodium salt), 4 ?g/mL 
azlocillin (sodium salt) and 10 ?g/mL cycloheximide (all from Sigma). Alternatively, homogenates 
were decontaminated by mixing with BBL Mycoprep (50:50 V/V), incubating for 5 min and 
neutralizing with PBS before plating 10-fold serial dilutions on 7H10 containing 0.4% activated 
charcoal to prevent carryover effects. All plates were cultured at 37°C for 4-5 weeks before CFU 
enumeration. 
In vivo and ex vivo imaging 
In vivo imaging of live animals and ex vivo imaging of lungs was performed with a Photon Imager 
Optima (Biospace Labs, France), equipped with an intensified CCD camera mounted on a light-
tight imaging chamber. Acquisitions were performed with Photo Acquisition (version 3.4.5.1169) 
software, f/1.2, without filters and integrated over 20 min for Balb/c mice and organs and 5 min for 
SHO mice and lungs. Luminescent signals were superimposed with black and white photographs of 
the specimen using M3 Vision image analysis software (version 1.1.2.30843). For quantification of 
the luminescence, a region-of-interest (ROI) tool was used. For whole body images, an elliptic ROI 
was drawn on the thorax and kept with the exact same shape and area for the analysis of all the 
animals. Radiance is expressed as photons per second per steradian (ph·s-1·sr-1). Organs were 
distributed in the wells of a 24-well black Ibidi plates for imaging. Quantification of the radiance 
was performed with a circular ROI adapted to the size of a single well. Alternatively, extracted 
lungs were imaged in a sealed plastic Petri dish and an ROI was drawn with the spline tool around 
the border of each organ. In the latter case, radiance was normalized according to the surface of the 
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ROI and expressed as photons per second per square centimetre per steradian (ph·s-1·cm-2·sr-1). For 
imaging of live animals, mice were anaesthetized with 5% isoflurane in an induction chamber and 
transferred on the heated stage (37°C) of the Photon Imager Optima. Mice were placed on their 
backs or slightly tilted towards their left side in front of a gas manifold to maintain them under 
isoflurane (reduced to 2%) anaesthesia during image acquisition. 
Statistics 
Statistical analysis was carried out with GraphPad Prism version 7.02. When two groups were 
compared, a Mann Whitney test was used. When more than two groups were compared, an 
ordinary one-way ANOVA followed by a Tukey’s multiple comparisons test were performed. To 
evaluate the correlation between luminescence measurements and CFU counts, a Pearson 
correlation test was used and linear regression analysis was applied were indicated. 
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SUPPLEMENTARY DATA 
 
 
Supplementary Figure 1. Measurement of the luminescence in excised lungs and enumeration 
of the CFUs at the time points indicated. Balb/c mice were infected with the M. tuberculosis 
Lux reporter. Both the luminescence and number of CFUs reach a plateau at 30 dpi. The 
number of CFUs remains stable for an additional month at 106 CFU/lung while the 
luminescence decreases at the last time point (arrow). 
 
 
 
Supplementary Figure 2. Luminescence imaging of excised lungs from the untreated group of 
SHO mice (40 dpi, left panel) or mice treated with INH for 4 weeks (right panel). Images show 
black and white pictures of the organs overlaid with the luminescence signal in false colours. 
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Chapter 6. Zebrafish Embryos for TB Drug Discovery 
The Zebrafish Embryo as a Tool for Anti-TB 
Drug Discovery and Development 
 
 
 
 
 
PREFACE 
During the last year and a half of my PhD studies, I had the great opportunity to learn innovative 
techniques and applications with a model to study tuberculosis in vivo that is becoming more and 
more popular: the zebrafish. Beside investigations on host-pathogen interactions, zebrafish 
embryos infected with mycobacteria can serve in primary assays to evaluate the efficacy of anti-
mycobacterial compounds in vivo, with major advantages over the mouse model of tuberculosis in 
terms of time and resources. In line with the general theme of my Thesis regarding the refinement 
of standard methods to study tuberculosis in vivo and to improve drug discovery, I present in this 
chapter four projects in which I implemented the zebrafish model to complement ongoing efforts 
on anti-mycobacterial drug development.  
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INTRODUCTION 
Danio rerio, commonly named zebrafish, has become a popular and attractive vertebrate model 
organism over the past twenty years, with a wide range of applications including in mycobacterial 
pathogenesis.1–4 Their small adult size, ease of breeding, genetic accessibility and larval 
transparency – just to name a few – are advantageous features favouring their popularity in 
biomedical research labs, as complements, even surrogates, to rodents. Zebrafish have been used as 
hosts for studying microbial pathogenesis with several human and fish pathogens.5 In order to 
model mycobacterial infections in zebrafish, Mycobacterium marinum, a species closely 
genetically related to M. tuberculosis and a natural pathogen of cold-blooded animals, is usually 
used for experimental infections in adult fish or in embryos. M. marinum infection causes disease 
in fish, recapitulating several features of M. tuberculosis infection in humans.6,7 Notably, infection 
by caudal vein microinjection in 24 h old embryos, which rely solely on their innate immune 
system, is sufficient to observe the formation of early granulomas following phagocytosis and 
migration of infected macrophages from the blood stream to deeper tissue.2,4 
This model has been extensively applied to study host-pathogen interactions, granuloma dynamics 
and the roles of mycobacterial virulence factors.8 Its application to anti-mycobacterial drug 
discovery and development began a few years ago.9,10 In 2014, a study reported the utilization of 
the zebrafish-M. marinum infection model to validate the in vivo anti-mycobacterial efficacy of 
second generation benzothiazinones (PBTZs), a new class of potent bactericidal anti-TB drugs, 
showing lower embryonic toxicity compared to the first BTZ generation.11 
As a starting point for the development of the assays described in this chapter, the following 
scheme was applied (Scheme 1). After collection and sorting fertilized eggs, embryos were kept at 
28°C in E3 (see Methods section). At 24 h post fertilisation, embryos were infected by 
microinjection into the caudal vein (~300 bacteria in 1-2 nL) to mimic systemic infection. 24 h post 
infection, groups of embryos were allocated to defined treatment conditions or left untreated. 4 d 
post infection (dpi), the embryos were euthanized, homogenized and decontaminated by alkaline 
treatment with the MycoPrep (BD) reagent (containing 1% NaOH and killing non-mycobacterial 
species in the fish lysate). Serial 10-fold dilutions were plated for colony forming unit (CFU) 
enumeration. Finally, zebrafish embryos have been used to model the pathogenesis of M. abscessus 
in vivo, as well as for drug discovery against this emerging pathogen.12,13 
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Scheme 1. General timeline to assess anti-mycobacterial drugs in infected zebrafish 
embryos. dpf = days post fertilisation. 
 
In line with these demonstrations,8–13 we applied similar approaches to the following contexts, 
which will be explained and discussed in this chapter: 
1) In vivo activity of pyridomycin in M. marinum-infected zebrafish embryos 
2) Investigating the role of fadD9 in clofazimine resistance in vivo 
3) Efficacy of inhibitors of mycobacterial virulence factor secretion in infected embryos 
4) Activity of arylvinylpiperazine amide derivatives against M. abscessus in vivo 
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IN VIVO ACTIVITY OF PYRIDOMYCIN IN M. MARINUM-INFECTED EMBRYOS 
Background Information 
Pyridomycin was initially described in 1935.14 This molecule (Figure 1), a natural compound 
produced by the actinomycete Dactylosporangium fulvum, exhibited specific antimicrobial activity 
against several mycobacteria and its mechanism of action has been discovered only recently.15,16 
These studies demonstrated that pyridomycin is a direct competitive inhibitor of the NADH-
binding site of the NADH-dependent enoyl-[Acyl-Carrier-Protein] reductase InhA, which is also 
the target of isoniazid, a frontline anti-TB prodrug. Inhibition of InhA by pyridomycin or isoniazid 
leads to the interruption of mycolic acid synthesis, which is one of the most powerful means to kill 
mycobacteria.15 However, the emergence of multidrug-resistant M. tuberculosis strains, which are 
resistant to isoniazid and other frontline drugs, compromise current available therapeutic strategies. 
Notably, pyridomycin kills isoniazid-resistant clinical isolates of M. tuberculosis. Furthermore, no 
cross-resistance has been observed between pyridomycin and isoniazid, making this compound a 
promising scaffold for the treatment of drug-resistant TB. 
Two 2,1’-dihydropyridomycin isomers have been recently synthesized.17 While the 2S isomer 
presented a much lower activity against M. tuberculosis, the 2R isomer only showed a fourfold 
increase in MIC, encouraging the production of other synthetic pyridomycin analogues. Among 
them, the synthetic compound DM122 (Figure 1) displayed similar activity as pyridomycin in vitro. 
Like pyridomycin, DM122 increases the viability of M. tuberculosis-infected THP-1 cells 
compared to untreated infected controls and the mechanism of action of DM122 is under 
investigation (Lupien A. et al., manuscript in preparation). 
 
Figure 1. Molecular structure of pyridomycin (PYR) and its synthetic analogue DM122. 
PYR DM122
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To complement in vitro and ex vivo data, the aim of our study was to test whether pyridomycin and 
DM122 can reduce mycobacterial loads in vivo. Using the zebrafish embryo model of M. marinum 
infection, we showed that exposure of infected larvae to pyridomycin and DM122 diminishes the 
number of CFU per fish. The zebrafish model is especially useful as the procedure does not require 
large amounts of drugs, usually difficult to obtain with synthetic experimental compounds such as 
DM122. This is, to our knowledge, the first demonstration of pyridomycin and DM122 efficacy in 
vivo. In addition, no toxicity was observed for zebrafish embryos exposed to these drugs at the 
concentrations tested. These results are encouraging for the further development of pyridomycin-
based anti-mycobacterial drugs, especially to treat drug-resistant infections. 
Pyridomycin and DM122 treatment reduces bacterial loads in M. marinum-infected 
zebrafish embryos 
The in vitro minimal inhibitory concentration (MIC) of pyridomycin and its most potent analogue 
DM122 against M. marinum were 3.16 and 6.3 μg/mL, respectively. To test whether pyridomycin 
and DM122 have antibacterial activity in vivo, zebrafish embryos were infected with M. marinum 
via microinjection in the caudal vein and drugs were added directly to fish water 24 h post 
infection. Larvae were exposed for 3 d to several concentrations of the drugs before lysis and 
plating of fish homogenates for CFU enumeration. CFU numbers recovered from infected embryos 
exposed to 2, 5 or 10× the in vitro MIC of pyridomycin or DM122, were similar to those counted 
for untreated embryos, indicating that the drugs are inactive in vivo at these concentrations (Figure 
2a). At 50× MIC, pyridomycin exposure led to a slight yet significant reduction of CFUs when 
compared to a non-treated group (Figure 2b). DM122 was still ineffective at 50× MIC and slightly 
precipitated. The concentration of DMSO was raised to 2% to aid solubilisation without affecting 
the bacterial load (Figure 2c). A significant reduction of the CFUs was observed for fish exposed to 
75 and 100× the MIC of pyridomycin and DM122 (Figure 2d). This therapeutic effect was 
similarly observed when fish were exposed to isoniazid. To compare the effect of both drugs at the 
same concentration, infected embryos were exposed to a molar concentration of pyridomycin or 
DM122 equivalent to 75× the in vitro MIC of pyridomycin. Both drugs significantly reduced the 
bacterial load in zebrafish embryos at this concentration (Figure 2e). The slightly attenuated 
efficacy of DM122 can be attributed to its weak solubility in water. Finally, similar conclusions 
could be drawn when fluorescence intensity of bacterial reporters was used as a readout instead of 
CFU enumeration, corroborating our observations (Figure 2f). Notably, exposure to pyridomycin, 
DM122 or 2% DMSO did not significantly impact embryonic development, as the length of 
embryos at 3 d of treatment was similar in treated and untreated fish (Figure 2g). Taken together, 
our observations indicate that both pyridomycin and DM122 reduce mycobacterial loads in 
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M. marinum-infected zebrafish embryos without affecting embryonic development, indicating a 
highly specific and effective anti-mycobacterial activity in this model with low side-effects. 
 
 
Figure 2. Anti-mycobacterial activity of pyridomycin and DM122 in M. marinum-infected 
zebrafish embryos. a, CFUs recovered from zebrafish embryos treated with pyridomycin 
(PYR) or DM122 at their indicated fold MIC. b, Enumeration of CFUs from infected zebrafish 
embryos treated with PYR at 50× its MIC. c, Number of colonies recovered from zebrafish 
larvae exposed to DM122 at 50× its MIC or 2% DMSO. d, CFUs recovered from fish larvae 
treated with isoniazid (INH, 400 μM), PYR and DM122 at the indicated multiple concentration 
of their respective MIC. e, Recovery of CFUs from zebrafish embryos treated with the same 
molar concentration of PYR or DM122 (drug concentration = 75× MIC of PYR). f, Evaluation 
of the bacterial load in zebrafish embryos infected with a fluorescent M. marinum reporter and 
exposed to 2% DMSO, PYR and DM122 (at 75× their respective MIC). g, The total length of 
the embryos is not affected by exposition to the compounds PYR, DM122 (at 75× their 
respective MIC) and 2% DMSO. NT = not treated, NI = not infected, E3 = E3 medium only. ns 
= not significant, **** P < 0.0001 on ordinary one-way ANOVA and Tukey’s multiple 
comparison test. * P = 0.0194 on Mann Whitney test.  
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INVESTIGATING THE ROLE OF FADD9 IN CLOFAZIMINE RESISTANCE IN VIVO 
Background Information 
Clofazimine (CFM, Figure 3) is a riminophenazine drug commonly used to treat leprosy. It is part 
of the multidrug therapy recommended for leprosy treatment by the WHO, along with rifampicin 
and dapsone.18 It was recently repurposed for the treatment of multidrug-resistant TB.19 Several 
preclinical studies reported the benefits of CFM-containing regimens to treat TB in mice20,21 and 
synergism could be observed when CFM was combined with benzothiazinones.22,23 The mode of 
action of CFM in M. tuberculosis and M. smegmatis has been investigated by others.24 The study 
reported that CFM can act as a prodrug that is reduced by type 2 NADH-quinone oxidoreductase 
(NDH-2). Its subsequent spontaneous nonenzymatic reoxidation releases reactive oxygen species 
(ROS). ROS at high concentration can trigger cell death but do not have a specific target, rendering 
CFM resistance difficult to characterize in this context. It has also been proposed that 
overexpression of MmpL5 (a multisubstrate efflux pump) can lead to low-level resistance to CFM 
and cross-resistance to bedaquiline, a new promising anti-TB drug inhibiting M. tuberculosis ATP 
synthase,25,26 by boosting efflux mechanisms.27 
 
Figure 3. Molecular structure of clofazimine. 
 
The precise mode of action and resistance mechanisms of CFM in the unculturable, intracellular 
pathogen, Mycobacterium leprae, the causative agent of leprosy, remain poorly understood, 
however. Comparative genomics on 154 M. leprae genomes revealed polymorphisms in the gene 
fadD9, occurring exclusively in multidrug resistant strains.28 The observed mutations are frameshift 
mutations, premature stop codons or non-synonymous mutations. Consistent with these 
observations, fadD9 which encodes a putative fatty-acid-CoA ligase, is not required for the in vitro 
growth of M. tuberculosis 29,30 This led us to hypothesize that the polymorphisms in fadD9 
CFM
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observed in M. leprae may be associated with drug resistance and play a role in the mode of action 
of CFM. As genetic modification of M. leprae is impossible, the role of fadD9 in CFM resistance is 
currently being investigated in M. tuberculosis and M. marinum as surrogate hosts. 
Preliminary data with an M. tuberculosis strain in which fadD9 had been deleted showed that the in 
vitro susceptibility to CFM was not significantly altered compared with the wild-type (WT) strain. 
However, when THP-1 cells were infected with M. tuberculosis, the deletion of fadD9 conferred 
resistance to CFM and viability of THP-1 cells was reduced, compared to cells infected with WT 
bacteria and exposed to the same amount of CFM. This led to the hypothesis that when 
M. tuberculosis or M. leprae bacteria grow intracellularly, then the activity of FadD9 contributes to 
their susceptibility to CFM. 
In an effort to validate this hypothesis, we worked with an M. marinum strain carrying a transposon 
in fadD9 (M. marinum fadD9::tn), thus abolishing the normal expression of this gene. Previous 
observations suggested that the CFM resistance phenotype appears only when bacteria grow inside 
macrophages, so we applied the zebrafish embryo model of mycobacterial infections to explore this 
hypothesis in vivo and upon exposure to CFM. 
 
 
 
 
 
 
 
Figure 4 (page vis-à-vis). Anti-mycobacterial activity of clofazimine in M. marinum-
infected zebrafish embryos. a-c, Photographs of infected zebrafish embryos taken 4 dpi, 
depicting their global morphology upon exposure to 1 ?g/mL CFM (b), 2 ?g/mL CFM (c) or 
left untreated (a). d, Close up of the morphology of uninfected fish (top panel) or infected fish 
(bottom panel) 4 dpi. Arrowheads indicate probable lesions caused by M. marinum. e-f, CFUs 
recovered from zebrafish larvae infected with M. marinum strain M WT (e) or fadD9::tn (f) 
and treated with the indicated dose of CFM. ns = not significant, * P < 0.05, ** P < 0.01 *** P < 
0.001 on ordinary one-way ANOVA and Tukey’s multiple comparison test.  
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An optimal compromise between drug toxicity and anti-mycobacterial activity of 
CFM is achieved at a concentration of 1 ?g/mL 
Before comparing the efficacy of CFM treatment in zebrafish embryos infected with WT or 
fadD9::tn M. marinum, we evaluated whether CFM was toxic to the embryos by exposing them to 
different concentrations of CFM. Addition of >1 ?g/mL CFM in fish water led to a slight orange 
coloration of the embryos, mainly visible in the yolk (Figure 4a-c). This is consistent with its 
known high lipophilicity, often leading to skin coloration in patients treated with this drug.31 At a 
concentration of >1 ?g/mL, embryonic malformations were visible as soon as 24 h after drug 
addition (Figure 4c). Notably, dorsal spinal curvature was visible in most of the embryos treated 
with 2 ?g/mL CFM suggesting that the compound is toxic for the embryos at this concentration. At 
>2 ?g/mL, most of the embryos died before the end of the experiment (3 d of drug exposure in 
total). No malformations were visible at concentrations ?1 ?g/mL and we therefore decided to use 
final concentrations ?1 ?g/mL for our assays, to minimize toxicity. Interestingly, dark areas 
(probably necrotic regions), absent in non-infected fish, were visible in untreated embryos at 4 dpi 
(Figure 4d, arrowheads). These regions are likely to be lesions triggered by early granuloma 
formation as previously reported.2 
fadD9::tn M. marinum do not display a CFM resistance phenotype upon zebrafish 
larvae infection 
The in vitro MIC of CFM in WT and fadD9::tn mutant M. marinum was 0.2 μg/mL for both 
strains, confirming that a disruptive mutation in fadD9 does not confer resistance to CFM in 7H9 
complete medium. To test whether a CFM resistance phenotype can be observed upon infection, 
24 h old zebrafish embryos were infected with either WT or fadD9::tn M. marinum bacteria by 
microinjection in the caudal vein. 24 h later, 1, 0.5 or 0.25 ?g/mL CFM was added directly in fish 
water and larvae were exposed to the drug for 3 consecutive days before homogenization and 
plating for CFU enumeration. As can be seen in Figure 4e, more than 1.5 log-fold reduction in 
CFUs was achieved on exposure to 1 ?g/mL CFM, validating the efficacy of this drug in the 
zebrafish model at a concentration as low as 5× its in vitro MIC. The antimicrobial activity was 
dose dependent and at 0.25 ?g/mL, no significant therapeutic effect could be observed (Figure 4e). 
Unexpectedly, similar dose-dependent antimicrobial activity was observed in embryos infected 
with the fadD9::tn mutant (Figure 4f), suggesting that an inactive FadD9 is not sufficient to confer 
resistance to CFM upon M. marinum infection in the zebrafish embryo model. 
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EFFICACY OF INHIBITORS OF MYCOBACTERIAL VIRULENCE FACTOR SECRETION  
Background Information 
Bacterial resistance to antibiotics has become one of the greatest threats to global health in the 
twenty-first century and new strategies to treat infectious diseases are being explored.32 An 
innovative proposal is to inhibit the virulence mechanisms of bacterial pathogens. This approach 
has the added advantage of lowering the risk of resistance developing.33 Anti-virulence compounds 
do not directly affect microbial growth and it is therefore postulated that bacteria are much less 
subject to selective pressure for resistance development.34 
M. tuberculosis’ most crucial virulence factor is a type VII secretion system named ESX-1, which 
is missing in the attenuated vaccine strain Mycobacterium bovis BCG. Although all the functions of 
ESX-1 effector proteins are not fully understood, these factors are required for mycobacterial 
survival in the host and escape from the phagosome of the macrophage into the cytosol. Taking this 
into account, it is legitimate to propose that ESX-1 inhibition could be a good strategy to control 
M. tuberculosis upon infection.34,35 
Two promising inhibitors of mycobacterial virulence, the benzothiophene BTP15 and the 
benzyloxy benzylidene hydrazine BBH7, have been identified in a cell-based anticytolytic screen.35 
BTP15 seemed to be a specific ESX-1 inhibitor, protecting lung fibroblasts from M. tuberculosis-
induced cell death and reducing intracellular bacterial load in infected THP-1 macrophages without 
affecting bacterial growth in vitro. The proposed mechanism of action of BTP15 is the inhibition of 
the histidine kinase MprB, which is part of a two-component system that directly regulates ESX-1. 
Indeed, BTP15 addition to M. tuberculosis cultures led to reduced detection of EsxA, an ESX-1-
secreted protein, in the culture milieu. Notably, EsxA has been associated with interruption of 
phagosome maturation, cytosolic escape and host cell lysis.36 
It has been reported that BTP15 does not inhibit bacterial growth in vitro.35 In order to appreciate 
its anti-virulence effect, ex vivo infections of lung fibroblasts or THP-1 cells are thus necessary. In 
addition, the zebrafish embryo model of mycobacterial infection seems well suited for this assay, in 
order to measure the anti-virulence properties of this inhibitor in vivo, and this is the subject of this 
study. It has been demonstrated that macrophages are functional in zebrafish embryos and these 
immune cells can phagocytose mycobacterial pathogens upon infection.2 We hypothesized that 
treatment of infected zebrafish embryos with inhibitors of mycobacterial virulence factors would 
promote phagolysosomal fusion and attenuate intracellular bacterial growth. We assessed this 
hypothesis by counting CFUs recovered from embryos and our observations are described below. 
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Optimization of an anti-virulence drug assay in the zebrafish embryo model of 
M. marinum infection 
For this assay, 24 h old zebrafish embryos were infected with M. marinum via caudal vein 
microinjection and subsequently exposed to the candidate compounds at different concentrations. 
The half maximal inhibitory concentration (IC50) of BTP15 in lung fibroblasts infected with 
M. tuberculosis was 1.2 ?M35 (equivalent to 0.43 ?g/mL) and embryos were exposed to 
concentrations ranging from 1 to 100 ?g/mL. We observed high toxicity towards zebrafish 
embryos in this range of concentrations: all the individuals of several groups had died the day after 
the drug was added, as indicated by absence of heart beat, shrinking and darkening of the larvae. 
The maximal tolerated dose of BTP15 for this assay was only 1 ?g/mL (Table 1). However at this 
concentration, no difference could be observed in the number of CFUs when treated and untreated 
groups were compared. (Figure 5a). 
Based on preliminary in vitro and ex vivo activity assays of several BTP derivatives with 
M. tuberculosis, (Lupien, A., et al, manuscript in preparation), a selection of 5 benzothiophene 
(BTP) analogues (Table 1) was made for application in the zebrafish model. As seen with BTP15, 
most of the molecules were found to be toxic for the embryos. The maximal drug concentrations 
tolerated for this assay are listed in Table 1. As BTP derivatives are anti-virulence drugs, we 
thought that the effect of the treatment would be more pronounced if the molecules were added 
immediately after infection at 24 h post fertilization (hpf). This was not the case, as similar 
numbers of CFUs were recovered from treated and untreated groups (Figure 5b). Furthermore, we 
observed a higher larval death rate when the inhibitors were added to the embryo medium at 24 hpf 
than at 48 hpf, at the same concentration (data not shown), suggesting that younger embryos are 
more sensitive to toxicity related to BTPs. These observations suggest that, at the maximal 
tolerated concentrations, the drugs do not prevent cytosolic escape and this does not reduce 
bacterial loads in zebrafish embryos when compared to untreated groups. 
Two BTP analogues, 11826191 and 11826192, were tolerated at concentrations of >10 ?g/mL. The 
assay was thus repeated with a higher number of larvae and the inhibitors were added at 50 ?g/mL 
immediately after infection. Although the embryos survived 4 d of drug exposure, CFU counts 
revealed no significant bacterial inhibition compared to untreated controls. A weak tendency 
nevertheless appeared for the embryos treated with 11826192 (Figure 5c). 
Finally, BTP15 was proven to prevent EsxA secretion and protect infected lung fibroblasts without 
impacting the growth of M. tuberculosis.35 We thus hypothesized that the bacteria could be 
chemically attenuated by exposure to the drug before zebrafish infection. 20 ?M BTP15 was added 
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in a culture of M. marinum 12 h before the bacteria were collected and prepared for microinjection 
in the embryos. Infected larvae were subsequently kept in the presence of 1 ?g/mL of BTP15 of 
left untreated. Again, no difference with the control could be observed upon CFU enumeration 
indicating that the inhibitor had no significant effect with this setup (Figure 5d). 
 
 
Figure 5. Anti-virulence activity of BTP analogues in M. marinum-infected zebrafish 
embryos. a, CFUs recovered from zebrafish embryos infected with M. marinum M and 
exposed to 1 ?g/mL BTP15 from 1 to 4 dpi, or left untreated (NT). b, CFU count from 
zebrafish larvae infected with M. marinum M and exposed to the indicated BTP analogues 
immediately after infection and for 4 d (11826037, 11826031: 1 ?g/mL; 11726131, 11826191, 
11826192: 5 ?g/mL). c, Same as b, with 11826191 and 11826192 added immediately after 
infection at 50 μg/mL. d, M. marinum (E11) cultures were treated for 12 h with 20 ?M of 
BTP15 prior to infection. NT – non-treated bacteria and untreated fish, BTP15 O/N – bacterial 
cultures treated with BTP15 before infection, BTP15 O/N* – bacterial cultures treated with 
BTP15 before infection and addition of 1 ?g/mL BTP15 in embryo medium immediately after 
infection. ns = non-significant. 
  
NT
BT
P1
5
0
2
4
6
lo
g
C
FU
pe
r
em
br
yo
ns
a b
NT
11
82
60
37
11
82
60
38
11
72
61
31
11
82
61
91
11
82
61
92
0
2
4
6
lo
g
C
F
U
pe
re
m
br
yo
ns
NT
11
82
61
91
11
82
61
92
1
2
3
4
5
6
lo
g
C
FU
pe
re
m
br
yo
ns
c d
NT
BT
P1
5 O
/N
BT
P1
5 O
/N
*
0
2
4
lo
g
C
F
U
pe
re
m
br
yo
ns
Zebrafish Embryos for TB Drug Discovery 
154 
Name Conc.
a 
(?g/mL)
BTP15 1 
11726131 5 
11826037 1 
11826038 1 
11826191 50 
11826192 100 
 
Table 1. Benzothiophene analogues used in this investigation. a Maximal concentration 
tolerated by zebrafish embryos when the drug was added at 48 hpf 
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ACTIVITY OF ARYLVINYLPIPERAZINE AMIDES AGAINST M. ABSCESSUS IN VIVO  
Background Information 
Mycobacteroides abscessus, subsp. abscessus (M. abscessus) is a ubiquitous emerging pathogen 
responsible for diverse nontuberculous mycobacterium (NTM)-related diseases in humans, mostly 
chronic pulmonary infections in immunosuppressed and cystic fibrosis patients.37 It is a rapidly 
growing mycobacterial species possessing some important pathogenic traits.12 Although 
M. abscessus is an opportunistic pathogen, this species is intrinsically resistant to many available 
antibiotics, rendering infections highly difficult to cure. For instance, M. abscessus is resistant to all 
frontline anti-TB drugs,38 which can pose serious problems, especially if misdiagnosed as an 
M. tuberculosis infection. Despite restricted availability of animal and cellular infection models, 
the zebrafish has proven to be a suitable organism to study M. abscessus pathogenesis.13 
Furthermore, M. abscessus is genetically accessible and fluorescent reporters have been used to 
evaluate the efficacy of antibiotics in vivo.12,39 
In 2013, 177 hit compounds were identified in a large scale phenotypic screen against 
M. tuberculosis and M. bovis BCG by GlaxoSmithKline.40 Among these hits, an 
arylvinylpiperazine amide compound, AX-35, showed potent activity against M. tuberculosis and 
its mechanism of action, as well as SAR studies, have been investigated in a recent study.41 QcrB, a 
subunit of cytochrome bc1 oxidase (one of the two terminal oxidases in the electron transport 
chain), was found to be the direct target of this compound, which displayed bacteriostatic activity 
in wild type M. tuberculosis. Notably, AX-35 exhibits anti-mycobacterial activity against several 
NTM including M. abscessus. The activity of arylvinylpiperazine amide derivatives against NTMs 
is currently under investigation and the in vivo activity of some of these derivatives in the zebrafish 
model is the subject of the study described below. 
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Optimization of an in vivo drug efficacy assay against M. abscessus with 
arylvinylpiperazine amide derivatives 
Infection of zebrafish embryos was performed by microinjection of an M. abscessus suspension, as 
for infections with M. marinum and as described elsewhere.13 Interestingly, M. abscessus does not 
tolerate alkaline decontamination and no mycobacteria were recovered after only 1 min of 
incubation with MycoPrep. M. abscessus-infected zebrafish embryos were thus disrupted in 5% 
SDS and homogenates were diluted and plated on 7H10 containing a mixture of polymyxin B, 
amphotericin B, nalidixic acid, trimethoprim and azlocillin (PANTA). Subsequent experiments 
revealed that nalidixic acid, azlocillin and cycloheximide (NAC) is sufficient to isolate 
M. abscessus from zebrafish lysates without additional decontamination. 
Embryos were exposed to several concentrations of arylvinylpiperazine amide analogues (Table 2) 
and drug-related toxicity was revealed by the death of all the larvae in several groups as early as 
one day after compounds were added, even at low doses. The maximum concentration tolerated in 
this assay was estimated for each compound (Table 2) and for all the drugs except AX-50, it was 
found to be lower than the in vitro minimal inhibitory concentration (MIC). The macrolide 
antibiotic clarithromycin (CLR), recommended to treat M. abscessus infections in humans,42 was 
used as a positive control for this assay. Exposure of infected embryos to 1 mg/mL CLR for 3 d led 
to a significant reduction in bacterial load, as previously reported,12 and embryos did not display 
any signs of toxicity-related malformation. In contrast, addition of 0.5 ?g/mL AX-35 for only 24 h 
(from 24 to 48 h post infection, followed by transfer into drug-free E3) led to the death of half of 
the larvae in that group, and the survivors had a similar bacterial load as the untreated group, at the 
end of the experiment (Figure 6a). Another positive control experiment with bedaquiline (BDQ, 
4 ?g/mL) led to a slight reduction in CFUs as previously observed by others (Figure 6b).39 
In an attempt to assess drug efficacy while reducing embryonic death rate, the drugs AX-35 and 
AX-50 were added immediately after the infection and larvae were homogenized 24 h later. 
However, the CFU numbers were similar between the treated and the untreated groups (Figure 6c). 
Finally, infected embryos were exposed to AX-35 and AX-50 only 2.5 h per day for 4 d, starting on 
the day of infection, and were maintained in drug-free E3 otherwise. After the fourth dose, all 
embryos exposed to AX-35 had died and no difference between AX-50-treated and untreated fish 
were observed upon CFU enumeration (Figure 6d). Taken together, these observations suggest that 
arylvinylpiperazine amide analogues are too toxic to be evaluated in zebrafish embryos, given the 
high drug concentration necessary to observe a reduction of M. abscessus load in this model. 
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Name Molecular structure Conc.
a 
(?g/mL) 
MICb 
(?g/mL) 
AX-35 
 
<0.5 3.3 
AX-50 
 
8 8.7 
JW010 
 
8 12.2 
JW011 
 
2 4.9 
CLR  >1000 0.9 
 
Table 2. Arylvinylpiperazine amide derivatives used in this study. a Maximal concentration 
tolerated by zebrafish embryos when the drug was added at 48 hpf. b Minimal inhibitory 
concentration for M. abscessus measured by REMA in vitro. 
 
 
Figure 6. In vivo activity of arylvinylpiperazine amide derivatives and control drugs 
against M. abscessus. a, M. abscessus-infected embryos were exposed to 1 mg/mL CLR from 
1 to 4 dpi or to 0.5 ?g/mL AX-35 for 24 h at 1 dpi. Surviving larvae were homogenized at 
4 dpi and samples were plated for CFU enumeration. b, Embryos were exposed to 4 ?g/mL 
BDQ from 1 to 4 dpi or left untreated, before homogenization, plating and CFU count. c, 
Embryos were infected with M. abscessus and immediately exposed to 0.5 ?g/mL AX-35, 
8 ?g/mL AX-50 or left untreated. Samples were homogenized and plated 24 h later. d, Infected 
zebrafish embryos were exposed to 10 ?g/mL AX-35 or 20 ?g/mL AX-50 2.5 h per day for 4 
successive days, or left untreated. All larvae from the AX-35-treated group died after the fourth 
dose and data are thus not displayed. ** P = 0.0008, *** P = 0.001, ns = non-significant. 
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GENERAL DISCUSSION 
Zebrafish embryos have become an attractive alternative to mouse models for the study of 
mycobacterial pathogenesis. Infection of zebrafish embryos permits for instance to rapidly assess 
the activity of antimicrobials in vivo over 5 d. In addition, low absolute amounts of drugs are 
necessary to treat up to 12 embryos simultaneously in 4 mL of fish water (concentrations are 
generally <500 ?g/mL), whereas drug efficacy assays in mice require several milligrams of 
compound (e.g. 25 mg/kg for INH) and daily administration to every animal for several weeks. 
This could be a serious issue when experimental synthetic compounds have to be tested in vivo. 
With the zebrafish model, we demonstrate here for the first time that the natural product 
pyridomycin and one of its synthetic analogues, DM122, have anti-mycobacterial activity in vivo, 
without causing side-effects in the larvae. We also demonstrate that the anti-leprosy drug 
clofazimine has specific anti-mycobacterial efficacy in zebrafish embryos infected with 
M. marinum, at concentrations as low as 1 ?g/mL. Our initial aim was to test whether an fadD9::tn 
mutant shows a CFM-resistance phenotype only intracellularly and the zebrafish was our model of 
choice. Our observations indicated that disruption of the fadD9 gene in M. marinum is not 
sufficient to confer resistance to CFM in our model. One can hypothesize that the resistance 
phenotype may appear later, following a change in host or pathogen metabolism in response to 
CFM. Testing this hypothesis would require extending the time window of our zebrafish-
M. marinum infection assay, which becomes then ethically debatable. CFUs recovered from 
infected and treated larvae were our main readout to assess drug efficacy. However, alternatives 
can be explored, such as larval survival, as already reported for M. abscessus-infected embryos.12,39 
Inhibitors of mycobacterial virulence factor secretion do not kill the bacteria but do attenuate 
virulence. Such “chemical attenuation” of pathogenic bacteria is a rather elegant strategy, however 
the toxicity of BTP analogues for zebrafish embryos greatly limited their use in our model. BTP15 
prevented the secretion of EsxA via the ESX-1 secretion system, a major virulence factor in 
M. tuberculosis.35 Alternatively, M. marinum mutants lacking the RD1 region43 (in which the genes 
required for a functional ESX-1 system are located) or with a disrupted ESX-1 system8 (in an 
eccCb1::tn mutant, EccCb1 being an essential component of ESX-1) were phenotypically 
characterized by reduced initial granuloma formation upon zebrafish embryo infection. If BTP 
analogues truly attenuate ESX-1-dependent secretion, one could look for inhibition of early 
granuloma formation in BTP-treated fish using fluorescent reporters instead of counting CFUs. 
Finally, BTP15 and BTP analogues have been characterized for their anti-virulence activity in 
M. tuberculosis, not in M. marinum. Differences in activities of BTP analogues between 
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M. tuberculosis and M. marinum could be explained by the presence of more efflux systems in the 
latter, as well as differences in the active site of the target, MprB. Microbiological and biochemical 
validation should be therefore undertaken with these inhibitors in M. marinum in further studies. 
Mouse models of M. abscessus infection for preclinical drug testing have been reported with 
granulocyte-macrophage colony-stimulating factor knockout (GM-CSF KO) mice and 
intrapulmonary delivery of bacteria,44 or nude mice (lacking T cells) with intravenous injection of a 
bacterial suspension.45 However, in wild-type mice, M. abscessus fails to establish a persistent 
infection after aerosol exposure.12 Zebrafish embryos may be a useful alternative to study 
M. abscessus pathogenesis13 and have already been used for drug discovery.12,39 We thus used 
zebrafish to test the in vivo efficacy of a new class of anti-mycobacterial compounds, 
arylvinylpiperazine amide derivatives. Notably, these drugs, targeting QcrB in M. tuberculosis,41 
display specific antimicrobial activity towards nontuberculous mycobacteria, including 
M. abscessus. All the tested compounds were found to be lethal for the zebrafish embryos and no 
therapeutic effect could be observed, despite variations of drug concentrations and exposure times. 
Although toxicity did not seem to be an issue in the mouse model of acute tuberculosis,41 our 
observations in zebrafish should be taken as a warning for potential side-toxicity or off-target 
consequences of this class of compounds which may delay progression to the clinic. Medicinal 
chemistry and toxicological investigations are thus necessary to identify causes of toxicity and to 
ameliorate the compounds accordingly. 
Finally, zebrafish embryo are versatile, faster and cheaper alternatives to rodents in anti-TB drug 
discovery, permitting an increase in throughput and boosting the development of anti-
mycobacterial compounds. One can safely conclude that zebrafish provide an excellent platform to 
investigate the mechanisms of mycobacterial pathogenesis, identify and understand key bacterial 
virulence factors and develop new approaches to anti-mycobacterial therapies.  
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METHODS 
Bacterial strains and culture conditions 
M. marinum strains E11,46 M47 and mutants, kindly provided by Astrid van der Sar and Wilbert 
Bitter, were grown in Middlebrook 7H9 medium (Difco) supplemented with 0.2% glycerol, 0.05% 
Tween-80 and 10% albumin-dextrose-catalase (ADC) or on solid 7H10 agar plates containing 
0.5% glycerol and 10% oleic acid-albumin-dextrose-catalase (OADC). Cultures were incubated at 
30°C. Hygromycin (HYG, 50 ?g/mL) or kanamycin (KAN, 25 ?g/mL) were added in culture 
medium when appropriate. Strain E11 was used for all experiments related to pyridomycin and 
DM122, except for fluorescence measurements in which case the reporter was constructed in an M 
background (see below). Strain M WT and fadD9::tn were used in all experiments with 
clofazimine. For assays with benzothiophene, the strains used are indicated in the figure legend. 
M. abscessus sensu stricto (rough variant of strain CIP104536T (ATCC19977T)) expressing 
tdTomato was a kind gift from Laurent Kremer.48 M. abscessus was grown at 30°C in 7H9 
containing 0.2% glycerol, 0.05% Tween-80 and 10% OADC or on 7H10 agar plates containing 
0.5% glycerol and 10% OADC, in presence of 500 ?g/mL HYG. 
Construction of an M. marinum fluorescent reporter 
To generate a fluorescent M. marinum reporter strain, the plasmid pCHARGE3,49 kindly provided 
by Tanya Parish (Addgene plasmid # 24658), was transformed in parental M. marinum strain M by 
electroporation, as previously described.50 This reporter constitutively (under the strong hsp60 
promoter) produces the far-red fluorescent protein Turbo-635 (also named Katushka51), whose gene 
was codon-optimized for expression in mycobacteria. 
Infection of zebrafish embryos 
Zebrafish embryos were infected with M. marinum or M. abscessus as previously described.8,10,13 
Briefly, 24 h old Danio rerio (AB) embryos were manually dechorionated and aligned on a 
custom-made agarose bed covered with E3 medium52 (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 
0.33 mM MgSO4) containing 0.4 mg/mL MS-222 (Sigma). A bacterial suspension containing ~300 
bacteria in 1-2 nL was microinjected in the caudal vein of anesthetized embryos using a heat-pulled 
glass capillary connected to a pneumatic PicoPump PV820 (World Precision Instruments). 24 h 
after infection, unless specified differently, embryos were split into groups of 8-12 and placed in 
4 mL of E3 in 6-well plates and drugs were added directly in E3 at the concentrations indicated. 
The embryos were maintained at 28°C until the end of the experiment (4 dpi unless specified 
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differently). For the measurement of embryonic lengths, pictures were taken with a Leica DFC295 
camera mounted on a Leica M125 stereomicroscope and analysed with ImageJ (v1.52h). 
Enumeration of mycobacteria in infected zebrafish embryos 
Lysis and decontamination of embryos was performed as described elsewhere8 for M. marinum 
isolation, with some modifications. At the end of the experiment, embryos were euthanized with an 
overdose of MS-222 and single specimens were incubated in for 5 min in 25 ?L 5% SDS in PBS. 
Larvae were disrupted by pipetting and 25 ?L of BBL MycoPrep (BD) was added. The samples 
were incubated at room temperature for 10 min under shaking and neutralized by addition of 
450 ?L of PBS. Serial 10-fold dilutions were plated on 7H10 medium containing 10 ?g/mL 
cycloheximide and cultured at 30°C for 8 d before CFU enumeration. 
M. abscessus-infected embryos were disrupted in 25 ?L 5% SDS in PBS, diluted in 500 ?L PBS 
and plated on 7H10 containing the antibiotic mixtures PANTA (40 U/mL polymyxin B, 4 ?g/mL 
amphotericin B, 16 ?g/mL nalidixic acid sodium salt, 4 ?g/mL trimetoprim and 4 ?g/mL azlocillin 
sodium salt) or NAC (16 ?g/mL nalidixic acid sodium salt, 4 ?g/mL azlocillin sodium salt and 
10 ?g/mL cycloheximide). Plates were incubated at 37°C for 3-4 d before CFU enumeration. 
M. marinum load evaluation with fluorescence measurement 
At 4 dpi, single anesthetized zebrafish embryos were dispensed in black clear-bottom 96-well 
plates. Twelve fluorescence reads per well were measured with a Tecan M200 plate-reader (top 
reading, excitation 558 nm and emission 653 nm) and the signal was averaged for each well. For 
fluorescence measurements, n = 12 embryos per group. 
Culture pre-treatment with BTP15 
M. marinum E11 was grown to an OD600 of 0.3, 20 ?M of BTP15 was added and the culture was 
further kept at 30°C under agitation overnight. The next morning, bacterial cultures were 
centrifuged, resuspended in 0.5% Tween-80 in PBS to disrupt clumps, centrifuged and resuspended 
in 7H9 at an OD600 of 4, diluted 1:4 in a 0.5% phenol red solution and prepared for injection as 
described above. An untreated control was prepared and administered in parallel to a separate 
group of fish. 
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Statistics 
Statistical analysis was carried out with GraphPad Prism version 7.02. When two groups were 
compared, a Mann Whitney test was used. When more than two groups were compared, an 
ordinary one-way ANOVA followed by a Tukey’s multiple comparisons test were performed. 
Groups contained between 8 and 12 elements unless specified differently. 
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The work presented in the previous chapters benefits from extensive interdisciplinarity involving a 
variety of approaches, ranging from chemical biology, genetic engineering of mycobacterial 
reporters and in vivo models of TB infection in mice (Mus musculus) and zebrafish (Danio rerio). 
Engineered mycobacterial species have been applied in different contexts, for instance as reporters 
to visualize TB infection in zebrafish and mice and, in the case of M. marinum and M. abscessus, 
as the basis of a zebrafish model of mycobacterial infection. Strong emphasis was placed on the 
application of these tools to anti-TB drug assessment thus highlighting the benefits of alternative 
approaches, in saving precious time and substantial resources. 
Innovative drugs and treatment strategies are necessary to stop the global TB epidemic and BTZs 
constitute a highly potent new class of anti-TB drugs, macozinone being undoubtedly the most 
promising one.1–3 Results presented in this thesis contributed to the validation of its efficacy in 
mouse and zebrafish models, evaluated not only by CFU enumeration but also with innovative 
quantitative in vivo imaging techniques. Besides its powerful anti-TB character, PBTZ169 proved 
to be an excellent scaffold to design specific and selective fluorescent probes, following a chemical 
biology approach.4 In chapter 2, we presented the development and characterisation of fluorophore-
coupled BTZ molecules permitting the subcellular polar and periplasmic localization of DprE1 to 
be visually assessed, by means of high- and super-resolution imaging techniques. A single amino 
acid mutation in DprE1 abolished the binding of the most advanced probe, JN108, which is 
consistent with the mechanism of action of BTZs. We further demonstrated that such observations 
were valid for other BTZ-sensitive actinobacterial species. 
Thanks to their high selectivity for DprE1, such probes are valuable tools for the detection of a 
defined number of bacterial species in different contexts, especially applicable to pathogenic 
mycobacteria such as M. marinum or M. tuberculosis. The application of fluorescent BTZs to 
potentially contaminated samples may therefore enable the presence of M. tuberculosis to be 
revealed, with patient derived sputum samples for example. More recently, the development of a 
Respiratory Aerosol Sampling Chamber (RASC), consisting of a personal clean room connected to 
sampling devices for sampling of airborne particles,5,6 may provide a cleaner source of patient-
derived samples that can readily be analysed with M. tuberculosis-specific probes, such as JN108 
(Digby Warner, personal communication). Furthermore, the development of such probes in 
appropriate formulations could enable the identification of mycobacterial pathogens in situ. This 
could be the case for cutaneous BTZ-susceptible pathogens such as M. marinum or M. leprae. 
Together, these considerations highlight the potential of fluorescent BTZ analogues for the 
development of innovative diagnostic tools for mycobacterial pathogen detection. 
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Interestingly, a recent study reported the development and application of a dual-targeting 
fluorogenic probe that selectively labels M. tuberculosis and other bacteria in vitro and in sputum 
samples.7 The probe was designed with a quencher that is released upon hydrolysis by the ?-
lactamase BlaC, naturally produced by M. tuberculosis. Hydrolysis of the quencher activates the 
fluorescent probe, which also carries a chemical group that covalently labels DprE1 with a similar 
mechanism to JN108. Notably, the reported specific probe is not derived from a BTZ moiety. By 
coupling DprE1- and BlaC-specific probes, the authors can discriminate live and dead 
mycobacteria as well as M. tuberculosis from other bacteria, and the utilization of a simple 
microfluidic chip facilitated their detection in vitro, corroborating the potential of DprE1-targeting 
probes for TB diagnostics. 
Given the high specificity of JN108 in vitro, we sought to evaluate its capacity to detect 
mycobacteria in vivo, for imaging purposes as discussed in chapter 3. This was attempted in 
infected zebrafish embryos but the probe could not specifically detect the bacteria over background 
fluorescence, although green fluorescent M. marinum reporters could be easily seen with confocal 
microscopy. For the application in infected mice, a NIR variant of JN108, JN139, was used. This 
probe is based on the Dy-750 fluorochrome that emits around 750 nm. JN139 could be detected in 
the abdomen after intraperitoneal injection into mice, confirming the high suitability of NIR probes 
for imaging in rodents. However, JN139 failed to label M. tuberculosis in the lungs sufficiently for 
detection, suggesting that the biodistribution of this probe was not adequate. A fluorogenic ?-
lactamase probe emitting at 795 nm has nonetheless been successfully applied for the quantitative 
detection of mycobacterial infection in mouse lungs.8–12 This probe was also designed with a 
quencher and ?-lactamase activated the probe upon hydrolysis of the quencher. Although ?-lactam 
probes may be sensitive to ?-lactamases from bacteria other than M. tuberculosis, the authors 
reported a high sensitivity, enabling the detection of <1000 CFUs in the lungs of live 
experimentally infected mice in their most recent study.8 Fluorogenicity and NIR wavelengths, 
combined with the best detection equipment, seem to be key for optimal and sensitive 
quantification of mycobacterial infection with fluorescent probes in mice. 
Beside fluorescent probes for in vivo imaging, reporters carrying genetically engineered fluorescent 
proteins have been applied for in vivo imaging of mycobacterial infection. Notably, tdTomato13,14 
and Turbo63515 enabled mycobacteria to be seen in vivo. In chapter 4, we reported for the first time 
the application to mycobacteria of the newly developed NIR fluorescent protein (iRFP).16 
Autofluorescent NIR reporter strains of M. smegmatis, M. marinum and M. tuberculosis have been 
successfully designed by cloning the iRFP gene together with ho1, encoding the heme oxygenase 1 
(HO1). HO1 generates an intrabacterial pool of biliverdin (BV), the cofactor necessary for iRFP to 
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fluoresce. The reporter strains emit at a maximal wavelength of 713 nm. NIR M. marinum could be 
visualized in zebrafish embryos and NIR M. tuberculosis in the lungs of infected SHO mice. In 
both cases, quantitative fluorescence measurements provided precise real-time information on 
antibiotic treatment efficacy. The successful visualization of M. tuberculosis in live mice can be 
attributed to the NIR emission wavelength of the reporters, less subjected to absorption and 
scattering by mammalian tissues than blue-shifted wavelengths, and the immunodeficient/hairless 
phenotype of the mice, more permissive to M. tuberculosis multiplication and therefore favouring 
fluorescence detection. One major disadvantage intrinsic to iRFP and other NIR fluorescent 
proteins is their relatively weak brightness, rendering the emitted fluorescent signal difficult to 
detect. For example, the molecular brightness (product of molar extinction coefficient and quantum 
yield) of iRFP is 6’200 and that of tdTomato, which remains one of the brightest red fluorescent 
proteins known to date, is 48’00017. Further biochemical improvement of NIR fluorescent proteins 
derived from bacterial phytochromes is being undertaken to design brighter reporters, especially 
well-suited for in vivo imaging.18,19 Although these NIR fluorescent probes seem more attractive for 
application to eukaryotic cells so far, our study demonstrated their suitability for designing 
mycobacterial reporters thus paving the way for the utilisation of such tools in bacteria in general. 
Fluorescence imaging requires irradiation with light at an appropriate wavelength to excite 
chromophores, which subsequently reemit photons that can be detected by the CCD camera. Mouse 
autofluorescence (skin, fur, food in the gut) is a major source of background signal although this 
phenomenon is attenuated in the NIR region. Deconvolution algorithms are necessary to improve 
the signal-to-noise ratio, while weak fluorescent signals may be completely masked by 
autofluorescence and therefore below the limit of detection. Bioluminescence on the other hand, 
does not require irradiation to produce photons and background autobioluminescence originating 
from mammalian tissues is null when measurements are performed on live animals. The 
luminescence imaging modality enables therefore the detection of dimmer signals without the need 
for spectral deconvolution. In chapter 5, we applied autobioluminescent M. tuberculosis reporters 
expressing the luxCDABE operon from P. luminescens to real-time imaging of TB in mice. This 
system did not require the exogenous administration of luciferin, as the luxCDABE cassette 
encodes the luciferase and the enzymes necessary for the biosynthesis of its substrate, providing a 
substantial advantage compared to firefly luciferase-based systems. Our protocol enabled the 
longitudinal imaging of the M. tuberculosis load in mice and a real-time assessment of isoniazid 
treatment, leading to a rapid reduction of the bacterial burden accompanied by a decrease in 
luminescence intensity in the thoracic area of mice. Our observations suggest that the kinetics and 
the temporal response to a treatment can be investigated in such a way, as well as the effect of drug 
dosage. This question is currently being investigated by repeating the key experiment described in 
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chapter 5, with different isoniazid dosages tested in parallel. Further characterisation of this 
infection system in SHO mice would be required to obtain a mathematical model that can predict 
the number of CFUs based on single bioluminescence measurements. 
Many luciferase-based systems have been discovered, developed and applied to generate genetic 
reporters. Biochemical engineering of luciferases and new synthetic substrates enabled more 
efficient and longer (“glowing”) luminescence reactions, shifted emission wavelengths and smaller 
enzymes, for applications in vitro and in vivo.20 Interestingly, NIR bioluminescent proteins for 
multimodal imaging have been recently developed.21 The authors designed chimeric probes based 
on Renilla luciferase fused with a NIR-fluorescent protein undergoing intramolecular 
bioluminescence resonance energy transfer (BRET), therefore spontaneously emitting a NIR signal 
without irradiation. BRET-probes are valuable tools for in vivo imaging, combining the advantages 
of spontaneous light emission and NIR wavelengths, and should be applied for the monitoring of 
bacterial infections. 
Overall, fluorescence and bioluminescence imaging are complementary approaches. The latter 
enables the detection of weak signals thanks to the absence of background noise but requires the 
availability of substrate and cofactors, while fluorescence imaging is a versatile tool that exploits a 
large diversity of proteins and dyes emitting at numerous wavelengths. The availability of both 
luminescence and fluorescence imaging modalities in most in vivo imaging platforms enables dual-
labelling possibilities, to study the metabolic state of mycobacteria upon infection, the response of 
the host (e.g. recruitment of immune cells) in real-time, the dissemination of bacteria in the 
organism and the response to antimicrobials. Further improvement of the detection devices (more 
sensitive CCD cameras) or optimized system design, including planar imaging and molecular 
tomography capabilities, would enable better spatiotemporal resolution and higher sensitivity. 
Finally, coupling optical imaging modalities with non-optical techniques, such as computed 
tomography and positron emission tomography, would also provide information about both the 
host and the pathogen upon infection. 
Following the very same purpose of improving and boosting TB drug discovery and development 
with alternative methods, we implemented the zebrafish embryo model of mycobacterial infection 
and applied it to four different projects, as discussed in chapter 6. We successfully applied this 
model to demonstrate antimicrobial activity of the natural product pyridomycin and its synthetic 
analogue DM122 in vivo (Lupien A., et al, manuscript in preparation). Similarly, an assay was 
optimized to assess the repurposed drug clofazimine, which displayed anti-mycobacterial activity 
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against M. marinum in infected zebrafish embryos, while our attempts to link the role of fadD9 
inactivation in clofazimine resistance were inconclusive with this model. 
Zebrafish embryos are an excellent platform to investigate mycobacterial pathogenesis and test the 
activity of new drugs. They provide observable readouts thanks to their optical transparency, rapid 
drug testing (results in <2 weeks), enable medium/high throughput screening and are genetically 
accessible for the study of important host factors during infection. One potential disadvantage, 
however, is the sensitivity of the embryos to drug-related toxicity, that arose for several compounds 
tested in our studies. Despite multiple optimization attempts, it was not possible to evaluate the 
anti-virulence properties of benzothiophene analogues and the anti-mycobacterial activity of 
arylvinlypiperazine amide derivatives in this model, as the compounds appeared toxic for fish 
larvae. One can speculate that the thiophene ring, also present in most arylvinlypiperazine amide 
derivatives tested, might be the source of embryonic toxicity in our assays. Daily and oral 
administration of these compounds to adult mice might enable a therapeutic effect to be observed, 
whereas a good compromise between antimicrobial activity and embryonic toxicity could not be 
determined with zebrafish larvae. These observations are nonetheless warnings of potential side 
effects that may arise and should therefore be taken into consideration. 
Altogether, the multiple approaches undertaken in the present work were aimed at providing 
innovative approaches for TB diagnosis, as well as finding solutions to boost and refine the 
assessment of new anti-tubercular compounds. Furthermore, the implementation of real-time 
imaging for anti-TB drug activity assessment combined with the zebrafish embryo model is fully 
compatible with the 3R policy on animal experimentation, promoting replacement, reduction and 
refinement of animal use in biomedical research. Notably, every “R” of this policy is met with the 
different projects proposed in this thesis: replacement of the mouse model with zebrafish larvae, 
reduction of the absolute number of animals enabled by longitudinal imaging, and refinement of 
the drug assessment process via quantitative in vivo imaging. Besides providing advantageous 
substantial resources for TB drug development, our approaches also offer more ethically acceptable 
methodologies and biomedical applications. 
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3R Replace, reduce, refine  MDR Multidrug-resistant 
AIDS Acquired immune deficiency syndrome 
 MIC, 
MIC99 
Minimal inhibitory concentration 
BCG Bacille Calmette-Guérin  min  Minutes 
BDQ Bedaquiline (TMC207)  MTBC M. tuberculosis complex 
BTZ Benzothiazinone  ND Not determined 
BV Biliverdin  NHP Non-human primate 
CCD Charge-coupled device  NI Not infected 
CFM Clofazimine  NIR Near-infrared 
CFU Colony forming unit  ns Not significant 
CLR Clarithromycin  NT Not treated 
CT Computed tomography  NTM Nontuberculous mycobacteria 
d Days  PBTZ Piperazine benzothiazinone 
dpi Days post infection  PET Positron emission tomography 
DprE1 Decaprenyl-phospho-?-D-ribose oxidase 
 
PYR Pyrdomycin 
FDG 2-deoxy-2-[18F]fluoro-D-glucose  RD1 Region of differentiation 1 
FFlucRT Red-shifted thermostable firefly luciferase-based reporter 
 
RR Rifampicin-resistant 
FMNH2 Reduced flavin mononucleotide 
 S.E.M., 
s.e.m. Standard error of the mean 
FP Fluorescent protein  SAR Structure-activity relationship 
h Hours  SCID Severe combined immunodeficiency 
HIV Human immunodeficiency virus  SD Standard deviation 
HO1 Heme oxygenase 1  SHO SCID hairless outbred 
hpf Hours post fertilization  TAMRA Tetramethylrhodamine 
INH Isoniazid  TB Tuberculosis 
Lux luxCDABE-based reporter  WHO World Health Organization 
MCZ Macozinone (PBTZ169)    
 

 183 
Curriculum Vitae 
 
 

 185 
  Education and Training    
PhD Candidate in Molecular Life Sciences Feb. 2015 to date 
Swiss Federal Institute of Technology (EPFL, Lausanne) 
Laboratory of Microbial Pathogenesis 
Thesis: Innovative Tools and in vivo Methods for Tuberculosis Drug Discovery 
and Development. 
Under the supervision of Prof. Stewart T. Cole and Prof. Andy Oates. 
• Characterization of drug-target interaction with antibiotic-derived, bacterial-
specific fluorescent probes, with applications in vitro and in vivo. 
• Design, construction and optimization of genetically engineered fluorescent 
and bioluminescent bacterial reporters, for imaging in mouse models. 
• Installation and operation of an in vivo imaging platform to assess the bacterial 
burden of M. tuberculosis-infected mice, evaluation of disease progression and 
drug efficacy in real time. 
• Implementation of a zebrafish embryo infection model as a tool for drug 
discovery and development. 
• Skills in bacteriology (M. tuberculosis and other mycobacteria), drug 
discovery and development, molecular biology and cloning, BSL2 / (A)BSL3 
expertise, mouse models (FELASA Cat. B), in vivo imaging, zebrafish 
models, microscopy (fluorescence, confocal, super-resolution), image analysis, 
infection biology and pathogenesis, in vitro and in vivo infection assays. 
MSc in Life Sciences and Technology 2012 – 2014 
(Engineer in Life Sciences and Technology dipl. EPF) 
Swiss Federal Institute of Technology (EPFL, Lausanne) 
Specialization in Molecular Medicine. Competences in disease biology (cancer, 
infection), immunology and pharmacology. Capacity to bring an innovative and 
molecular-oriented approach to cellular biology. 
BSc in Chemistry and Chemical Engineering 2008 – 2012 
Swiss Federal Institute of Technology (EPFL, Lausanne) 
Synthetic, medicinal and biological chemistry, biochemistry, mathematics, physics. 
 Professional Experience    
Master Thesis 02 – 08, 2014 
Institute for Bioscience and Biotechnology Research, Rockville (MD), USA 
• Production, purification and study of recombinant proteins, to investigate their 
potential roles in tumor development. Technical skills in PCR, molecular 
cloning, expression and purification of recombinant proteins, fast protein 
liquid chromatography (ÄKTA), affinity studies (ITC). Adaptation to 
international environment, communication in English. 
Engineering Internship in Industry 07 – 09, 2013 
Debiopharm International SA, R&D Unit, Ecublens (VD) 
• Development of an optimized formulation for a poorly soluble API and 
excipient screening. Skills: work in private sector, teamwork and reporting, 
solubility analysis, basics in pharmaceutical formulation. 
Teaching Assistant 2010 – 2018 
Swiss Federal Institute of Technology (EPFL, Lausanne) 
• Supervision of practical work and theoretical exercises. Acquired 
competences: communication and teaching skills, public speaking. 
Raphael Sommer, PhD
MICROBIOLOGIST 
 
Profile 
Expertise in drug discovery 
targeting infectious diseases 
and imaging technologies 
Background in biology, chemistry 
and biological engineering  
Integrated and multidisciplinary 
scientific approaches 
Interest in health-related 
disciplines and life sciences 
 
raphael.sommer@epfl.ch
raphael.sommer@bluewin.ch
 
+41 79 265 08 25 
EPFL SV GHI UPCOL
Station 19
CH-1015 Lausanne
Switzerland
 
Mycobacteriology  ? 
Drug discovery  ? 
Mouse models  ? 
Zebrafish models  ? 
Molecular biology  ? 
Microbial pathogenesis  ? 
(A)BSL3 expertise  ? 
Languages:
French (native)
English (C1)
German (B1) 
swiss
not married
*03.04.1990
driving license cat. B 
 186 
 
 List of Publications    
Comparative analysis of luciferase-based systems for bioluminescence imaging of tuberculosis 
infection in mice. Sommer, R., and Cole, S. T: 2019 (in preparation) 
Monitoring tuberculosis drug activity in live animals by near-infrared fluorescence imaging. Sommer, 
R., and Cole, S. T: 2019 (in preparation) 
Fluorescent benzothiazinone analogues efficiently and selectively label DprE1 in mycobacteria and 
actinobacteria. Sommer, R., Neres, J., Piton, J., Dhar, N., van der Sar, A., Mukherjee, R., Laroche, T., 
Dyson, P. J., McKinney, J. D., Bitter, W., Makarov, V., and Cole, S. T: ACS Chem. Biol. 2018, 13, 3184–
3192. 
Arylvinylpiperazine amides, a new class of potent inhibitors targeting QcrB of Mycobacterium 
tuberculosis. Foo, C. S., Lupien, A., Kienle, M., Vocat, A., Benjak, A., Sommer, R., Lamprecht, D. A., 
Steyn, A. J. C., Pethe, K., Piton, J., Altmann, K.-H., and Cole, S. T: mBio 2018, 9 (5), e01276-18 
The inosine monophosphate dehydrogenase, Guab2, is a vulnerable new bactericidal drug target for 
tuberculosis. Singh, V., Donini, S., Pacitto, A., Sala, C., Hartkoorn, R. C., Dhar, N., Keri, G., Ascher, D. 
B., Mondésert, G., Vocat, A., Lupien, A., Sommer, R., Vermet, H., Lagrange, S., Buechler, J., Warner, D. 
F., McKinney, J. D., Pato, J., Cole, S. T., Blundell, T. L., Rizzi, M., and Mizrahi, V: ACS Infect. Dis. 2017, 
3, 5–17. 
 Talks and Posters    
Le poisson zèbre – un modèle animal pour la recherche biomédicale 
Sommer, R., ‘Association Suisse pour la Formation en Soins Animaliers – formation continue’, October 04, 
2018, Lausanne, Switzerland. Invited talk for an animal care continuous education program (in French) 
Zebrafish embryos as models to study tuberculosis and their application in drug discover 
Sommer, R., Cole, S. T and Oates, A. C. ‘Global Health Institute retreat’, June 18-20, 2018, Zermatt, 
Switzerland. Prize for the Best Talk by a PhD student 
Zebrafish embryos as models to study tuberculosis and their application in drug discovery 
Sommer, R., Cole, S. T and Oates, A. C. ‘11th Swiss Zebrafish Meeting’, May 18, 2018, Lausanne, 
Switzerland. Contributed talk 
Tuberculosis imaging 
Sommer, R. ‘My Thesis in 180 Seconds Competition’ (https://www.youtube.com/watch?v=zD70ySvSqnY) 
October 10, 2016, Lausanne, Switzerland. Finalist at the EPFL contest (in French) 
Mycobacterial imaging with fluorescent benzothiazinones for in vitro and in vivo applications 
Sommer, R. and Cole, S. T. ‘EMBO Conference Tuberculosis 2016’, September 19-23, 2016, Paris, France. 
Poster presentation 
 
 Computer Skills    
 
 Other Interests    
 
? MS Office (Word, PowerPoint, Excel) 
? GraphPad Prism, Fiji, ImageJ 
? SnapGene, Adobe Illustrator  
 
Movies, sports (ski, via ferrata), 
music (clarinet), traveling. 
 
 
 

Ce document a été imprimé au Centre d’impression EPFL, 
imprimerie climatiquement neutre, certifiée myClimate.
